1 IMPLICATIONS OF OXIDATIVE STRESS IN DIFFERENT STAGES OF DIABETES. NEW ASPECTS ON NITRIC OXIDE METABOLISM, SERUM AMILOID, AND SIRTUIN ACTIVITIES…. [601917]

1 IMPLICATIONS OF OXIDATIVE STRESS IN
DIFFERENT STAGES OF DIABETES.
NEW ASPECTS ON NITRIC OXIDE METABOLISM,
SERUM AMILOID, AND SIRTUIN ACTIVITIES.
HABILITATION THESIS
Ionel Octavian Savu, MD, PhD
Carol Davila University of Medicine and Pharmacy, Bucharest

2 Content
Section I – Original contributions
I.1. Significance of hyperglyc emia and hypoxia in the
pathophysiology of chronic complications of diabetes
I.2. Evaluation of the an tioxidant status and oxidative stress in the
serum and erythrocytes of pa tients with different stages of diabetes
mellitus, especially at the first medical onset
I.3. Involvement of the erythrocytes in L-arginine dependent nitric
oxide metabolism in diabetes
I.4. The impact of basa l insulin analogues on glucose variability in
patients with type 2 diabetes undergoing renal replacement therapy
for end stage renal disease I.5. Concluding remarks
Section II – Perspectives Section III – References

3 Section I –Original Contributions
I.1. Significance of hyperglycemia and hyp oxia in the pathophysiology of chronic
complications of diabetes

4 I.1.1. Significance of hyperglycemia a nd hypoxia in the pathophysiology of
chronic complications of diab etes – the state of the art
I.1.1.1. The burden of diabetes and its specific chronic complications
Nowadays it is well known that diabetes mellitus (DM) is a serious health problem,
either worldwide or in our country, affect ing developed countries mainly. Increasing
prevalence, severe specific complicati ons, and major economical concern are essential
contributors to this scenario. Thus, a recent report published by the World Health
Organization (WHO) estimates that the global prevalence of this disease is expected
to grow from 171 million in 2000 to 366 mill ion by 2030 (Shaw, Sicree et al.). From
this perspective, it is notable that the incid ence of patients with type 1 diabetes
increased worldwide from 2% to 5% over last 20 years (Maahs, West et al.). The
same tendency was confirmed by very recent data obtained from PREDATORR
cross-sectional epidemiologic study estimating the actual prevalence of diabetes
mellitus, chronic renal disease and associated comorbidities in romanian population
(http://predatorr-study.com ). It has been therefore shown that more than 1.5 milion
romanian adults between 20 and 79 years of age are suffering from diabetes mellitus.
The corresponding disease prevalence is 11.6%, accordingly. Furthermore, the
prevalence for glucose metabolism disturba nces (i.e. impaired fasting glucose – IFG
or impaired glucose tolerance – IGT) in the same study is even higher (18.4%). All
together, this epidemiological data support the epidemic burden of diabetes disease.
Both type 1 and type 2 diabetes markedly increase the risk of microvascular and
macrovascular complications. Microvascular complications are characterized by
wide-range dysfunction in the capillary bed of tissues, and include the retinopathy,
nephropathy, and neuropathy – that eventually affects nearly all patients with DM,
since early stages of the disea se. Diabetic retinopathy (D R) is the leading cause of
blindness in adults from many different geog raphic areas (Klein, Klein et al. 1992).
On the other hand, diabetic neuropathy (DN) is the most common cause of non-
traumatic amputations (Feldman 2003) and diab etic nephropathy (DNf) is the major
cause of end-stage renal dise ase (Bo, Ciccone et al. 2005).
Atherosclerosis process occurs earlier, a nd follows a more aggressive course in
diabetes (Haffner 2000). Macrovascular compl ications originate from accelerated

5 atherosclerosis and remain the major cause of death in diabetic patients (Haffner
2000). Hence, major vascular events such as myocardial infarction, stroke, and
peripheral vascular disease are two to four ti mes more prevalent in these patients.
Diabetic environment induces the same rate of cardiovascular events as documented
coronary artery disease (Schulman, Hartmann et al.) in people without diabetes
(Haffner 2000). The mortality following myoc ardial infarction is hig her in patients
with diabetes compared with subjects without diabetes (Haffner 2000).
Premenopausal cardio-protection is lost in women with diabetes who therefore
become as vulnerable to CAD as men (H u, Stampfer et al. 2001). Foot ulcers
represent a major chronic complication in patients with diabetes. The global burden of
diabetic foot disease is reflected by the fact that on every 30 seconds one diabetic foot
is lost in the world by amputation (Boulton, Vileikyte et al. 2005).
Thus, these data represent strong evidence at testing that chronic complications of
diabetes represent a major medical and economical concern.
I.1.1.2. Pathogenic mechanisms involved in chronic complications of diabetes
mellitus
The potential pathogenic mechanisms have been proposed to be responsible for the
development of long-term complications of diabetes include: increased polyol
pathway flux, increased advanced glycat ion end products, activ ation of proteinkinase
C, increased hexosamine pathway flux) (Brow nlee 1995; Lee, Chung et al. 1995;
Sayeski and Kudlow 1996; Koya and King 1998).
I.1.1.2.a. The polyol pathway converts gl ucose to fructose (Vincent, Russell et al.
2004). Glucose is first reduced to sorbitol by a ldose reductase (AR), and then sorbitol
is oxidized to fructose by sorbitol dehydrog enase (SDH). When glucose is in excess,
both enzymes are overexpressed mainly in tissues prone to diabetic complications.
Sorbitol oxidation to fructose is a chemical reaction that is dependent of NADPH
consumption. NADPH pool is also required for maintaining the reduced form of the
antioxidant glutathione. Thus, these depletive mechanisms increase the cell
susceptibility to oxidative stress (Vincent, Russell et al. 2004).

6 I.1.1.2.b. The production of advanced gl ycosylated end products (AGEs) involves
non-enzymatic reactions between reactive dicarbonyls and various intracellular or
extracellular substrates such as proteins, DNA or lipids (Ahmed 2005; Toth, Rong et
al. 2008). Three compounds are mainly generated: glyoxal (by glucose oxidation),
Amadori products (by degradation of fructose-lysine adducts); and methylglyoxal
(through the abnormal metabolism of glycolyt ic intermediates). AGEs exert their
deleterious effects mainly due to two different mechanisms : structural modifications
and impaired activity of various intracellular or extracellular proteins (Miyazawa,
Nakagawa et al. 2012); and extracellular activation of a specific cell-surface receptor
(Hartter, Svoboda et al.), which is responsible for the secretion of cytokine and
growth factors and inflammation mediated vasculature damage (Ahmed 2005; Toth,
Rong et al. 2008). Moreover, it has been shown that high glucose enhances RAGE
expression (Yao and Brownlee 2010).
I.1.1.2.c. Hyperglycemia excessively increases the synthesis of diacylglycerol
(Sarkar, Dash et al.) which over-stimula tes the PKC pathway (Koya and King 1998).
Consecutively, vaso-active proteins are over-expressed such as vascular endothelial
growth factor (VEGF), PAI-1, NF- κB, and TGF -β, supporting the role of this pathway
in angiogenesis and vasc ular permeability, vascular occlusion or inflammatory
processes (Koya and King 1998).
I.1.1.2.d. The hexosamine biosynthetic pathway is essential for (1) synthesis of
glycosaminoglycans, glycolipids or glyc oproteins, and (2) regulation of the protein
transcription and translation (Kolm -Litty, Sauer et al. 1998). In this pathway, the
glycolysis intermediate fructose-6 phosphate is first converted to the active form of
glucosamine – uridine diphosphate-N-acet yl glucosamine (UDP-GlcNAc) (Kolm-
Litty, Sauer et al. 1998). N-acetyl glucosamine further serves as substrate for O-linked
glycosylation of various proteins to serine or threonine residues within the cytosol and
nucleus. As with polyol pathway, when intracel lular glucose concentration is high, the
UDP-GlcNAc is excessively pr oduced (Kolm-Litty, Sauer et al. 1998). The excess of
sugar residues can compete with phosphate groups al tering gene expression of various
proteins functioning as transcription factors, such as SP1, TGF- α and TGF- β (Kolm-
Litty, Sauer et al. 1998; Brownlee 2001).

7 I.1.1.2.e. It has been shown that hyperglycaemia in diabetes is responsible for the
excessive production of reactive oxygen species (ROS) by the mitochondrial electron-
transport chain and has been suggested to be a common mechanism for all the others
mentioned above (Nishikawa, Edelstein et al. 2000). Mitochondrial superoxide
overproduction further induces a reversible decrease in glyceraldehyde phosphate
dehydrogenase (GAPDH) activity. The superoxide exerts this inhibitory effect either
direct (Du, Edelstein et al. 2000) or indirect, as a c onsequence of poly(ADP-ribose)
polymerase (PARP) activation by ox idative lesions of mitochondrial DNA (Garcia
Soriano, Virag et al. 2001; Du, Matsumura et al. 2003). Irrespective how modulation
is performed, superoxide GADPH inhibition induces the above-mentioned
mechanisms.
I.1.1.3. Mitochondrial respiratory chain as source of ROS in diabetesIt is a general agreement that excessively ROS (i.e. superoxide) originate in diabetes
from two major sources in mitochondrial respiratory chain: complex I
(NADH:ubiquinone oxidoreductas e or NADH/FADH
2dehydrogenase) and complex
III (ubiquinol:cytochrome c oxidoreductase) (T urrens and Boveris 1980; Beyer 1992;
Turko, Li et al. 2003; Murphy 2009).
Mitochondrial oxidative phosphorylation is a process where electrons from reducing
substrates (i.e. NADH or FADH 2/succinate) are transferred to molecular oxygen (O 2)
in a step-by-step manner involving respiratory chain complexes I – IV (Murphy
2009). These complexes couples the elec trons transfer with the transfer of protons
(H+) establishing a hydrogen gradient ac ross the inner mitochondrial membrane. It is
therefore created an electrochemical proton gradient that drives ATP synthesis, or the
generation of chemical energy in the form of adenosine triphosphate (ATP) by ATP
synthase (complex V). Four membrane-bound complexes have been identified in
mitochondria. The NADH –ubiquinone oxidoreductase (complex I) accepts electrons
from the Krebs cycle e lectron carrier NADH a nd transfers them to ubiquinone
(coenzyme Q) pool. In the complex II (suc cinate dehydrogenase) additional electrons
originating from succinate are transferred via FAD into the coenzyme Q pool and
used to oxidize succinate to fumarate. When compared to complex I, complex II is a
parallel electron transport pathway to compl ex I where no protons are transported to

8 the inter-membrane space. Hence, the pa thway through complex II generates no
electrochemical proton gra dient and therefore contributes less energy to the overall
electron transport chain process. The elect rons transferred to the coenzyme Q pool are
further passed to ubiquinol – cytochrome c oxidoreductase (complex III), and
subsequently to cytochrome c oxidase (complex IV), both processes contributing to
the electrochemical proton gradient. Finally, the electrons are used to reduce
molecular oxygen to water. The majority of molecular oxygen is reduced at complex
IV to water via the mitochondrial respiratory chain. Though, 1 –4% of the oxygen is
incompletely reduced to superoxide (O 2-).
I.1.1.4. The cross talking between pathogenic factors in diabetic wounds
Among chronic complications of diabetes, diabetic foot ulcers potentially induce
major health disability and hospitalization costs (Boulton, Vileikyte et al. 2005).
There is a combination of multiple mec hanisms that contribute to pathophysiology of
this condition (Shaw and Boulton 1997; Ricco, Thanh Phong et al. 2013), which
includes sensory, motor and autonomic neuropathy, pe ripheral vascular disease,
microangiopathy, impaired wound healing related to reduced blood supply, and chronic hyperglycemia. Re petitive mechanical stresses (i.e. poorly fitting footwear or
high foot pressures), which the patient applies on a wound -prone foot, are also
essential for the occurrence and persistence of the ulcerative lesion (Murray and
Boulton 1995).
I.1.1.5. The importance of hypoxia in the chronic complications of diabetes Accumulating data suggest a role for hypoxia, in the development of chronic
complications of diabetes (Botusan, Sunkari et al. 2008; Curtis, Gardiner et al. 2009;
Regazzetti, Peraldi et al. 2009; Vil laret, Galitzky et al. 2010).
Thus, in spite that endothelial hypoxia has been re cognized as the major initiator of
the atherosclerotic plaque in animal models more than twenty years ago (Boxen
1985), a direct evidence of hypoxia in human atherosclerosis has only recently
emerged (Sluimer, Gasc et al. 2008). It has been shown that the combination of
increased oxygen demands with insufficient oxygen supply, particularly in

9 macrophage-rich zones f rom atherosclerotic lesions, ge nerates hypoxia (Bjornheden,
Levin et al. 1999). Accumulating data su ggest hypoxia as a key factor in the
development and progression of atherosclerosis through several potential
mechanisms: lipid accumulation, inflammati on, ATP depletion and angiogenesis
(Hulten and Levin 2009). Promoting angiog enesis within the plaque has a dual effect:
compensates for low tissue oxygenation and ATP levels (Hulten and Levin 2009), and
may also induce lesion instability (Hulten and Levin 2009). Recently, it has been
proposed that blood flow abnormaliti es and hypoxia in the inner layer of the media
reflect alterations into the architecture of the vasa vasorum (Jarvilehto and Tuohimaa
2009). In accordance, the development of atherosclerosis initi ates from the opposite
direction, i.e. the end arteries of vasa vasorum.
Increasing evidences suggest that chronic hypoxia of the tubulointerstitium has an
important pathogenic role not only in early stages of chronic renal diseases, but also is
a common pathway to end-stage renal failure. Thus, it seems that hypoxia per se is a
fibrogenic stimulus for tubular epithelial cells, interstitial fibroblasts and renal
endothelial cells leading to apoptosis or epitheli al-mesenchymal trans-differentiation
since early stage of renal disease, ev en before the development of structural
tubulointerstitial injury (Fine, Bandyopadhay et al. 2000; Nangaku 2006). A primary
glomerular lesion further reduces the amount of functional peritubul ar capillaries due
to decreased capillary flow, increased va soconstriction and decreased vasodilation
from affected glomeruli, thus leading to tubular dysfunction and fibrosis (Nangaku
2006). In the late stages, renal fibrosis is the hallmark of chronic kidney diseases in
spite of the etiology, and therefore g lomerulosclerosis and tubulointerstitial fibrosis
are the best indicators for progression to end- stage disease (Nangaku 2006; Fine and
Norman 2008).
Chronic hypoxia seems to be involved in th e pathogenesis of early diabetic
retinopathy. The lost of the trophic effect of the Muller cells under hypoxic conditions
(Tretiach, Madigan et al. 2005) suggests a potential role of chronic hypoxia in
neuroglial dysfunction which recently has been shown to occur at very early stages of
the disease (Antonetti, Barber et al. 2006). The direct evidence that chronic hypoxia
could be related to retinal hypoperf usion are controversial (Pournaras, Rungger-
Brandle et al. 2008; Curtis, Gardiner et al. 2009). Though, lower vitreal P O2 was

10 reported on diabetic patients undergoing vit rectomy (Holekamp, Shui et al. 2006).
The indirect evidences seem to be mor e consistent. Thus, it has been reported that
patients with very incipient lesions of retinopa thy improved ocular function under
pure oxygen atmosphere (Curtis, Gardiner et al. 2009). Furthermore, intermittent
chronic hypoxia seems to be also a ssociated with retinopathy since sleep apnea
syndrome has been related with diabetic ma cular edema and higher levels of
circulating retina-specific rhodopsin mRNA we re observed in obese type 2 diabetic
patients with more than 5 dips/hr (Wong, Mer ritt et al. 2008). Chronic hypoxia may
be either involved in shifting from hypo to hyperperfusion in diabetic retinopathy
since a certain threshold of hypoxia may over come the early retinal vasoconstriction
in diabetes (Curtis, Gardiner et al. 20 09). The implications of chronic hypoxia in the
occurrence and progression of advanced retinopathy are consistent and originates
from both in vitro and in vivo studies using growth factors, especially VEGF (Chiarelli, Santilli et al. 2000; Arjamaa and Nikinmaa 2006; Crawford, Alfaro et al.
2009). Thus, it has been recently shown that intravitreous VEGF is increased and correlates with the severity of retinopathy and angiogenesis in diabetic patients with
proliferative diabetic retinopath y (Wang, Wang et al. 2009).
Hypoxia and reduced nerve blood flow are early observed in both humans and
animals with diabetic polyneuropathy (Ca meron, Eaton et al. 2001; Sima 2008). It
could be also speculated that hypoxia may be involved as trigger for endoneurial
microangiopathy, which may further exacerbate hypoxia by reducing the oxygen
diffusion (Malik, Tesfaye et al. 1993; Came ron, Eaton et al. 2001). The beneficial
effects of vasodilator treatm ent on nerve conduction velocit y (NCV) or blood flow in
humans or animals (Cameron, Ea ton et al. 2001; Sheetz and King 2002) are also
indirect proofs for the role of chronic hypoxia in the development of diabetic neuropathy.
I.1.1.6. Hypoxia-inducible factor-1 as main mediator of the adaptive responses of
cells to hypoxia
Hypoxia refers to the condition when the oxygen delivery does not meet the oxygen
demands of the tissues. The partial pr essure of the oxygen at tissue level varies from
10 to 110 mmHg (1 to 10%). Hypoxia defines any condition characterized by levels

11 of oxygen lower than above mentioned. Adaptive responses of cells to hypoxia are
mediated by the hypoxia-inducible factor-1 (HIF-1).
HIF is a heterodimeric complex belong ing to the PER-ARNT-SIM (PAS) subfamily
of the basic-helix-loop-helix (bHLH) fami ly of transcription factors (Crews and Fan
1999), which are proteins essential for development and homeostasis.
HIF structure is complex, consisting of two subunits: α-subunit and β-subunit (Wang
and Semenza 1995). The oxygen regulates the α-subunit only, whereas the β-subunit
is oxygen independent and is known as aryl receptor nuclear tr anslocator (ARNT)
(Hoffman, Reyes et al. 1991; Wang, Jiang et al. 1995). All three isoforms of the α-
subunit and only two isoforms of the β-subunit (ARNT and ARNT2) are thought to be
involved in the in vivo response to hypoxia (Bra himi-Horn and Pouyssegur 2009).
Whereas HIF-1 αis ubiquitously expressed, HIF-2 α and HIF -3αexpression is more
restricted (Berchner-Pfannschmidt, Frede et al. 2008).
Different HIF members have specific particularities but also share some common
characteristics (Berchner-Pfannschmidt, Fr ede et al. 2008; Brahimi-Horn and
Pouyssegur 2009).
The N-terminal part is si milar to all HIF members and contains bHLH/PAS domain
which mediate DNA binding and induces dimerization.
The C-terminal region confers specificity for HIF members; it is present only in HIF-
1α and HIF -2α and is involved in transactivati on of HIF complex by two specific
domains (N-TAD of C-TAD, transactivation domains).
N-TAD domain contains the oxygen-dependent degradation domain (ODDD) and the
two proline residues (P402 and P564) involved in HIF- α degradation in normoxia.
HIF- β and HIF -3α lack C -TAD region.
As a common characteristic for all HI F members, bHLH motif a nd C-terminal contain
nuclear localization signals (NLS). When stable, NLS allows HIF to translocate into
nucleus (Kallio, Okamoto et al. 1998).
HIF degradation is essentially proteosomal depende nt, involves prolyl hydroxylase
domain-containing proteins (PHDs) – von Hippel Lindau protein complex (pVHL)
pathway, and exerts in normoxia.

12 Thus, whe
n the oxygen is present (i.e. normoxia) HIF protein degradation is mainly
initiated by the hydroxylation of the ODDD at two critically proline residues (P402,
from N-terminal region a nd P564 from C-terminal reg ion), a reaction which is
catalyzed by PHDs (Ke and Costa 2006; Bra himi-Horn and Pouyssegur 2009). Their
activity is dependent on substrates (oxygen an d 2- oxoglutarate, 2-OG) and cofactors
(Fe2+ and ascorbate). The “hypoxia mimetics” are chem ical substances, which inhibit
PHDs and stabilize HIF by different mechanisms (iron chelators, such is
desferoxamine – DFX; iron competitors, such is transition metals – cobalt; or
oxoglutarate analogs, such is dymethyloxalylglycine – DMOG). It is important to note
that PHDs are not able to catalyze HIF proline hydroxylation (Jaakkola, Mole et al.
2001). There are three PHDs isoforms described in humans, but PHD2 only seems to
be the key limiting enzyme for HIF α stability (Berra, Benizri et al. 2003), and is able
to shuttle between the cytoplasm and the nucleus, contributing to HIF- 1α degradation
in both compartments (Ke and Costa 2006).
It is important to note that HIF α inactivation in normoxia implies not only a
modulation at the protein levels, but a lso a post-translational regulation of
transactional domains. Thus, additional hydrox ylation of asparagines 803 (N803)
located at the end of C-TAD results in the inhibition of HIF activation by
transcriptional co-activators, such as p300, steroi d receptor coactivator-1 (SRC-1) or
CBP (CREB-binding protein) (Ke and Costa 2006; Brahimi-Horn and Pouyssegur
2009). The reaction is catalyzed by Factor I nhibiting HIF-1 (FIH-1), which belongs to
the dyoxygenase family of proteins. As PHD s, FIH-1 needs 2-OG and oxygen as
substrates and Fe2+ as cofactor, but the k m for oxygen is lower. Therefore, the enzyme
is more sensitive to oxygen gradients. In other words, a certain oxygen level may by low enough to limit the transactivation but not enough to promote HIF degradation.
The adaptive response is also modulated by the availability of the co-activators that
limits HIF transactivation.
After ODD-hydroxylation, HIF protein is fur ther degraded by ubiquitination. The
process implies its interac tion with the von Hippel Lindau protein complex (pVHL), a
component of an E3 multiprotein ubiquitin-li gase complex known as VHL/elongin

13 B/elongin C (VBC) (Ivan and Kaelin 2001). When polyubiquitinilated, HIF protein is
further directed to 26S proteasome for degradation.
VHL-dependent HIF protein degradation ma y by accelerated in normoxia by different
mechanisms. Thus, the Arest Defect ive Protein-1 (ARD-1) acetylation of lysine
located in the ODDD (Jeong, Bae et al. 2002) increases the affinity of HIF for pVHL,
that accelerates its prote osomal degradation.
HIF protein degradation can occur also through pathways that are PHDs independent
and pVHL dependent.
It has been reported that HIF α degradati on can occur also through other pathways
which are pVHL independent (Ke and Costa 2006). Thus, SUMOylation may
represent a possible alternative for this patt ern of HIF degradation. SUMOylation is a
system which is very similar to ubiquitin pa thway (Sarge and Park-Sarge 2009),
where the small ubiquitin-like modifier (Tsumoto, Ra et al.) is the most known
component. The SUMOylated proteins are specifically degraded by a de-
SUMOylation system consisting of differe nt cysteine proteases (SUMO specific
proteases – SENP, 1-6 in humans). The effects of SUMOylation – de-SUMOylation
on HIF activity are still debated (Bae, Jeong et al. 2004; Berta, Mazure et al. 2007;
Huang, Han et al. 2009).
HIF degradation may also occur in a pVHL independent manner, either in hypoxic
conditions or in cells defective of VHL (VHL -/- cells) (Kim, Safran et al. 2006).
HIF- 1α may also be degraded independent of proteosomal degradation, in the
lysosomes through chaperone-mediated autophagy (Hubbi, Hu et al. 2013).
HIF is stabilized unde r hypoxic conditions . PHDs and FIH are both inactive, HIF- α
translocates into nucleus, dimerizes with HIF- β, and binds to a specific region of the
hypoxia response elements (HREs) that is locate d in the promoter gene of the target
genes (Lisy and Peet 2008).

14 Stabilized HIF-1 regulates the expression of many genes trough direct or indirect
mechanisms (Semenza 2011). Thus, by direct bi nding to HRE and recruiting of co-
activator proteins more than 60 well-define d target-genes involved in different
processes (i.e. angiogenesis, tum or development, erytropoiesis, metabolism,
inflammation) are either up-regulated (Semenza 2003) or repressed (Manalo, Rowan
et al. 2005), thus mediating the adaptive responses to hypoxia. Indirectly, there are
several ways through HIF-1 can modulate gene expression: (a) by functioning as co-
activator or co-repressor of specific genes; (b) by activation of target genes encoding
microRNAs; (c) by transcription factors, that are either direct activated or inhibited or
that are encoded by the target-genes activ ated in the first line; (d) and by the
activation of the transcription of ge nes encoding proteins with histone-demethylase
(HDM) activity, thus modulating the activity of a second line of target-genes by
altering their chromatine structure. Opposite to HIF-1 α or HIF-2 α, the HIF- 3α
isoform has been reported to ha ve a dominant negative act ivity (Makino, Cao et al.
2001; Brahimi-Horn and Pouyssegur 2009). HIF target gene expression is also
conditioned by modulation of C-TAD and N- TAD activity (Lisy and Peet 2008;
Brahimi-Horn and Pouyssegur 2009). Thus, N-TAD confers specificity for HIF-target
gene expression. Furthermore, both TAD domains are sequential activated in
gradients of hypoxia. Hence, in mild hypoxia HIF stability is rescued but only N-TAD
activity is preserved, whereas in full hypoxia both N-TAD and C-TAD activities are
present. The gradual act ivation is due to higher affinity for oxygen of FIH when
compared with PHDs.
NEDD8 is an ubiquitin-like protein impli cated in cell cycle progression and
cytoskeletal regulation (Kamitani, Kito et a l. 1997). It has been also shown that it
mediates an alternative mechanism for HIF stabilization in a ROS-dependent –
pVHL-independent manner (Ryu, Li et al. 2011 ). This alternative pathway of HIF
regulation in hypoxia seems to be importa nt since approximately 30% of HIF
stabilization in hypoxia is NEDD8-dependent (Ryu, Li et al. 2011).
HIF- 1α stabilization may also occur independent of oxygen regulation (Ke and Costa
2006). This manner of HIF activity modulation has been described for several
hormones (i.e. insulin) and growth fa ctors (i.e. IGF-I, IGF-II, EGF) (Zelzer, Levy et
al. 1998; Feldser, Agani et al. 1999; Treins, Giorgetti-Peraldi et al. 2005).

15 I.1.1.7. HIF-1 /g68 is essential for the control of mitochondrial ROS production under
hypoxic condition
Several reports have shown an increase in oxidative stress when different cells and
tissues are exposed to hypoxia (Poyton, Ball et al. 2009; Poyton, Castello et al. 2009).
It seems that increased ROS production in mitochondria originates from complex II
and III (Chandel, McClintock et al. 2000; Paddenberg, Ishaq et al. 2003). The
mechanism responsible for the increased oxidative stress when the oxygen tension
decreases is not clear but it might be a consequence of a slower rate of electron
transport across inner membra ne of mitochondria. However, HIF-1 /g68 is essential for
the control of mitochondrial ROS producti on under hypoxic condition (Semenza
2011). The mechanisms behind are complex, and imply the regulation of the balance
between oxidative and glycolytic metaboli sm of the cell (Semenza 2011). The end-
point of these metabolic responses seems to be to reduce the mitochondrial mass and
to increase the glucose shift from aerobic to anaerobic glycolysis.
A very recent paper disc usses the mechanisms by which hyperglycaemia contributes
to HIF repression in diabetes, also providing a comprehensive analysis of the
functional relevance of how hypoxia a nd HIF contribute to the development of
chronic diabetes compli cations (Catrina 2014).
I.1.1.8. Mitochondrial DNA (mtDNA) and ROS I.1.1.8.1. MtDNA as particular target to oxidative damage Once generated, ROS can interact with different macromolecules including DNA.
When compared with nuclear DNA (nD NA) the mitochondrial DNA (mtDNA) is
particularly susceptible to oxidative damage. The close association with the inner
mitochondrial membrane and the specific histone deficiency represent the main
explanations behind the mtDNA sensitivity to ROS aggression (Yakes and Van
Houten 1997).

16 Human mtDNA is a highly conserved double-s tranded circular molecule of about
16,5 kb located into mitochondrion (Fernandez-Si lva, Enriquez et al. 2003). The name
of its two strands – i.e. the guanine-rich, heavy (H) and cytosine-rich, light (L),
originates from the differences in guanine content, which allow the separation on a
cesium chloride gradient. mt DNA is packaged by pr oteins. The most important one
seems to be TFAM, a transcr iption factor suggested to regulate the mtDNA copy
number in mammals (Ekstrand, Falkenberg et al. 2004). In each normal cell, a
mixture of wild-type (normal) and mut ated mtDNA can coexist. This particular
condition for the mitochondrial genome is cal led heteroplasmy (Wal lace 1992). The
gene sequence in mtDNA contains no introns, and only two noncoding (control)
regions (Fernandez-Silva, Enriquez et a l. 2003). The largest non-coding segment in
human mtDNA is called the displacement loop (D -loop), reaches about 1 kb length,
and it has a triple-stranded structure, in w hich a nascent H-strand DNA segment of
500-700 nucleotides remains annealed to the parental L-strand.

In humans, mtDNA is the smallest chromosome, coding for only 37 genes and
containing approximately 16,600 base pairs (F ernandez-Silva, Enriquez et al. 2003).
Mammalian mtDNA genes encode for a small number of polypeptides that are
subunits of the respiratory chain. The rest of different mitochondrial proteins are
encoded by nDNA. Furthermore, nDNA is responsible for the mtDNA maintenance
and expression.

In spite of some exceptions (Schwartz and Vissing 2002) the inheritance of mtDNA is
almost exclusively maternal. Though, the mutations transmitted to the offsprings by
mtDNA occur more rapid as a result of the fact that only a small numbers of mtDNA
molecules are transmitted to the offsprings (Marchington, Macaulay et al. 1998). This
is recognized as bottleneck phenomenon. He nce, the level of expression of mtDNA
mutations may considerably differ in differ ent cells or tissues (Clayton 1982). There
are several explanations for this fact. First, de novo mutations may occur in one
molecule of mtDNA that can increase th e amount of mutated mtDNA to homoplasmy,
i.e. presence of only mutated mtDN A (Trifunovic 2006; Trifunovic and Larsson
2008). Second, in case of mtDNA the repli cation is not coupled to cell cycle meaning
that one of the daughter cells may have an unbalanced load of mutated mtDNA
(Clayton 1982). Third, a certain threshold level of mtDNA mutati on load must be

17 overcome in order to cause mutat ion expression (89). F ourth, there is a variation in
the distribution of mutated mtDNA either in different cells, tissues and organs (due to
heteroplasmy), in different cells of the sa me organ (due to different intracellular
distribution of mtDNA), or in mitochondria located in different intracellular sites (due
to a dynamic compartimentalization of mtDNA within the mitochondria) (Trifunovic
2006; Trifunovic and Larsson 2008).
I.1.1.8.2. MtDNA oxidative damage and ageing The close proximity of mtDNA to the mi tochondrial inner membrane where most of
ROS are generated (Yakes and Van Houten 1997) explains the reason why the
alterations of mtDNA may be essential c ontributors to the ageing process. Therefore,
it has been suggested (Harman 1972 ) that accumulation of somatic mutations in
human mtDNA might produce cells with a re duced oxidative capacity which can be
responsible for ageing. Thus, the damage to mtDNA is associated with either
increased number of cytochrome c oxidase (COX) deficient cells or a imbalanced
activity of different complexes in mitochondrial respiratory chain in various tissues
(i.e. skeletal muscle, liver, hea rt and brain) leading to increased ROS production
(Harman 1972).
Several extensive reviews discuss the implicat ions of somatic mtDNA mutations in
ageing (Trifunovic, Wredenberg et a l. 2004; Kujoth, Hiona et al. 2005; Trifunovic
2006; Trifunovic and Larsson 2008; Vermulst, Wa nagat et al. 2008; Kukat and
Trifunovic 2009).
Animal studies performed on genetical ly-modified (knock-in) mice expressing a
proofreading deficient form of the nuclear-encoded mtDNA polymerase (Polg)
(Trifunovic, Wredenberg et al. 2004; Kujoth, Hiona et al. 2005; Vermulst, Wanagat et
al. 2008) have directly shown that somatic mtDNA mutations may induce a variety of
ageing phenotypes in mammals. Thus, the Polg express a profoundly reduced
exonuclease activity with a normal DNA po lymerase activity. Therefore, mtDNA
mutator mice express rapid-progressive altered phenotypes with age. They are
completely normal in phenotyp e expression at birth, show signs of premature ageing
in early adolescence (about 25 weeks of ag e), and die prematurely before age of about

18 60 weeks. Their genotype is also severe al tered. Hence, mtDNA point mutations and
deletions accumulate progressively and randomly in differe nt levels and various
tissues. It is not yet clear how any of these specific mutations contribute to accelerate
aging process in these anima ls (Kukat and Trifunovic 2009).
The majority of the mtDNA deletions obser ved in human aging tissues are similar
with the ones detected in pa tients suffering from mi tochondrial diseases (Kukat and
Trifunovic 2009). Most of them are located in the major arc between the two
proposed origins of replication (O H and O L; Mitomap), and are mainly flanked by
short direct repeats.
Thus, one of the most frequent deletion observed in human tissues is a 4,977
nucleotides deletion that occurs at a del etion “hot spot” between two 13-bp direct
repeats at positions 13447-13459 and 8470 -8482 in human mtDNA, and is often
associated with other two deletions (mtDN A7436 and mtDNA10422 ) (Kukat and
Trifunovic 2009). Due to the fact that is the common cause of several mitochondrial
diseases (such as chronic prog ressive external ophthalmoplegia – CPEO), the deletion
is called the “common” deletion. Moreover, it a lso accumulates in different levels and
various tissues during aging, therefore being used as biomarker of mtDNA damage
(Kukat and Trifunovic 2009).
The analysis of human different single cel ls revealed also a significant proportion of
different deletions in mtDNA with age. Thus, various COX deficient cells (i.e.
skeletal muscle fibers, cardiomyocytes, or subs tantia nigra neurons) isolated from
aged individuals carried a significant proportion of different mtDNA deletions or even
often no detectable full-length mtDNA (Kukat and Trifunovic 2009). Though, in spite
that the amount of the mutations in the cells can be substantial, the overall tissue level
may be low (Kukat and Trifunovic 2009).
The accumulation of mtDNA point mutation with age in human tissues is
controversial (Kukat and Tr ifunovic 2009), mainly for technical reasons. Several
reports describe A to G tra nsitions (i.e. A8344G, A3243G) a nd transversions (T414G)
accumulating with age in different tissues, but not in others. Though, one mutation
(A13167G) declined significantly with ag e in muscles of infants 1 hour to 5 weeks

19 old (Zhang, Liu et al. 1998). Murdock et al. (Murdock, Christacos et al. 2000), also
found by a different approach no age- dependent accumulation of A3243G and
A8344G mutations in skeletal muscle and brain. Notably though, there is clear data on
mtDNA point mutations acc umulation with age in studies performed in different
human single cells, even in human stem cells (Kukat and Trifunovic 2009).
I.1.1.8.3. MtDNA protection against oxidative damage Irrespective how are generated, ROS are responsible for various damages on mtDNA
in humans (Yakes and Van Houten 1997). Hence, ROS can induce many types of
DNA lesions, i.e. abasic (apurinic-apyrimidinic) sit es (AP), oxidize d DNA bases or
sugars, or DNA strand breaks (single-strand breaks – SSBs, double-strand breaks –
DSBs) (Maynard, Schurman et a l. 2009). Therefore, it can be assumed that mtDNA
protection against oxidative damage ma y involve beside antioxidant enzymes an
efficient repair system.
The base excision repair (BER) pathway repairs the vast majority of the mtDNA
lesions, those induced by ROS being also include d (Maynard, Schurman et al. 2009).
Briefly, the process involves several steps, as follows (Maynard, Schurman et al.
2009).
1. Excision of the damaged base by a DNA glycosylase, due to its specific
(glycosylase) activity. An abasic site (AP) is consecutively generated. AP sites result
also from ROS attack. The ir removal is critical because of highly mutagenicity.
Several glycosylases are designated to repair certain lesions. One specific glycosylase
may repair more than one type of damage. Mono-functional glycosylases have only
glycosylase but not lyase activity, meaning that for the 3` incision at AP site they
need an AP-endonuclease (APE) providing the lyase activity. The left over 5` –
deoxyribose (dRP) residue is further removed by lyase activity of mtDNA polymerase
γ. Bi -functional glycosylases have glycosylase and lyase activity, meaning that they
are able to perform both base excision a nd incision to the AP site. In this case, the
leftover is a 3´ unsaturated aldehyde (UA) derived from deoxyribose, or a phosphate
(P), which is subsequently removed by lyase activity of APE.
2. The cleavage of AP site and 5’ – leftovers is indirectly able to generate a SSB.
SSBs may be produced also directly by ROS. The direct ROS attack results in an AP

20 site and a 3´ leftover (phosphoglycolate – PG), which is removed specifically by APE
lyase activity. Irrespective how is generated, the SSB is further replaced by mtDNA
polymerase γ (Polγ), the only polymerase existing in mitochondria. Presence of both
polymerase and lyase acti vities make this enzyme the most important for the repair
synthesis step in BER (Maynard, Schurman et al. 2009).
3. The final step is the ligation of the re maining nick by a specific ligase complex.
This is the short-patch BER pathway, whe re only one nucleotide is incorporated
instead of the damaged base.
4. If the polymerase cannot access the 5´ e nd and the leftover residue is resistant to its
lyase activity, the process of removi ng the blocking fragment requires incorporation
of several (from 2 to 6) nucleotides. This is long-patch BER pathway and involves
several new enzymes, i.e. FEN 1 (flap endonuclease 1) which is a 5´ exo/endonuclease
recently isolated in mitochondrial extrac ts from human cells (Liu, Qian et al. 2008;
Szczesny, Tann et al. 2008).
I.1.1.8.4. MtDNA mutations in diabetes Data referring to the significance of mt DNA mutations in diabetes are relatively
limited. Thus, it has been shown that specifi c mtDNA mutations are associated with
diabetes (Ballinger, Shoffner et al. 1992; Ballinger, Shoffne r et al. 1994), and one
particular mtDNA point mutation causes the dis ease in 0.5-1% of the patients with
diabetes (Kadowaki, Kadowaki et al. 1994). The same mtDNA somatic mutation has
been found to accumulate with age in patients with diabetes (Nomiyama, Tanaka et al.
2004), and its incidence correlated with the durati on of diabetes (Liang, Hughes et al.
1997). The same ageing a ssociation and accumulation in diabetes has been reported
for a 4977 bp deletion in mtDNA (Suzuki, Hino kio et al. 1999). However, the data
available are still limited, originating fr om cross sectional studies (Kamiya and Aoki
2003; Garcia-Ramirez, Francisco et a l. 2008), on the unevenly somatic point
mutations and deletions of mtDNA (usua lly associated with excessive ROS) in
diabetes (Khaidakov, Heflich et a l. 2003; Trifunovic, Wredenberg et al. 2004), or
from peripheral blood mononuclear cells (PBMC) (Kamiya and Aoki 2003; Garcia-
Ramirez, Francisco et al. 2008) that mig ht not reflect the changes in the tissues that
develop chronic complications.

21 I.1.2. Significance of hyperglycemia and hypoxia in the pathophysiology of
chronic complicat ions of diabetes – original contribution beyond the state of the
art

Thus, one of my important research interest has been the study of the significance of
hyperglycaemia and hypoxia in the patoph ysiology of chronic complications of
diabetes, in order to identify new therape utic strategies designated to improve their
actual poor outcome. Hence, I have first investiga ted the effect of hyperglycemia and
hypoxia on the stability and function of 1-a lpha subunit of the HIF in either primary
fibroblasts cultures and diabetic wounds collec ted before developing diabetes and
after 24 weeks of diabetes from a well va lidated animal model of type 2 diabetes
(db/db mouse). Our animal model has thoug h the advantage of the homogenous
genetic background and of determine d diabetes duration. I have shown that
hyperglycaemia has a repre ssive effect on both HIF-1 α stability and function, by a
complex mechanism involving either the von Hipple Lindau dependent degradation
and transactivation. Then, I have shown that th e negative regulatory effect of the
hyperglycaemia is reversible by blocking HIF-1 α hydroxylation through chemical
inhibition. Moreover, by local adenovirus- mediated transfer of two stable HIF
constructs, I have demonstrated that stabilization of HIF-1 α is necessary and
sufficient for promoting wound healing in a diabetes.

Then, by using primary human dermal fibrob lasts and several diabetes-targeted
organs collected from the above-mentioned animal model, I have investigated the
stability of mtDNA against hyperglycaemia and hypoxia-mediated ROS
overproduction in diabetic condition. I was able to show that mtDNA damage
accumulates only in cells exposed to both hyperglycaemia and hypoxia – hence,
confirming the pathogenic role of the c ombination of these factors in diabetes, and
that mtDNA was fully protected in cells treated with specific inhibitors of the
mitochondrial respiratory chain. I therefor e here made the first observation that
pathogenic mechanisms relevant in diabetes (i.e., hyperglycaemia and hypoxia) can
induce mtDNA lesions through mitochondrially produced ROS. I have also shown
that mtDNA accumulates in vivo less damage in diabetes, in spite of increased levels
of ROS. This was explained by an increas e in the antioxidant capacity (i.e.,
expression of Mn Superoxide Dismutase – SOD 2, and Catalase – CAT) and of the

22 mtBER activity (i.e., the activity of APE ) in the targeted organs of the diabetic
animals.
Hyperglycemia represses HIF- 1α stability
The hyperglycemia repression on HIF- 1α stability was first documented in db/db
mouse primary fibroblasts (Fig. 1A) and then confirmed in diabetic wounds of the
db/db mice (Fig. 3A). The two different approaches of blocking p-VHL machinery
demonstrated that the effect of gluc ose was dependent on the VHL-mediated
degradation mechanism. Thus, HIF- 1α stability was not modulated by hyperglycemia
in renal carcinoma cells that constitutionall y lack functional pVHL (Fig. 1B Left).
VEGF expression – one of the most important target gene for HIF – was also not
influenced by hyperglycemia in human de rmal fibroblasts where VHL expression was
down-regulated by treatment with siRNA (Fig. 1B Right).
Hyperglycemia inhibits HIF- 1αfunction
The negative effect of hyperglycemia on HIF- 1α function was first demonstrated in
vitro . Both CTAD and NTAD activity were repressed (Fig. 1C) and the expression of
several HIF- 1α target genes essential for wound healing (Fig. S1) was down regulated
by hyperglycemia. The same repressi ve effect of hyperglycemia on HIF- 1α function
was then confirmed in vivo . Db/db wounds expressed significant lower HIF- 1α (Fig.
3A), in spite more pronounced hypoxia (Fig . 3B). The expression of HIF-1 target
genes essential for cell motility (i.e., HSP- 90), angiogenesis (i.e., VEGFA and VEGF-
R1), and recruitment of CAG (i.e., SDF-1 α, SCF, and Tie -2) was also repressed in the
diabetic wounds (Fig. 3C).
HIF stabilization counteracts the repressi ve effect of hyperglycemia on its
stability and function
The stability and function of HIF- 1α is essentially regulated by the hydroxylation of
N-TAD – ODDD located prolyl and C- TAD located asparaginyl residues (Ivan,
Kondo et al. 2001; Jaakkola, Mole et al. 2001; Lando, Peet et al. 2002). The influence
of the inhibition of hydroxylase activity on the negative regulatory effect of

23 hyperglycemia was therefore studied. Two structurally different hydroxylase
inhibitors were used, i.e., dimethyloxalylglycine (DMOG) and deferoxamine (DFX).
DMOG is a 2-oxoglutarate analogue while DMOG is an iron chelator, therefore
stabilizing HIF-1 by different mech anisms (Hirota and Semenza 2005). Both
inhibitors stabilized the HIF- 1α to similar levels in hyperglycemia and normoxia
compared to hypoxia in normal glucose c oncentrations in primary db/db mouse
fibroblasts (Fig. 2A). The expression of HI F target genes was also induced (Fig. 2B)
even in the cells exposed to high glucose c oncentrations, or in hypoxia as illustrated
for VEGF (Fig. S2). Both treatments im proved healing process in diabetic wounds
(Fig. 4 A and B), and the effect persists in spite of persistent chronic hyperglycemia,
without interfering with the animal’s weight. Both inhibitors were used as the highest
efficient doses as titrated in pilot experimen ts. Though, DMOG was at least equally as
efficient as DFX, if not more effective (Fig . 4E). Different other proprieties may
count for these differences. Hence, in spite of its antioxidant pr oprieties (Emerit,
Beaumont et al. 2001), which could be of relative importance considering the
essential role of the ROS in the pathogenesis of chronic complications of diabetes
(Brownlee 2001), DFX has anti-proliferative ef fects (Dayani, Bishop et al. 2004), also
observed in vitro (data not shown). Prese nt data represent strong evidence showing
that the hyperglycemia-induced HIF-1 destabil ization can be satisfactorily overcome
by blocking the prolyl hydroxylation. This is in spite of a clear mechanism behind
(Ivan, Kondo et al. 2001; Jaakkola, Mole et a l. 2001; Jeong, Bae et al. 2002; Pereira,
Zheng et al. 2003; Cheng, Kang et al. 2007).
Defective wound healing in diabetic mice is critically improved by HIF
stabilization
In order to proof a direct evidence for the central role of HIF in wound healing in
diabetes a stable mutated HIF- 1α variant was cloned by homologous recombination
into a specific serotype of adenovirus plasmi d. Two different point mutations in
which both the critical proline residues (P402A/P563A) have been substituted with
alanine generated two constitutively stable forms of HIF- 1α (V -N and V-NC). In the
V-NC construct CTAD was addit ionally substituted with the potent VP16 TAD (Fig.
S2). These structural modificat ions of HIF molecule are gain-of-function mutations
changing the gene product such that it ga ins an amplified function . The same positive

24 effect on wound healing in diabetic animals as pharmacological inhibitors (Fig. 4C)
was obtained. The V-NC construct had no additive effects compared with the V-N
construct (Fig. 4D). The result is a strong argument showing that CTAD repression is
not critical for wound healing. The central pathogenic role for the NTAD without any
additional regulatory effect from the CTAD has also been reported for HIF- 2α-driven
renal carcinogenesis (Yan, Bartz et al. 2007). The lack of superiority observed for V-
NC construct compared with VN may also be explained by the squelching effect (Gill
and Ptashne 1988) of a highly active transactivation acti vity classically described for
VP16. The data provided by the present expe riments were though of highly relevance
for future development of hydroxylase inhibitors as potential therapy.
A stable HIF- 1α activates several processes involved in wound healing
In order to evaluate the tre atment efficacy with a stable HIF molecule a histological
analysis of diabetic wounds was perfor med on deparaffinized, rehydrated and
hematoxylin and eosin stained samples by two independent observers unaware of the
identity of the biopsy. A semiquantitative scor e to evaluate vascularity, granulation,
and dermal and epidermal re generation was used. The micro-vessel density was
measured using semi-quantitative – double blind analysis of the specific binding of
GS-1 isolectin to microvascular structures. All essential steps of wound healing were
improved by the treatment with either hydroxylase inhibitor or inoculation of the
stable over-expressed form of HIF- 1α (Fig. 5A and B).
Furthermore, the histological changes observed here were sustained by the increased
expression of HIF- α target genes encoding angiogenic cytokines (Fig. S4) also
previously reported by others (Bosch-Marce, Okuyama et al. 2007; Li, Li et al. 2007).
It is important to note that edema was not observed following the induced
angiogenesis. This observation is in agree ment with the phenotype of transgenic mice
over-expressing HIF (Elson, Thurston et al. 2001) and in c ontrast to the mice over-
expressing VEGF (Thurston, Suri et al. 1999) in the skin. The recruitment of
angiogenic cells is delayed in diabetic wounds (G allagher, Liu et al. 2007). Though, it
is not yet known if this is the result of a d ecreased mobilization or homing processes
at the wound level. The direct detection of angiogenic cells is limited by small
numbers usually present in tissues (Bosch-Marce , Okuyama et al. 2007). Therefore,
an indirect method to evaluate the recruitment of angiogenic cells to the wounds was

25 used. The levels of the cytokine receptor expression typically present on these cells
were measured. HIF- 1α stabilization was followed by an increase at the wound level
of these cytokine receptors (i.e., CXCR 4, C-Kit, Tie-2) (Fig. 5C).
Hence, the key point of present research is that hyperglycemia-induced destabilization
and inhibition of HIF- 1α is a central pathogenic mec hanism for delayed wound
healing in diabetes. HIF stabilization is e ssential and sufficient for improving wound
healing in diabetes.

26 Figure 1. Hyperglycemia destabi lizes and inhibits HIF-1 /g68/g68. (A) Immunoblots
detecting HIF-1 /g68 in db/db mouse primary fibroblasts cultured for 48 h in different
glucose concentrations (5.5 and 30 mM) and then exposed for 6 h in either normoxia
(21% O 2) or hypoxia (1% O 2). (B Left) Immunoblot detecting HIF-1 /g68 in renal
carcinoma cells (SKRC7) expressing functi onally inactive VHL cells (SKRC7). (B
Right) Relative expression of VEGF in human dermal fibroblast cells exposed to
different glucose concentra tions after transfection with VH L-specific siRNA or
scrambled siRNA. (C) Relative luciferase acti vity in the extract of 3T3 cells exposed
to different oxygen and glucose concentrat ions after co-transfection with CTAD
(GAL4/mHIF-1 /g68 722-822) or NTAD (GAL4/mHIF-1 /g68 531-584) and GAL-
responsive reporter gene plasmid (*, p<0.05, 5.5 mM glucose vs. 30 mM glucose).

27 Figure 2. Inhibition of HIF hydroxylases can reverse the glucose inhibition of
HIF-1 /g68/g68. (A) Immunoblots detecting HIF-1 /g68 in mouse db/db skin fibroblasts show
destabilization of HIF-1 /g68 in high glucose concentrations (30 mM). This effect is
overcome by treatment with hydroxylase inhi bitors (DMOG [2 mM] or DFX [100
/g80M]. (B) Hydroxylase inhibitors induce expression of HIF-1 /g68 target genes essential
for wound healing (DMOG [2 mM] or DFX [100 /g80M]) even in presence of high
glucose levels (*, p<0.05, treatme nt vs. control). (No, nomoxia (21% O 2); Hy,
hypoxia (1% O 2); G, glucose).

28 Figure 3. HIF-1 /g68/g68 function is negatively regulate d in diabetic wounds. (A)
Wounds in diabetic mice are more hypoxic than in normoglycemic control mice as
evaluated by pimonidazole adduct formation; note the detailed granulation tissue
(Inset). (B) Immunoblot detecting HIF-1 /g68 in a whole-cell extract from the wound of
diabetic or normoglycemic mice. (C) The expr ession of HIF target genes involved in
wound healing is down-regulated in wounds of db/db mice (*, p<0.05 expression in
db/db mice vs. normoglycemic litter-mates).

29 Figure 4. Local stabilization and activation of HIF1- /g68/g68 by hydroxylase inhibitors
of direct transfer of stabilized HIF im prove wound healing in diabetic mice.
(Top) The healing rate of full-thickne ss wounds in db/db mice is promoted by local
treatment with DMOG (2 mM; A1), DFX (1 mM; B1 ) or by adenovirus-transferred of
stable forms of HIF-1 /g68(V-N; C1), (V-NC; D1) compared with placebo or empty
virus (LacZ), respectively (values are means /g114 SEM; *P<0.05 db/db treated vs. db/db
placebo or LacZ). C1, Inset: virus expression at the edge of the wound as revealed by
/g69-galactosidase staining. (Lower) Repr esentative examples showing wound healing in
db/db mice treated as in Upper. (D). Immunoblot detecting HIF-1 /g68 in whole-cell
protein extracts from wounds. Note that inhibition of hydroxylase activity by local
treatment with either DMOG (2 mM) or DFX (1 mM) overcomes hyperglycemia-
dependent negative regulation of HIF-1 /g68.

30

31 Figure 5. Stabilization and activation of HIF-1 /g68/g68 in diabetic wounds is followed
by activation of granulation angiogenesis and recruitment of CAG. (A)
Hematoxylin and eosin staining shows im provement in the granulation tissue and
visualization of the wounds in db/db mice locally treated with DMOG (2 mM) or
DFX (1 mM) or by adenovirus-mediated expression of a stable HIF-1 /g68(V-N; original
magnification X25). (Right) Semiquanti tative evaluation for granulation,
angiogenesis, and dermal and epiderma l regeneration. Graphs represent means /g114
SEM. Vehicle-treated or empty virus trea ted (LacZ) normoglycemic heterozygous
diabetic db/db mice (gray bars), and DMOG, DFX, or HIF V-N treated homozygous
db mice (white bars) are shown (*, P<0.05) . (B) Left: vascular density in wounds
evaluated by Griffonia si mplicifolia 1 (GS-1) lectin staini ng is increased in the db/db
diabetic animals after treatment with DMO G (2 mM), DFX (1 mM), or V-N. (Right)
The semiquantitative evaluation of vessel density evaluated by GS-1 lectin staining.
Vehicle-treated or LacZ-treated homozygous diabetic mice (gra y bars), and DMOG,
DFX, or V-N-treated homozygous diabetic mice (white bars) are shown. Graphs
represent mean /g114 SEM. (*, P<0.05). (C) Local tr eatment with DMOG, DFX, or V-N
in wounds of diabetic mice increases mRNA expression of cytokine receptors
typically present on CAG (*, P<0.05 treated vs. placebo or LacZ).

32

Figure S1. Repression of expression of HIF-1 /g68/g68 target genes essential for wound
healing in db/db fibroblasts by high glucose levels. (#, P<0.05 hypoxia vs.
normoxia in 5.5 mM glucose, *, P<0.05 30 mM glucose vs. 5.5 mM glucose in
hypoxia).

Figure S2. Hydroxylase inhibitors (DMOG or DFX) ar e able to counteract the
hyperglycemia-depende nt VEGF repression even in hypoxia (*, P<0.05 vs.
hypoxia 30 mM). No, normoxia (21% O
2); Hy, hypoxia (1% O 2); G, glucose.

33 High glucose and/or hypoxia increase the mitochondrial RO S production in
HDFs.
Fibroblasts are well recognized as important effectors involved in chronic
complications in diabetic skin and wound healin g (Ngo, Hayes et al. 2005). The
glucose transport across the plasma membr ane of human fibroblasts (HDF) is
mediated by at least three genetically distinct facilita tive glucose transporters
(GLUT), i.e. GLUT-1, -3 and -4 (Lon go, Bell et al. 1990). Thus, oxidative damages
induced in diabetic environment may targe t fibroblasts, also. Hyperglycemia and
hypoxia gathered increasing pathogenic significance related to oxidative damage in
diabetes. Therefore, the ROS production was evaluated in HDF cultured in
hyperglycemia and hypoxia (figure 6A). Carboxy-methyl-H 2DCFDA was used as
ROS detector. The probe is an ester compound that loses the acetate groups when
cleaved by esterases after cell entry. The cleavage leads to intracellular trapping of the
nonfluorescent 2’,7’ -dichlorofluorescein (DCF) that b ecomes highly fluorescent when
is oxidized. Thus, a wide spectra of ROS can be detected (Wardman 2007). High
glucose and hypoxia induced each other the ROS production. Though, their
combination only was able to generate the highest level of ROS in HDF (Figure 6A
upper panel). Because of its relative less specifici ty, the quantity of the probe oxidized
does not reflect the amount of free ra dicals generated. Though, the level of H 2DCFDA
oxidation may at least represent a quali tative tool to compare the intracellular oxidant
formation between different cellular conditions. He nce, it may suggest that the ROS
levels are highest when the cells are exposed to hyperglycemia and hypoxia in
combination. Moreover, along with its re lative lack of specificity in terms of what
ROS are generated, the level of H 2DCFDA oxidation does not necessarily reflects
where these species are originating. Therefore, HDFs were cultured in normal and
high glucose concentrations in the presence or absence of carbonyl cyanide m-
chlorophenyl hydrazine (CCCP), an uncoupler of mitochondrial respiration. At the
end of the incubation period under different experimental conditions, the cells were
loaded with MitoSOX Red, a mitochondria se lective superoxide indicator (Batandier,
Fontaine et al. 2002). The excessive ROS production was specifically blocked from
cells exposed to CCCP, demonstrating that it originates in mitochondria (figure 6A
lower panel). These data suggest a dose-dependent effect of ROS on mtDNA stability.

34 In other words, the highest level of mtDNA damage was observed only in cells
exposed to the combination of hyperglyce mia and hypoxia, where ROS reach the
highest concentrations (Figure 6A upper panel). Further more, the critical influence of
ROS levels for inducing mtDNA damages was co nfirmed by the cumulative effect of
H2O2 concentrations on the mtDNA da mage (figure 6B Inset). A similar observation
was also reported by others in differe nt context (Yakes and Van Houten 1997).
Moreover, it has been reported that mtDNA stabili ty is altered either by glucose alone
but only at extreme high concentrations (Li, Mei ninger et al. 2001) or when the time
of exposure is long enough to permit accumulat ion of sufficiently high levels of ROS
(Palmeira, Rolo et al. 2007). As the combina tion of high glucose and hypoxia,
palmitate is another factor potentially re levant for the complications in diabetes that
has been shown to induce probably ROS media ted mtDNA damages in vitro (Rachek,
Musiyenko et al. 2007). Though, the present study is the first observation that
pathogenic mechanisms relevant in diabetes (i.e., hyperglycaemia and hypoxia) can
induce mtDNA lesions through mitochondrially produced ROS.
High glucose and/or hypoxia in duce mtDNA damage in HDFs.
MtDNA stability against excessive ROS pr oduction was evaluated in HDFs cultured
in different glucose concentrations and oxygen tensions using long DNA targets by
quantitative polymerase chain reaction (qPCR) (Santos, Meyer et al. 2006). The
method rely on the fact that lesions in long mtDNA fragments will slow down or
block the progression of DNA polymerase on template that results in the decrease in
DNA amplification in the damaged template when compared with the undamaged
DNA. In order to correct for the va riations in mitochondrial copy number, a short
mtDNA fragment was amplified by an addit ional reaction. After amplification, both
mtDNA fragments were quantified using a hi gh sensitive fluorescent dye. The ratio
between absolute amplification values for the large and small mtDNA fragments
defines the normalized amplification. Assumi ng a random distribution of lesions and
using the Poisson equation for non-damaged templates, the average lesion frequency
per strand expressed the ac tual mtDNA damage (Yakes and Van Houten 1997). For a
better accuracy, the num ber of mitochondria was also ev aluated by quantitative real-
time polymerase chain reaction.

35 As for the ROS overproduction, when compared with normal conditions
(normoglycemia and normoxia), mtDN A normalized damage was significantly
increased only in HDFs cultured in th e combination between high glucose and
hypoxia (figure 6B). To validate the sensitivity of the long fragment PCR
amplification method to detect mtDNA lesions , HDFs were exposed to increased
concentrations of H 2O2 as exogenous donor of ROS. The treatment with H 2O2 results
in a dose dependent increase of the normalized da mage in mtDNA (Inset). In order to
verify if the source of increased ROS pr oduction observed in hyperglycemia and
hypoxia together is mitochondria, the cells were cultured in these conditions with or
without CCCP and mtDNA damage was c ompared with normal conditions (figure
6C). The lack of the excessive accumulat ion of mtDNA lesions in hyperglycemia and
hypoxia if the respiratory chain is bloc ked with CCCP certify the mitochondrial origin
of increased ROS product ion in these states. Again, these data confirm for the first
time that pathogenic mechanisms relevant in diabetes (hyperglycemia and hypoxia)
can induce mtDNA damage through mitochondria-produced ROS (figure 6C).
In spite of increased ROS levels, db/db mice accumulate less mtDNA lesions in
heart and kidney.
It is well known that diabetes targets certa in tissues. Among them, the heart and
kidney are classically affected. On the other hand, the leptin receptor deficient db/db
mouse is a very consistent validated animal model for the study of type 2 diabetes.
That is because the db/db mouse progressive ly develops obesity, insulin-resistance
and type 2 diabetes after 12 weeks of age. The animal model used here – db/db mice
at different ages, has though some essential advantages in comparison with other
observations (Liang, Hughes et al. 1997; Garcia-Ramirez, Francisco et al. 2008).
First, the animals originate fr om breeding pairs as an inbre d strain, therefore having a
homogenous genetic background. Second, they have different ages that allow a clear
control over the time of exposure of the tissues to diabetes. The “young” (10 weeks)
animals were young- enough before diabetes occurs, while the “old” (34 weeks) ones
were old-enough to develop specific diabetes-r elated chronic complications. In other
words, if the estimated life expectancy for db/db mouse is about 2 years (i.e. 104
weeks), the mean duration of chronic hy perglycemia for “old” db/db mice was
therefore about 20 weeks. That is around 1/5th from the estimated lifetime expectancy.

36 When compared to mean life expectanc y of 70 years for a human subject with
diabetes, 1/5th means about 14 years of exposure to chronic hyperglycemia.

The normalized damage in long fragments of mtDNA from heart and kidney of both
“young” and “old” diabeti c mice and their age -matched controls was therefore
estimated in the present study (figure 7A lower panel). The incidence of mtDNA
damage was not increased in control “old” non -diabetic animals, while significantly
less mtDNA damage was observed in both heart and kidney from “old” db/db mice
when compared either with young animals or with non- diabetic “old” littermates
(p<0.01). This apparent surprising re sult needs to rule out some possible
methodological errors. First, an eventual bias from a selection after mitochondrial
drop-out was excluded, as no differe nce in mitochondria numbers is found (data not
shown). Second, an additional valida tion of the long fragment QPCR method to
evaluate the mtDNA damage in vivo was performed. The animal model used was the
knock-in mice expressing an exonuclease -deficient version of the mtDNA polymerase
γ (PolgD257A) (PolgAmut/PolgAmut) (Trifunovic, Wredenberg et al. 2004) and their
heterozygous knock-in mice ( +/PolgAmut), also at different ages (9 and 24 weeks,
respectively), in order to control over the time of exposure of the mtDNA to age. The
heart of these animals ha s been described to accumula te the highest leve ls of mtDNA
damages with age (Trifunovic, Wredenberg et al. 2004). Hence, the widespread
damage of mtDNA in hearts of PolgAmut/PolgAmut mice was measured. A significant
increase of the mtDNA damage with age (p =0.025) was observed (figure 7 A upper
panel).

Thus, mtDNA stability in both tissues analyzed exhibited similar behavior. The result
has consistency, as either hearts or kidne ys are preferential targets for chronic
complications of diabetes and have differ ent numbers of mi tochondria. The present
observation may have therefore more releva ncies compared to former data obtained in
peripheral blood mononuclear cells (PBMC ) (Kamiya and Aoki 2003; Garcia-
Ramirez, Francisco et al. 2008). Low mutag enicity of ROS in ageing cells was though
previously reported (Shokolenko, Venediktova et al. 2009) and may validate the
present result. In the same line is the fa ct of increasing evidence attesting an
overestimated susceptibility of mtDNA to the accumulation of oxidative base
substitution (Anson, Hudson et al. 2000). Furt hermore, it seems that there is no

37 typical age-dependent mtDNA lesions in a nimals without diabetes (Wang, Wong et
al. 1997; Bender, Krishnan et al. 2006). The observ ation is in line with the decrease of
mtDNA damage in “young” db/db mice re ported in the present study. On the other
hand, the lack of mtDNA damage in non diabe tic mice at the same age was also
recently reported (Lee, Choi et al. 2010) but identified in older animals (18 months).
Taking together, all these data demons trate that the method used here is sensitive
enough to detect the classical age related mtDNA damage.
Further, the levels of ROS were measur ed in hearts and kidneys from db/db mice and
their age-matched controls. For this purpose the levels of nitrosylation were evaluated
in tissue samples. Peroxynitrite is conside red the main reactive species that is
responsible for the nitrosylation of the tyrosine residues from proteins in vivo,
generating 3-nitrotyrosine (3-NT). Though, there is data suggesting in vivo
peroxynitrite-independent nitrosylation of proteins that occurs especially in
inflammatory processes (Gaut, Byun et al. 2002; Duncan 2003). Nitric monoxyde
(NO) may react with oxygen ge nerating nitric dioxide (NO 2), a compound with a high
oxidative potential. Though, NO 2nitrosylation of tyrosine is less probable to occurs in
vivo (Crow and Ischiropoulos 1996). Two main re ason may explain this fact. One is
that the reaction is very slow: 25 nM of NO 2needs 0.7 h to be generated from NO.
Second, NO 2nitrosylation of tyrosine has very less efficiency. Though, it may
generate 3-NT in acidic environment, such is the gastric cavity (van der Vliet,
Eiserich et al. 1996). That is why the levels of nitrosylation of tyrosine residues may
be considered a direct consequence of increased levels of peroxynitrite production,
mainly from the reaction between nitric ox ide and superoxide (Ceriello, Mercuri et al.
2001).
Thus, the hearts of the “ old” db/db mice were exhibit higher levels of nitrosylation of
the protein tyrosine residues (figure 7B), in spite of the lower incidence of mtDNA
damage. High levels of ROS production in the organs analyzed may also be
confirmed by up-regulation of the two major antioxidant enzymes SOD isoenzyme –
SOD 2 and CAT. In this line is the observation that both CAT and SOD 2 activity is
increased in cells chronically exposed to high glucose concentrations (Weidig,
McMaster et al. 2004). The incr eased activity of SOD 2 but not CAT only in hearts but
not in kidneys observed in the present study (figure 8) may reflect a specific tissue

38 modulation of the antioxidant enzymes. Such data were already reported in other
animal models (Esposito, Melov et al. 1999; Kowluru, Kowluru et al. 2006).
Furthermore, the differences in antioxidant acti vity of the enzymes were not reflected
in a different tissue accu mulation of mtDNA damage, as it was previously reported in
a different scenario (Esposito, Melov et al. 1999).
The “old” db/db mice exhibit an increased mitocho ndrial base excision repair
(BER) system.
MtDNA uses the base excision repair (BER) system for repairing most lesions that are
generated endogenously or by environmental agents (Hegde, Hazra et al. 2008). This
pathway represents the second line of defense against oxidative stress for mtDNA.
The repairing machinery involves seve ral excision steps that, along with ROS,
generate apurinic/apyrimidinic (AP) sites. AP-endonuclease (APE) repairs AP sites
generated by both ROS and excision steps. That is why APE is a key enzyme in this
process.
APE activity was therefore analyzed in mitochondrial extracts from the hearts of the
“old” db/db mice (Figure 9A, upper and middle panels). An increased specific activity
was observed. The APE up-regulation may be a possible explanation the lower
amount of mtDNA lesions accumul ated in these mice. It has to be noted that this is
observed in “old” but dia betic animals. The observation deserves to be underlined, as
the decrease in the BER activity with age ha s been reported both in mice and humans
(Chen, Hsieh et al. 2003; Imam, Karahalil et al. 2006). It is not clear why this it
happens in diabetes. One possible explanation is that in diabetic environment the
mitochondrial aggression by ROS triggers a retrograde signaling from the
mitochondria to the nucleus resulting in some protective effects. The phenomenon
was previously described for the anti -apoptotic response in transgenic mice that
develop cardiomyopathy due to the accumul ation of mtDNA mutations specifically in
the heart (Mott, Zhang et al. 2001). Thus, in these animals the mechanism of
pathogenesis does not involve increased oxidative stress. On the contrary, the mtDNA
mutations induce a cytoprotective response including increases in pro-survival
proteins that specifically inhibit apoptosis. Thus, a signaling pathway between the

39 mitochondrion and the nuc leus could mediate the pathogenic ef fect of mitochondrial
DNA mutations.
Furthermore, the APE was not induced after a 48-h exposure to hyperglycemia and a
48-h additional exposure to hypoxia (Figure 9A, lower panel). That could mean that
the induction of the APE needs probably a chronic exposure to ROS, at least in
diabetic environment.
In conclusion, the present study shows for the first time that hyperglycemia and
hypoxia, together, are able to induce mtDNA damage through induction of
mitochondrial ROS production. The pathogenic mechanism was successfully
compensated for in diabetic animals, possibly by the repair mechanisms and therefore
may not represent a major factor for the development of chronic complications.

40 Figure 6. High glucose and/or hy poxia increase the mitoc hondrial reactive
oxygen species production a nd induce mitochondrial DNA (mtDNA) damage in
human dermal fibroblasts. Human dermal fibroblasts were exposed to different
glucose concentrations and oxygen tensions (< 1% for hypoxia) in the presence or
absence of an uncoupler of mitochondrial respiration – carbonyl cyanide m-
chlorophenyl hydrazone. (A) Re active oxygen species production as evaluated by
CM-H2DCFDA (upper panel) or MitoSOX Red fluorescent probe (lower panel) is
expressed in fluorescence units as pe rcentage of control. Values are mean /g114 standard
error of mean (SEM) from 9 to 21 observations. *p<0.05, Bonferoni test versus
control; #p<0.05 versus normoxia and high glucose . (B) mtDNA integrity is measured
as normalized damage in long frag ments. Upper panel: Values are mean /g114 SEM from
nine observations. Analysis of variance one way (Bonferoni test versus control).
*p<0.05. Inset: A dose-dependent increase of normalized damage frequency in
mtDNA is induced by treatment with H2O 2. Cells grown in normal glucose
concentration and normoxia were exposed for 30 min to different concentrations of
H2O2. Values are mean /g114 SEM from six observations. Lowe r panel: In the presence
of carbonyl cyanide m-chlorophenyl hydraz one, mDNA integrity is preserved. Values
are mean /g114SEM from four to five observations. *p<0.01.

41 Figure 7. Db/db mice accumulate less mitochondrial DNA (mtDNA) lesions in
the heart and kidneys despite increase in reactive oxygen species. (A) Normalized
damage in the long fragment (10 kB) of mtDN A from heart (lower left panel) and the
kidney (lower right panel) in “old” and “young” db/db mice compared with their age –
matched controls (heterozygotes). Values are the mean /g114 standard error of the mean
from eight observations. Analysis of varia nce one way (Tukey test) between groups:
*p<0.001 for heart and p<0.003 for kidney versus control. Note instead a significant
(p=0.025) increase of damage in mtDNA fragments from mtDNA mutator mice hearts
(upper panel). Values are mean /g114 standard error of the mean from four observations
(t-test versus control). (B) Whole tissue homogena te from the hearts of “old” db/db
mice and their age-matched litt ermates were prepared and analyzed by competitive
chemiluminescence enzyme-linked immunos orbent assay for nitrosylated proteins.
Graph shows the nitro-bovine se rum albumin equivalents ( /g80g/ml) from seven
different samples. *p<0.001 (t-test).

42 Figure 8. Specific activity of serum sup eroxide dismutase 2 and catalase is
different in the tissues of db/db mice. Enzymatic activity for superoxide dismutase 2
(A) and catalase (B) in the heart and kidney from “old” and “young” db/db mice
compared with their age-matched controls. Values are mean /g114 standard error of the
mean from 8 to 12 observations. *p<0.05 (analysis of variance one way).

43 Figure 9 . The mitochondrial base excision repair system is increased in the “old”
db/db mice and is not modulated in mito chondrial fractions isolated from human
dermal fibroblasts exposed to hyperglycemia and hypoxia. (A). Mitochondrial
extracts were isolated from “ old” db/db mice heart and their age -matched littermates
and from human dermal fibroblasts cultured 48 h in hyperglycemia and 48 h
additional in hypoxia. Equal amounts of mouse (upper panel) and human (lower
panel) mitochondrial protein extra cts were incubated with labeled tetrahydrofuran
substrate for 1 h at 37 /g113C. Formamide (80%) was added to the mix to stop reactions,
and the reaction products were analyzed by electrophoresis in 25% polyacrylamide, 8
M urea gels. Repaired substrate (arrow) is quantified as perce nt versus control (A1,
lower panel). Values represent means of OD /g114 standard error of the mean for three
observations. Human apurinic/apyrimidinic endonuclease or mitochondrial protein
extract was used as negative control. *p= 0.045 (t-test). (B) and (C). Purity of the
mouse (upper panels) and human (lower pane ls) mitochondrial extracts was verified
by immunoblotting against c-AMP response element binding protein (B) and by
lactate dehydrogenase activity assay (C).

44 Section I –Original Contributions
I.2. Evaluation of the antioxidant status and oxidative stress in the serum and
erythrocytes of patients with different stages of diabetes mellitus, especially at
the first medical onset

45 I.2. Evaluation of the antioxidant status and oxidative stress in the serum and
erythrocytes of patients with different stages of diabetes mellitus, especially at
the first medical onset –the state of the art
I.2.1. Antioxidant status of the blood
An antioxidant system exerts its specific effect by stopping a radical reaction or
stabilizing a free radical (Gutteridge and Halliwell 2007). The antioxidants are most
convenient divided into two categories, i.e. en zymatic and non-enzymatic. The latter
are further classified as hydrophylic and ly pophylic (Gutteridge and Halliwell 2007).
I.2.1.1. Enzymatic antioxidants The enzymes act as antioxidants have intra-cellular distributi on. The antioxidant
enzymes essentially involved in the meta bolism of superoxide anion and peroxide
consist of: superoxid dismutase (Lipcsey, Soderberg et al.), catalase (CAT),
glutathion peroxidase (GPx) and peroxyredoxins (Prdx).
Superoxid dismutase (Lip csey, Soderberg et al.) catalyzes the dismutation of
superoxide anion to anion peroxide, as follows: O
2/g120/g16 + O 2/g120/g16+2 H+/g198 H2O2 + O 2.
Three SOD iso-enzymes has been described in humans: the cytosolic Cu,Zn-SOD
(SOD 1), the mitosolic Mn-SOD (SOD 2), and the extracellular SOD (SOD 3). In the
catalytic center of the enzyme, the copper is essential, while zinc only stabilizes the
protein (Fridovich 1995) .It seems that SOD 2is essential for survival, as the knock-out
mice die few days after born by renal failure (Lebovitz, Zhang et al. 1996) .The
resulting hydrogen peroxide (H 2O2) is furthermore essentially neutralized by
combinant action of CAT and Prdx.
Catalase (CAT) is essential for the neutralization of the H 2O2. Several mutations
have described in certain diseases, such as diabetes mellitus, hypertension or vitiligo
(Goth, Rass et al. 2004).

46

Peroxidases also neutralizes the H 2O2, using different substrates as reductive agents,
as follows: H 2O2 + DH 2 /g198 D + 2H 2O. When the reduced gluthathione (GSH) is used,
the enzymes are called gluthathione peroxidases (GPx).

Gluthathione peroxidases (GPx) are selenium dependent antioxidant enzymes that
might neutralize various pe roxides, and include at least four different families. They
generate the oxidized gluthathione (GSSG ) that has to be further reduced by
gluthathione reductase (GRed) – a NADPH dependent antioxidant enzyme. As the
NADPH mainly originates from the pentoses pa th, the intra-cellular level of GSH is
essentially dependent by this metabolic shunt. The first GPx iso-enzyme (GPx 1) is
considered the most important member of the family, probably due to its
mitochondria expression and the pr esumed protection against free-radicals damage
(Legault, Carrier et al. 2000).

Gluthathione transferase (GST) is essential for the neutralization of different
organic peroxides by reduced gluthathione (GSH) (Vos and Van Bladeren 1990). The
GSH regeneration is also mediated by g luthathione reductase that is a process
dependent of intra-cellular concentration of NADPH de rived from pentose pathway.

Peroxyredoxines (Prdx) consist of six types of cysteine dependent antioxidant
enzymes that are organized in three different categories, in accordance with their
common function – that also is the peroxides-neutraliza tion (Rhee, Chae et al. 2005).
Their ubiquous cellular distribution highly sugg ests a paracrine-type of peroxide-
neutralization (Wood, Sc hroder et al. 2003). The cystein e along with thioredoxin and
NADPH are essential cofactors for the Prdx en zymatic activity (Rhee, Chae et al.
2005).

The erythrocytes (RBCs) are permanently exposed to significant levels of
superoxide anion essentially derived from hemog lobin (Hb) (Sadrzadeh, Graf et al.
1984). From this perspective the enzymes neutralizing this particular free radical are
essential for the RBCs function and stability. Hence, the erythrocytes contain CuZn
SOD (EC 1.15.1.1) – SOD 1, catalase (EC 1.11.1.6), – CAT, seleno-dependent

47 gluthathion peroxidase (EC 1.11.1.9) – GPx, and gluthathion transferase (EC
2.5.1.18) – GST. The pentose pathway is therefore essential in these cells as NADPH
is essential for gluthathione regeneration.
I.2.1.2. Non-enzymatic antioxidants in plasma are essentially divided in two main
groups, i.e. water – soluble (mainly albumin, uric ac id, bilirubin and thiols), and lipid
–soluble (especially tocopherols, ubiquinone, and carotenoids). The efficacy of the
antioxidant response is a difficult issue. On on e side, there is always a dynamic
interaction between the specific internal de posits, dietary source and intensity of the
free radical aggression. On the other hand, the cooperative interactions between
different antioxidants at a certain state ex plain the synergistic effect that provide
better protection against free radical a ggression than any single antioxidant alone
(Packer, Slater et al. 1979). There is a ge neral agreement that a lbumin, uric acid and
bilirubin are the most important components of the antioxidant defence in plasma.
Bilirubin has controversial antioxidant effects. In vitro studies (Stocker 2004) suggest
either the scavanger efficiency against peroxyl radicals of unconjugated bilirubin or
the ineficiency of conjugated bilirubin as sc avanger against superoxide anion and
hydrogen peroxyde. In vivo studies has been shown that, when in normal range for
healthy adults, the conjugated bilirubin efficiently scavanges peroxyl radicals and
protects fatty acids against oxidation (Stocke r, Glazer et al. 1987). Furthermore,
several epidemiological studies (Bre imer, Wannamethee et al. 1995; Mayer 2000)
suggest a decrease in cardiovascular risk with lower plasma bilirubin concentration.
Uric acid (UA) is responsible for about 1/3rd of plasma total antioxidant capacity
(Waring, Maxwell et al. 2002). Depending of its concentrations and the oxidative
status of plasma, UA might act either as a ntioxidant. The hydroxyl and peroxynitrite
radicals neutralization is mainly responsible for the antioxidant effect of UA (Scott
and Hooper 2001). Especially when excessive the UA is pro-oxidant by several
mechanisms. Along with reduced copper accelerates LDL oxidation (Bagnati,
Perugini et al. 1999); with peroxynitrite furth er generates aminocarbonyl radical, thus
accelerating initial tissue damages (Sa ntos, Anjos et al. 1999); ac tivates platelets and
increases the risk of thrombosis in patients with coronary heart disease (Johnson,
Kivlighn et al. 1999). Recent studies have suggested that hyperuricemia is a risk

48 factor for cardiovascular disease (CVD) in the genera l population (Meisinger, Koenig
et al. 2008) and may play a causal role in the development of metabolic syndrome
(Nakagawa, Hu et al. 2006). Hypouricemia ma y be encountered in patients with either
type 1 (Shichiri, Iwamoto et al. 1987) or type 2 diabetes (Shichiri, Iwamoto et al.
1990). The condition reflects an increased of uric ac id renal clearance and occurs only
in patients with normal GFR levels (Shichiri, Iwamoto et al. 1987).
Albumin encounters for more than 70% of seru m antioxidant activity (Bourdon and
Blache 2001). The main mechanism behind the antioxidant proprieties of albumin
consists in its ability to bind various mol ecules (Peters 1996). Essentially, the albumin
is always an antioxidant; it ne ver has pro-oxidant activity. Currently, it is accepted
that three essential factors contributes to antioxid ant abilities of a lbumin (Halliwell
and Gutteridge 1990; Roche, Rondeau et a l. 2008), i.e. its capacity to bind transitional
metals; its propriety to scaven ge free radicals that is mediated by several active sites
located in specific amino acidic residues; and it s structural integrity. It has to be noted
that the structural integrity of the albumin molecule has only recently accepted as
essential for its antioxidant proprieties. Hence (K agan, Tyurin et al. 2003), a change
in the protein conformation that is induced by either excessive binding of free fatty
acids (i.e. diabetes or pre-eclampsia) or hy perglycemia mediated glycosylation (i.e.
diabetes) might induce protein bind copper disch arge. Thus, the plasma free copper
concentration increases that arguments its availability for redox reactions therefore
consuming plasma antioxidants.
I.2.2. Antioxidant status of the blood in type 2 diabetes
The chronic hyperglycemia, as the main metaboli c characteristic of type 2 diabetes,
generates excessive reactive oxygen spe cies (ROS) that virtually affects all the tissues
and organs, including the pancreatic β-cells (Newsholme, Haber et al. 2007).
Excessive oxidative damage specifically deteriorates pancreatic β -cell, therefore
essentially contributing to the pathogenesis of diabetes (Kaneto, Katakami et al.
2007). Type 2 diabetes angiopathy, both mi crovascular or macrovascular, is
essentially associated with ox idative stress (Giuglia no, Ceriello et al. 1996). Though,
it is generally accepted that in diabetic environment the chronic hyperglycemia is
associated with increased oxidative stre ss (Wright, Scism-Bacon et al. 2006). It also a

49 general agreement about the fact that the antioxidant systems are involved in redox
regulation of the cell acting as the major tools to neutralize the oxidative stress and
therefore protecting the cells from oxidative stre ss-induced damages. Furthermore, the
contribution of the imbalanced redox mecha nism to the diabetes pathogenesis or its
specific complications has been already ra ised (Ceriello 2000; Opara 2002). However,
the antioxidant status of plasma in type 2 diabetic patie nts remains controversial
(Lodovici, Bigagli et al. 2009; El Boghdady and Badr 2012). The controversy persists
also as essential issue in patients with type 2 diabetes, in early stages – i.e. at the first
medical onset – meaning those of no previous medical history of type 2 diabetes – or
wihtout apparent evidence of specific chronic complications (Guldiken, Demir et al.
2009; Lodovici, Bigagli et al. 2009; El Boghdady and Badr 2012).
The nature of this c ontroversy is though difficult to be explained. On one side it might
be the fact that in diabetes different types of (plasma) antioxidants may be generated
in response to specific types of ROS produced in a certain cellular or tissular state
(Halliwell and Gutteridge 1995). On the other side the differences may reside in the
type of method used to measure a specific anti oxidant (Feillet-Coudray, Rock et al.
1999). Hence, such type of differences were previously described in experimental
diabetes and were correlated with the plasma levels of vitamin E (Feillet-Coudray,
Rock et al. 1999).

It has been previously shown in type 2 diabetes that oxidative damage is different in a
certain cell or organ and is more expr essed in tissues with high metabolic demans,
such as blood cells (Sailaja, Baskar et al. 2003). From this perspective the red blood
cells (RBCs) are essential effectors of the defense system against oxidative stress in
blood (Prior and Cao 1999). Rece nt data raised showing that in pa tients with late type
2 diabetes, the RBCs are exposed to hig her oxidative damage and expressed a
decreased life span (Calderon-Salinas, Munoz-Reyes et al. 2011; Maellaro, Leoncini
et al. 2011). It is well established that the erythrocytes possess enzymatic and non-
enzymatic antioxidants that protect the cell from the damages induced by ROS
overproduction. If the importance of supe roxide anion for the chronic complications
in diabetes is considered, than the study at least three enzymes – the superoxide
dismutase (Lipcsey, Soderberg et al.) that converts superoxide into hydrogen
peroxide, together with the glut athione peroxidase (GPX) and catalase (CAT) that
convert hydrogen peroxide to water – might be significant. Hence, all these

50 antioxidant enzymes in blood have been reported as markers of vasc ular injury in type
2 diabetes (King 2008). Thought, data about th eir activities are still conflicting
(Sundaram, Bhaskar et al. 1996; Peuchant, Delmas-Beauvieux et al. 1997; Kesavulu,
Giri et al. 2000; Seghrouchni, Drai et a l. 2002). Furthermore, when data about the
non-enzymatic antioxidant capacity in RBCs are analyzed, very few reports are
available (Calderon-Salinas, Munoz-Reyes et al. 2011; Maellaro, Leoncini et al.
2011) that refers to patients with late type 2 diabetes.
I.2. Evaluation of the antioxidant status and oxidative stress in the serum and
erythrocytes of patients with different stages of diabetes mellitus, especially at
the first medical onset –original contribution beyond the state of the art
Another important domain of my research act ivity is the evaluation of the antioxidant
status and markers of oxidative stress (i.e., total antioxidant capacity – TAC, different
antioxidant enzymes) in the serum and erhytrocytes (red blood cells – RBCs) of
patients with different stages of diabetes mellitus, especially at the first medical onset
–meaning those of no previous medical history of type 2 diabetes (T2DM).
I have shown that TAC increases in the serum a nd RBCs of the patients with early
T2DM (at first clinical onset or with no evidence of chronic complications) when
compared with the standard antioxidant power of a water soluble equivalent of
vitamin D (TROLOX). I therefore here made the first observation on the TAC
alteration in human RBCs in diabetes. Furthermore, I was able to show that specific
antioxidant capacity (i.e., the activity of SO D and CAT) increases in the erythrocytes
of the patient with T2DM at first clinical onset, and occur even in RBCs with a
decreased life span (i.e., increased caspase-3 activity).
Oxidative stress and total an tioxidant status of plasma increased in patients with
early type 2 diabetes.
The levels of ROS were evaluated in blood samples of all subjects included in the
analysis (i.e. subjects without diabetes – as controls, and patients with type 2 diabetes
either at first clinical onset or without evidence of diabetes-related chronic
complications – as target group) by measuring th e concentration of lipid peroxides.

51 The plasma instead of serum was used to estimate oxidative stress parameters having
in mind the fact that the platelet activation is followed by free radicals release (Leo,
Pratico et al. 1997). There is sufficient data showing that lipid peroxides are essential
effectors of the ROS-mediated oxidative damage. Furthermore, the measurement of
malondialdehyde (MDA)-TBA adduct is a wide-accepted and validated method used
for the quantification of lipid perox idation (Kedziora-Kornatowska , Luciak et al.
1998), and recently have been shown that it positively correlate s with type 2 diabetes
duration, irrespective of age, ge nder, HbA1c and plasma SOD (Nakhjavani,
Esteghamati et al. 2010). ROS overproducti on was documented in plasma samples of
all patients included in tar get group, either diabetic pa tients at first clinical onset
(figures 10 B) or without evidence of chronic complications (figures 11 C).

As already mentioned, the effect of a ntioxidants in human plasma is synergic
(Valkonen and Kuusi 1997). Hence, the total antioxidant capacity (TAC) of a sample
better estimates the free radica l neutralizing efficacy when compared to any specific
activity of a certain antioxidant prese nt in that sample. Though, the plasma also
contains some traceable compounds that migh t influence its oxidative status, such is
ascorbic acid, vitamin E, and flavonoids. Th eir specific activity may be better
expressed by the antioxidant gap (GAP) or the residual antioxidant activity. That is
calculated by subtracting the antioxidant acti vity of albumin and uric acid (the
principal antioxidants in human plasma) from the total antioxidant capacity.

The total and residual antioxidant capacity wa s therefore estimated in plasma of all
subjects included in the analysis. A signi ficant increase of TAC and GAP was
observed in patients with diabetes (figure 10 A and figures 11 A and 11 B). These
results are in line with previous data publi shed in plasma of late type 2 diabetic
patients, where a similar incr ease was observed irrespective of chronic complications
(Guldiken, Demir et al. 2009; El Boghdady and Badr 2012). Thus, TEAC was
increased in plasma of patie nts with type 2 diabetes and pe ripheric neuropathy when
compared to subjects without diabetes (El Bo ghdady and Badr 2012) and also in
plasma of patients with type 2 diabetes and stroke when compared to subjects (with or
without type 2 diabetes) without cerebrovascul ar events (Guldiken, Demir et al.
2009). The method used was similar with that in the present study. That might be of
importance if the heterogeneity of the reports about antioxidant status of plasma in

52 diabetes is considered. Thus, it is well known that plasma antioxidant status can vary
depending of which antioxidant is pr edominantly detected by the method used
(Feillet-Coudray, Rock et al. 1999). In experimental diabetes such differences were
observed and correlated with plasma levels of vit amin E (Feillet-Coudray, Rock et al.
1999).
Figure 10. Oxidative stress and total an tioxidant status of p lasma increases in
early type 2 diabetes patients. Plasma from type 2 diabetes patients at first clinical
onset and from non-diabetes age-matched subjects was evaluated for Trolox
equivalent antioxidant capacity (TEAC) (A ) and malondialdehyde-thiobarbituric acid
(MDA-TBA) adducts (B). Values are mean /g114 SE. *P<0.01, #P<0.001 vs. controls
(analysis of variance Kruskal-Wallis test).

53

Figure 11. Total and residual p lasma antioxidant activities and plasma
concentrations of peroxid e, albumin, and uric ac id in patients with
uncomplicated type 2 diabetes and healthy control subjects. (A) Total antioxidant
activity; (B) residual antioxidant activity; (C) lipid peroxides; (D) albumin and uric
acid. ABTS, 2,2’ -azino-bis(3-ethylbenzothi azoline-6-sulphonic acid); MDA,
malondialdehyde. Data presented as mean /g114 SE. The entire study cohort is not
included in all graphs due to sample hemoly sis or exclusion of outliers (mean /g114 2
SD).

54 Oxidative stress and tot al antioxidant status of RBCs is increased in type 2
diabetes patients at first clinical onset.
Recent evidence suggest that the erythrocytes (RBCs) are mainly targeted by
oxidative damage in patients with type 2 diabetes (Jay, Hitomi et al. 2006).
Furthermore, it has been shown that, as pr obably the most proeminent cellular
components of the blood tissue, the RBCs ar e essential effectors of the defense
system against oxidative stress in blood str eam (Ahmed, Naqvi et al. 2006). As
previously mentioned, the erythrocytes are permanently exposed to significant levels
of superoxide anion essentially derived from he moglobin (Sadrzadeh, Graf et al.
1984). Moreover, the present da ta have shown that lipid pe roxidation is increased in
plasma of patients with diabetes (figures 10 B and figures 11 C), suggesting that the
blood cells, and therefore the RBCs, are exposed to an environment with excessive
free radicals production. On the other hand, it has been re ported that the erythrocytes’
membrane is permeable to free radicals, i.e. sup eroxide anion and hydrogen peroxide
(Lynch and Fridovich 1978; Mathai and Sitaramam 1994).
Thus, the magnitude of lipid peroxidation a nd non-enzymatic antioxidant activity in
RBCs of subjects with type 2 diabetes at first clinical onset was investigated. The
malondialdehyde (MDA)-TBA adduct and the Trolox equivalent antioxidant capacity
(TEAC) respectively, were therefore measured. A significant increase of
malondialdehyde (MDA)-TBA adduct (figure 7 B) and TAC (figure 12 A) in RBCs of
patients with diabetes when compared with non-diabetic subjects was observed.
As probably expected, the increased lipid peroxides shown here in RBCs exposed to
diabetic environment are in line with pre vious studies that documented significantly
higher levels of various markers of ROS in type 2 diabetic subjects (Nourooz-Zadeh,
Tajaddini-Sarmadi et al. 1995; Aguirre, Martin et al. 1998; Pasaoglu, Sancak et al.
2004). Interesting though, the total antioxidant capacity was increased in erythrocytes
of patients with early type 2 diabetes (f igure 12 A). It is important to mention that
TEAC assay is validated as standard method to measure the total antioxidant capacity
of a biological sample (Prior and Cao 1999). To date, the present study is the first

55 report that uses TEAC assay to evaluate the non-enzymatic antioxidant defense in
RBCs.
Figure 12. Oxidative stress and total antioxidant status of RBCs is increased in
type 2 diabetes patients at first clinical onset. Red blood cells (RBCs) from early
type 2 diabetes patients and from non-diabe tes age-matched subjec ts were evaluated
for TEAC (A) and MDA-TBA adducts (B). Values are mean /g114 SE. *P<0.01.
#P<0.001 vs. controls (analysis of variance Kr uskal-Wallis test). Hg, hemoglobin.
Antioxidant enzymatic activity is early up -regulated in erythrocytes from
patients with type 2 diabetes.
It has been previously outlined the fact that SOD, CAT and GPx are the main
enzymatic antioxidants in the RBCs and al so the major enzymes neutralizing
superoxide anion and hydrogen peroxide radical.
Hence, the enzymatic antioxidants in RBCs of all subjects included in the present
study were analyzed by measuring the SOD, CAT and GPx ’sactivities (figure 13). A
significant increase for SOD and GPx, but not for CAT activity was therefore
observed in patients with type 2 diabetes. T he significant increase of SOD and GPx
activities only shown here might ha ve some possible explanations. First, the

56 difference in activity could be a conseque nce of a tissue-specific modulation of the
antioxidant enzymes (Wassmann, Wassmann et al. 2004). Second, it has been shown
that different antioxidant enzymes have va rious substrate affinities. That is the case
for increased affinity for hydrogen pe roxide of GPx when compared to CAT (Jones,
Eklow et al. 1981; Michiels, Raes et al. 1994) . Third, it has been reported that under
some circumstances an increased SOD acti vity induces increased GPx and reduced
CAT activities as compensation (Ceballos, Delabar et al. 1988; Kelner and Bagnell
1990).
Figure 13 Antioxidant enzymatic activity is up-regulated early in erythrocytes
from type 2 diabetes patients. Superoxide dismutase (Lipcsey , Soderberg et al.) (A),
catalase (CAT) (B), and glut athione peroxidase (GPX) (C) activity was measured in
erythrocytes from type 2 diabetes patients at first clinical onset and from non-diabetes
age-matched individuals. Values are mean /g114 SE. *P<0.05, #P<0.01 vs. controls
(analysis of variance, one-way Tukey test).

57 Up to this point the present study has sho wn that since early diabetes, RBCs are
exposed to ROS overproduction originating ei ther from inside or outside of the cell,
and exhibit an increased both nonezymatic an d enzymatic antioxidant defense. Early
activation of the antioxidant defense obse rved here could be an argument for the
controversial effects of antioxidant suppl ements in patients with diabetes (Neri,
Calvagno et al. 2010; Golbidi, Ebadi et al. 2011; Bjelakovic, Nikolova et al. 2012).
Though, the compensatory efficiency of the response remains to be elucidated,
especially when oxidative stress mediated apopto sis of RBCs in diabetes is taken into
account (Maellaro, Leoncini et al. 2011).
Apoptosis is activated in RBCs of type 2 diabetes patients since first clinical
onset.
When senescent, experience various inj uries or clinical disorders the erythrocytes
should be removed from circulation. Under such c onditions, a progressive process of
coordinated, programmed cell death that eventual ly leads to disposal of affected cells
and precedes hemolysis (i.e. does not involve rupture of the cell membrane and
release of intracellular material) has been recently described as erythrocyte apoptosis
or eryptosis (Lang, Gulbins et al. 2010). In spite of controversies, the phenomenon is
nowadays accepted as particular for the RBCs since it shares but also lacks several
hallmarks of apoptosis (Lang, Gulbins et al. 2010). Thus, eryptosys exhibits essential
steps as apoptosis, such is cell shrinkage, cell membrane blebbing, and cell membrane
scrambling leading to phospha tidylserine (PS) exposure at the cell surface (Lang,
Gulbins et al. 2010), and the dysfunctional ery throcytes are recognized and destroyed
by macrophages (Lang, Gulbins et al. 2010). Instead, as do not have nuclei and
mitochondria, the RBCs undergoing apoptosis do not exhibit mitochondrial
depolarization and condensation of nuclei (Lang, Gulbins et al. 2010).
An enhanced eryptosis has been described in several diseases characterized by high
levels of oxidative stress, such is diabetes a nd chronic kidney disease (Calderon-
Salinas, Munoz-Reyes et al. 2011; Maellaro, Leoncini et al. 2011). Hence, Calderon-

58 Salinas and colab. (197) have studied the externalization of PS in erytrhrocytes of
patients with type 2 diabetes with or without chronic kidney disease (CKD). They
found that that erythrocytes from diabetic pa tients have a rise in erythrocyte PS
externalization, that was furthermore increased by the duration of the diabetic
condition and the presence of CKD. Ma ellaro and colab. (198) investigate in RBCs
from patients with late type 2 diabetes whe ther the activation of caspase-3 is
operative. The authors concluded that in diabe tic erythrocytes caspase-3 activation
occurs and is correlated to the degree of hyperglycaemia and plasma (rather then
intracellular) level of oxidative stress, sugge sting that extracellular oxidative stress,
likely induced by hyperglycaemia, could play a causative role.
Figure 14. Caspase-3 is activat ed in RBCs of type 2 diab etes patients from first
clinical onset. Caspsase-3 activity was measured in RBCs from early type 2 diabetes
patients and from non-diabetes age-mat ched subjects. Values are mean /g114 SE. #P<0.05
vs. controls (analysis of varia nce Kruskal-Wallis test).

59 We therefore investigated the caspase-3 ac tivity in all our subjects. Caspase-3
activation was found to occur early in diabetes (figure 14). Interestingly, we found a
negative correlation between caspase-3 activity and MDA-TBA adducts values in
diabetic erythrocytes that reach the significance in RBCs from patients with type 2
diabetes and hypertension only (Spearman r=-0.662, p=0,0219). Moreover, caspase-3
activity positively correlated with the levels of TAC in RBCs from patients with
diabetes, especially in hypertensive subgroup (Spearman r=0.724 vs 0.8172, and
p=0.0049 vs 0.0019, respectively). The result sugg ests that lipid peroxides exhibits a
strong inhibitory effect on caspase acti vity. A possible explanation might be that the
caspases are a family of cysteine proteases containing a thiol group as active site
necessary for their activity (Thornberry and Lazebnik 1998). This thiol group renders
them particularly susceptible to redox modification by S-nitrosylation or oxidation.
Such modifications result in the inhibiti on of their catalytic activities (Curtin,
Donovan et al. 2002).
In conclusion, our study shows that the patter n of defense against free radicals
aggression is early activated in blood stream of patients with type 2 diabetes, and
occurs even in RBCs with an increased apoptotic activity. By showing that
antioxidant defense is up regulated since fir st clinical onset in type 2 diabetes, we
question the beneficial effec ts of antioxidant supplements for clinical practice.
Nevertheless, the evaluation of antioxidant status has to be considered for clinical
applicability despite the presence of an y specific diabetes chronic complication.

60 Section I –Original contributions
I.3. Involvement of the erythro cytes in L-arginine dependent nitric oxide
metabolism in diabetes

61 I.3. Involvement of the erythro cytes in L-arginine dependent nitric oxide
metabolism in diabetes –the state of the art
Nowadays, it is well known that L-Arginine (L-Arg) is an important source to
generate nitric oxide (NO) in many human cel ls and that L-Arg exerts its important
cardiovascular role mainly via nitric oxide (NO)-dependent processes (Wu and Morris
1998). Besides, L-Arg has other NO-indep endent roles in various physiological
processes (Wu and Morris 1998). Thus, L- Arg is involved in post-translational
modifications of some proteins that allow to be targeted for degradation by the
ubiquitin-dependent proteolyt ic pathway. L-Arg is also regulator of its own
metabolism, by modulating an essential cofactor of carbamoyl-phosphate synthase I, a
key enzyme for arginine dependent urea synthesis. L-Arg is also an essential
stimulator for hormone secretion, i.e. insulin or growth hormone.
L-Arg is considered as a semi-essential amin o-acid, meaning that in certain conditions
(i.e. children or during recovery afte r infection and inflamm ation) the endogenous
synthesis may not fulfill the physiological requirements (Wu and Morris 1998). The
sources of L-Arg that is found in adult p lasma in post-prandial state are exogenous
(i.e. diet) and endogenous (i.e . protein degradation and citrulline) (Wu and Morris
1998). Hence, citrulline is the main de novo source for L-Arg in adults, and is
essentially derived from glutamate that or iginates in the mitochondria of enterocytes
(Wu and Morris 1998). Following release fr om the small intestine, the kidneys take
up primarily the citrulline for L-Arg production. Thus, the circulation of the citrulline
from the enterocytes to the proximal tubul es of the kidney is also known as the
intestinal-renal axis of arginine synthesis. The liver is not essentially involved in
extracting either citrulline or L-Arg fr om the blood stream. Furthermore, this organ
contains an exceedingly arginase activity to hydrolyze Arg into urea plus ornithine
thus explaining why the hepatic urea cycle doe s not lead to a net synthesis of L-Arg
(Wu and Morris 1998). The cit rulline is up-taken into the cells by a selective transport
system (i.e. N-system) that is specific for amino-acids having amide group as side-
chain (Wu and Brosnan 1992).

62
L-Arg degradation produces NO, cit rulline, ornithine, urea, polyamines, proline,
creatine, glutamate, and/or ag matine and involves severa l pathways (Wu and Morris
1998). These pathways are initiated by arginases, three isoforms of NOS, L-
Arg:glycine amidinotransferase , and L-Arg decarboxylase.
The arginase pathway is quantitatively most important for L-Arg catabolism in human
generating urea and ornithine (Wu a nd Morris 1998). Two arginase isoforms are
expressed. While type II argina se is synthesized in all mitochondria-containing
extrahepatic cells (Li, Meininger et a l. 2001), type I arginase is produced mainly in
hepatocytes (Morris 2007), and, to a li mited extent, in extrahepatic cells (Li,
Meininger et al. 2002), including red blood cells (RBCs) (Kim, Iyer et al. 2002).
In the cells expressing NOS, L-Arg degr adation might generate citrulline along with
NO. Though, in some extent, the citrulline can be furthermore recycled to L-Arg by
the combined action of two specific enzymes (i.e. argininosuccinate synthetase and
argininosuccinate lyase) through a pathway cal led the citrulline-NO cycle (Hecker,
Sessa et al. 1990). The signific ance of this metabolic alte rnative it might be the
potential support of citrulline instead of L-Arg in sustaining NO synthesis. This
hypothesis is mainly accepted in the light of in vitro studies, showing higher levels of
induced NO in vascular smooth cells over-ex pressing argininosuccinate synthetase
(Xie and Gross 1997). Though, the contribution of the arginine recycling pathway to
NO synthesis in vivo is compl etely unknown (Wu and Morris 1998).

The critical role that nitric ox ide (NO) plays in vascular homeostasis in well known
(Ignarro 1989). The synthesis of NO ge nerally follows two main routes. On one side,
NO can be enzymatically synthesized in a reaction catalyzed by nitric oxide synthase
(NOS) (Alderton, Cooper et al. 2001). Nowadays, there are three isoforms of NOS
already described: neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2),
and endothelial NOS (eNOS or NOS3). Currently, the existence of mitochondrial
NOS isoform (mtNOS) is still debated. In spite of controversy (Chen and Popel
2009), recent data (Kleinbong ard, Schulz et al. 2006) have shown that NOS3 is
expressed in RBCs and is potentially used as vascular source of NO. On the other
side, when NO production from NOS is impa ired the non-enzymatic NO synthesis is
activated (Li, Cui et al. 2008). This altern ative route of nitrite-derived NO production

63 is particularly active under ischemia conditions (Zweier, Wa ng et al. 1995) in either
different tissues (Li, Cui et al. 2008), and erythrocytes (Huang, Shiva et al. 2005).

Decreased plasma levels of L-Arg charac terize the endothelial dysfunction in patients
with diabetes (Wu and Meininger 2000; Kashyap, Lara et al. 2008). However, data
based on clinical studies using L-arg inine supplementation in subjects with diabetes
are still conflicting (Wu and Meininger 2000; Kashyap, Lara et al. 2008).

Thus, oral supplementation of L-arg at a dosag e of 7 g/day for 4 weeks in patients
with type 1 diabetes mellitus did not impr ove endothelial function (Mullen, Wright et
al. 2000). Under contrary, long-term oral L-Arg administration (9 g/day for 3 months)
has been shown to improve but not comple tely normalize periphe ral and hepatic
insulin sensitivity in patients with type 2 diabetes (Piatti, Monti et al. 2001). Similar
results were obtained by Lucotti P et al. (L ucotti, Setola et al. 2006) where 8.3 g/day
L-Arg continuously administered for 21 days resulted in an additive effect compared
with a diet and exercise training progra m alone on glucose metabolism and insulin
sensitivity. Furthermore, it im proved endothelial function, oxidative stress, and
adipokine release in obese type 2 diabeti c patients with insulin resistance.
When L-Arg L-arginine (1 g/min) was intravenous infused during the last 30 min of
the glucose clamp (at 18 mmol/l for 2 h) to newly diagnosed complication-free diet-
treated type 2 diabetic patients, ha s reduced blood pressure and improved
hemodynamic function (Marfella, Nappo et al. 2000). Though, the acute intravenous
L-arginine perfusion (625 mg/m in x 10 minutes) in normotensive nonsmoking
patients with type 2 diabetes and angiogra phically normal corona ry arteries and
normal plasma cholesterol was followe d by no improvement of coronary artery
responses to physiological stimuli (Nitenberg , Paycha et al. 1998). On the contrary, an
intravenous bolus of L-Arg up to 5 g admi nistered to patients with type 1 diabetes
reduced mean blood pressure and decreased platelet aggregation (Giugliano, Marfella
et al. 1997).

Up to date, the implication of the RBCs in NO-dependent L-Arg metabolic pathways
has been studied in several reports (Che n and Mehta 1998). Though, the present study
investigates for the first time the involvement of RBCs in Arg metabolic pathways in
type 2 diabetes at first clinical onset.

64
I.3. Involvement of the erythro cytes in L-arginine dependent nitric oxide
metabolism in diabetes – original contribution beyond the state of the art

As another distinctive part of my research activity, I have also studied the
involvement of the RBCs in L-arginine (L-Arg) dependent nitric oxide (NO)
metabolism in diabetes. Thus, L-Arg content, ar ginase activity and nitrate/nitrite
concentrations were assayed in the RB Cs and plasma collec ted from patients with
type 2 diabetes at first clinical onset and age-matched non-diabetes subjects as
controls.

I found that L-Arg content remained uncha nged in RBCs while decreased in the
plasma of patients with type 2 diabetes. The RBCs expressed lower arginase activity
while plasma exhibit an increased enzymatic activity in patients with diabetes. Both
nitrite and nitrate concentrations where high er in RBCs of patients with type 2
diabetes, while remained similar in the plasma of all subjects analyzed.

In this original contribution I was able to show for the first time that in patients with
type 2 diabetes at first clinical onset the L-Arg catabolism is driven mainly towards
NO synthesis, suggesting that the RBC pool represents a potentially compensatory
intravascular compartm ent for the endothelial dysfunction in diabetes.

L-Arginine pool is unchanged in RBCs and decreased in the plasma of patients
with diabetes.

The L-arginine (L-Arg) pool in RBCs and the plasma of all subjects included was
measured by capillary electrophoresis (CE). The method is well recognized as a
sensitive approach for qu antification of ionic charged trace analytes (Chien and Burgi
1991). Thus, it permits both a rapid and effic ient separation of charged compounds
present in small sample volumes. When adequate conditions are chosen, the
separation can often be achieved dire ctly in aqueous media, without sample
pretreatment, giving simple, fast, reliable, and easily automated methods (Barbas,
Adeva et al. 1998). CE also has a good detect ion limit 5-50 mg/l, wide linearity range

65 20-1000 mg/l, good reproducibility, short time of analysis (more than 30 compounds
can be analyzed in 30-40 min) (Soga and Imaizumi 2001).

As show in Figure 15 A and 15 B, the L- Arg content remained similar in RBCs
(Figure 15 A) while decreased in the plasma (Figure 15 B) of all the patients with
type 2 diabetes, even when hypertension was documented at first clinical onset.

Figure 15. L-Arginine p ool is unchanged in RBCs (A) and decreased in plasma
(B) of patients with diabetes. Erythrocytes (RBCs) and plasma from patients with
type 2 diabetes at first clinical onset and from non-diabetes age-matched subjects
were assayed for L-Arginine content. Values are mean /g114 SEM. P=0.045 vs. controls,
ANOVA Kruskal-Wallis test.

66
This original contribution represent the first report to measure the L-Arg content in
RBCs from patients with no previous medical history of diabetes. In the RBCs of
subjects with type 2 diabetes at different stage s of the disease, Ramirez-Zamora et al.
(Ramirez-Zamora, Mendez-Rodriguez et a l. 2013), have found lower L-Arg when
compared with healthy indivi duals. The authors suggested that L-Arg pool is capable
of regulating serum levels of L-Arg through buffering its concentrations. In other
words, the L-Arg is released from eryt hrocytes in order to maintain within normal
range the serum level of L-Arg in patients with diabetes.

The present data show that the lack of difference has maintained even when
hypertension was documented in subjects with diabetes (Figure 15 A).

It seems that documented systemic hypertension has by itself a repressive effect on
the rate of L-Arg cellular transport. It has been shown that the transport of L-Arg in
RBCs is mediated via the cationic amino acid transport (CAT) systems y+ and y+L
(Deves, Chavez et al. 1992). Thus, Moss et al. (Moss, Brunini et al. 2004) has
previously show that the bioavailability of L- Arg from the red blood cells is decreased
in patients with known medical history of syste mic arterial hype rtension. The authors
concluded that the diminished rate of L-Ar g transport in human erythrocytes in
hypertension is mediated selectively by a down regulation of the specific transport
system y+L activity (Moss, Brunini et al. 2004). Hence, the mechanisms by which
system y +L is impaired in hyperte nsion and also its relevance for further insights into
the pathophysiology and treatment of this particular condition are not yet clearly
revealed (Moss, Brunini et al. 2004).

Under contrary, in other chronic medical c onditions that are characterized by systemic
high blood pressure, i.e. uremia a nd heart failure, an adapti ve increase in the activity
of the cationic amino acid transport system y+, elevating the transport of L-Arg in red
blood cells is reported (Hanssen, Brunini et a l. 1998; Mendes Ribeiro, Brunini et al.
1999). The occurrence of the same phe nomenon, i.e. increase in transport capacity for
L-Arg, in various clinical syndromes characteriz ed by very different causes suggests a
possible common trigger. Accumulating data has been shown that some circulating
cytokines that are increased in both conditions (i.e. IL-1, IL-6, TNF-alpha) might up-

67 regulate the expression of the cationic amino acid transport system and iNOS in
platelets and RBCs precursors. Hence, the pre-thrombotic state and potential
thrombotic events that characterize either hear t or renal failure might be further
minimized. On the other hand, the iNOS- mediated increases in NO synthesis is a
failing contra-regulatory mechanism, as the wide-spread vasoconstriction encountered
in heart failure and progressive systemi c hypertension documented in renal failure
cannot be reversed.
Thus, the result reported here in the present pa per suggested that L-Arg pool from red
blood cells is not yet depleted in early sta ges of diabetes, even when systemic
hypertension was documented.
Arginase activity decreased in RBCs and incre ased in the plasma of patients with
diabetes.
As previously mentioned, the arginase pa thway is quantitatively most important for
L-Arg catabolism (Wu and Morris 1998). Tha t is why the erythrocyte and plasma
arginase activity in all subjects recruited was further analyzed. The arginase activity
was lower in RBCs (Figure 16 A) while increas ed in the plasma (Figure 16 B) of all
patients with early type 2 diabetes when compared with subjects without diabetes.
Previous reports analyzing protein disregulation in red blood cells membranes of the
patients with type 2 diabetes (Jiang, Jia et al. 2003) show increased arginase activity
in RBC membranes. In spite of both cytopla sm and membrane activity, up to date
there is no direct comparison of the enzy matic activities of arginase in both the
membrane and cytoplasm of RBCs in diabetes (Jiang, Ding et al. 2006). This may be
of interest as long as indirect evidences (Jiang, Ding et al. 2006) suggest different
activities between the two cellular compartm ents even that are presumed to be the
consequence of the different ratio of a mount of arginase in membrane and cytoplasm.
It could be speculated that these differences are generated by arginase-flotilin
interactions in RBC membrane (Jiang, Ding et al. 2006). Human flotillins are highly
conserved hydrophobic proteins isolated from cav eolae/lipid raft domains of cellular
membranes consisting of two family membe rs: flotillin-1 (reggie-2) and flotillin-2
(reggie-1) (Malaga-Trillo, Laessing et al. 2002). Flotillin-1 and flotillin-2 are the most

68 abundant membrane proteins expressed in red blood cells lipid rafts (Baumann, Ribon
et al. 2000). They have been implica ted in numerous cellular processes including
signal transduction and membrane trafficking (Baumann, Ribon et al. 2000). Flotillin-
1 plays an important role in the second sig naling pathway required for insulin-
stimulated glucose transport, i.e. insulin-stimulated translocation of glucose
transporter 4 in adipose and muscle cells (Bryant, Govers et al. 2002; Ducluzeau,
Fletcher et al. 2002).
Figure 16. Arginase activity decreased in RBCs and increased in plasma of
patients with diabetes. RBCs and plasma from patients with type 2 diabetes at first
clinical onset and from non-diabetic age-matched individuals were evaluated for
arginase activity. Values are mean /g114 SEM. P=0.001 vs. controls (A and B), ANOVA
Kruskal-Wallis test.
RBCs Arginase activity
(μmol of urea/g Hb/min)
Plasma Arginase activity (μM/min)

69 It is notable that decreased arginase acti vity was maintained in RBCs of patients with
diabetes and documented high blood pressure (Figure 16 A). This observation could
represent an adaptive response of RBCs against endothelial dysfunction. That is,
arginase inhibits the NO producti on through several mechanisms, including
competition with NOS for the substrate L-Ar g (Durante, Johnson et al. 2007).
Therefore, upregulation of arginase in endothelial cells inhibits eNOS-derived NO
production, and may contribute to endothelial damage in different conditions such as
hypertension and diabetes (Durante, Johnson et al. 2007). Furthermore, it has been
shown that intraplatelet arginase activity in patients with syst emic arterial
hypertension is not affected (Moss, Siqueira et al. 2010), suggesting that other blood
cells may exhibit similar adaptive behavior. Hence, the arginase-mediated up-
regulation of NO synthesis in blood cells wou ld not further deplete intravascular
concentration of NO.
When plasma samples were assayed in all subjects included in the present study L-
Arg content was decreased (Figure 15 B) while arginase activity increased (Figure 16
B) in patients with early diabetes. The same tendency was maintained when systemic
hypertension was documented in subjects with di abetes (Figure 15 B and Figure 16
B).
These results are in line with previous data (Kashyap, Lara et al. 2008). Kashyap et al.
were measured plasma arginase activit y, arginine metabolites, and skeletal muscle
NO synthase (NOS) activity in patients with uncomplicated ty pe 2 diabetes and age-
/BMI-matched subjects without diabetes and examined the effect of physiologic
hyperinsulinemia on plasma arginase activity before and following a 4-h euglycemic-
hyperinsulinemic clamp. Percutaneous muscle bio psies were collected from the vastus
lateralis muscle 60 minutes before the start of the clamp (Kashyap, Lara et al. 2008).
The main results of the study were that plasma arginase activity is increased and NOS
activity is impaired in subjects with type 2 diabetes and is markedly reduced by short-
term (4 h) physiological hyperinsulinemia. These data suggest an increased arginine
catabolism in the plasma of patie nts with type 2 diabetes.

70 As for the L-Arg content of the red blood cell s, the plasma levels of L-Arg is different
in patients with systemic hypertension alone compared to various clinical syndromes
characterized by hypertension. Hence, the plasma levels of L-Arg increase in patients
with systemic arterial hypertension (Moss, Bru nini et al. 2004) and decrease in
medical conditions characterized by hyperte nsion, such as chronic renal or cardiac
failure (Mendes Ribeiro, Brunini et al. 2001). On the other hand, Kashyap et al.
(Kashyap, Lara et al. 2008) reported inst ead low concentrations of L-Arg in plasma
samples collected from normotensive patients with type 2 diabetes. There is no clear
explanation for these differences. Thoug h, the most important mechanisms behind
these variations include alterations of L-Arg transport or arginase activity, and
increased plasma concentrations of L-Ar g analogues, i.e. ADMA (asymmetric
dimethyl-L-arginine) and SDMA (symmet ric dimethyl-L-arginine). All together,
these data suggest a complex modulation of plasma L-Arg in patients with diabetes
and hypertension at first clinical onset.

There is one more important a spect that needs to be discussed here. Hence, it has to
be mentioned that L-Arg may be found either in plasma and RBC (i.e., RBC/plasma
L-arginine ratio). In other words, the above-m entioned ratio might potentially reflect a
relationship between plasma levels and cel lular transport of L-Arg in various
conditions. In terms of the present result s, one therefore could suppose that the
reduced plasma L-arginine (Figure 15 B) could compromise its uptake by RBC
(Figure 15 A). Although it cannot be ex cluded, this alternative is questionable since
the “arginine paradox” is taken into consideration.

The concept has been extensively discussed in relative recent reviews (Mann,
Yudilevich et al. 2003; Moss, Brunini et al. 2004; Dioguardi 2011).

Hence, the “arginine paradox” has been primarily described in endothelial cells,
where acute supplementation with exogenous L-Arg induced a paradoxical increase in
NO production, in spite of the fact that the cytoplasm of these cells exhibits an
intracellular concentration of arg inine that is more than suff icient to saturate the
eNOS activity (Kurz and Harrison 1997). In other words, in spite of high levels of
cellular L-Arg in tissue culture media (i.e. 400 μM), because the Km of arginase for
L-Arg is high (1 –3 mM) whereas the Km of NOS isoforms for L-Arg is relatively low

71 (3–10μM) (Buga, Singh et al. 1996), in cell- free systems (i.e. cultured endothelial
cells) arginase may not necessarily limit the av ailability of intracellular L-Arg for NO
production. Nevertheless, Wa ddington et al. have been reported that the inhibition of
NO synthesis in renal mesangial cells is not associated as probably expected with
enhanced arginase activity (Wadding ton, Tam et al. 1998). Moreover, further
experimental data suggest that intracellular transport and metabolism of the L-Arg is
rather independently modulated by plasma arg inine concentrations (Dioguardi 2011).
Thus, overexpression of the specific arg inine receptors induces both arginine uptake
and nitric oxide production, while their speci fic blockade (i.e. by competitive amino
acids) reduces arginine uptake but not nit ric oxide production. Furthermore, the
presence of citrulline in the cell cultur e media has no influence upon intracellular
concentration of L-Arg, while it stimula tes nitric oxide production even in a medium
containing saturating levels of arginine (Dioguardi 2011).
The “arginine paradox ” phenomenon appears to be even more exace rbated by the
observations resulting from in vivo data. Thus, it seems that L-Arg supply is rate
limiting for NO synthesis (i.e. re ducing NO production) in patients with
hypercholesterolemia and impaired e ndothelium-dependent vasodilation (Creager,
Gallagher et al. 1992). Moreover, the long-term supplementation with L-Arg does not
improved eNOS activity, as it has been shown by in vitro and in vivo data on healthy
human vessels (Chin-Dusting, Alexande r et al. 1996). Further, when L-Arg has been
chronically supplemented in patients recove ring after myocardial infarction, an
increased of cardio-vascular mortality has be en reported instead of the expected effect
of promoting vasodilation (Schulman, Becker et al. 2006). Taken together, all these in
vivo observat ions support the persistence of the “arginine paradox” when L -Arg is
also chronically supplemented in various clinical scenarios.
These data suggest a pa rticular intracell ular transport, metabolism and NO regulation
of L-Arg, and a discrepancy in the sensitivity of eNOS to extracellular L-arginine in
cell-free systems and studies in vivo irrespecti ve of high intracellular and circulating
levels of L-arginine.
In their review Mann et al. (Mann, Yudilevic h et al. 2003) suggest several potential
mechanisms explaining the phenomenon. First, in patients with renal and heart

72 failure, hypercholesterolemia and ather osclerosis the presence of increased plasma
concentrations of ADMA (asymmetric dime thylarginine) could be one explanation for
the L-Arg paradox (Boger 2003). Then, the co-localization of eNOS and CAT
(chloramphenicol acetyltransferase) transporte rs in the caveolae (i.e. invaginations of
the plasma membrane or “lipid rafts”) of the endothelial cells could also help to
explain the phenomenon (Solomonson, Flam et al. 2003). That is in spite of the fact
that NOS is cytosolic in macrophages and other cells. Moreover, Mann et al. have
found no evidence that arginase and eNOS are co-localized in plasmalemmal caveolae
(Mann, Yudilevich et al. 2003). Finally, another report suggested that, in
macrophages and endothelial cells, iNOS and eNOS respectively, have access to
different intracellular L-Ar g pools (Closs, Scheld et al. 2000).
In his quite recent review, Dioguardi (Dio guardi 2011) proposes as more consistent
explanation for the endothelial arginine pa radox the tight coupling of NO production
to the citrulline-NO cycle (Flam, Eichler et al. 2007). Therefore, NO production
depends mostly on the efficient recycling of arginine-derived citrulline back to
arginine, and not so much on exogenous arginine supply.
Furthermore, in order to understand the clinica l paradox of arginine, that is reflected
in its inefficiency or even damaging eff ect when supplemented chronically, the same
author (Dioguardi 2011) suggests as possi ble mechanism the profound repressive
impact on NOS activity exerted by arg inase-driven arginine metabolism, that is even
more amplified by ageing (Santhanam, Christianson et al. 2008) or diabetic
environment (Kashyap, Lara et al. 2008), i.e. degree of hyperglycemia and insulin
deficiency. Exogenous supplementation with L-Arg in such conditions may be
therefore potentially harmful, as it has been demonstrated that induces the expression
of both types of arginases (Grody, Argyle et al. 1989). In addition, oral arginine
supplementation may inhibit the recycling of citrulline to arginine by urea produced in
excess and also promotes insulin resistance, as ar ginine is recognized as a potent
stimulator of glucagon synthesis (Dioguardi 2011).
As concluding remarks, the “arginine paradox” has been primarily described in
endothelial cells and refers to the discrepancy that, even at physiological L-Arg
concentrations, eNOS should be well sa turated with substrate, and the addition of

73 exogenous L- Arg should not affect the enzyme’s activity (Boger 2004). There have
been several explanations postulated, although none of them can fully explain the
phenomenon (Moss, Brunini et al. 2004; Dioguardi 2011).

The erythrocytes NO production increased in patients with diabetes

The measurement of nitrate and nit rite levels in blood stream (i.e. plasma) is
considered a valuable index of e stimating NO production (Viinikka 1996).
Furthermore, accumulating data have been suggested that hemoglobin (Hb) is playing
important roles in NO metabolism in blood stream , being recognized as a powerful
catalyst of NO oxidation (Kim -Shapiro, Schechter et al. 2006). Therefore, the L-
Arg/NO metabolic pathway in the erythrocy tes and plasma of all subjects included in
the present study was further investigated. Fi gure 3 shows significantly higher levels
of NO production in RBCs from all early type 2 diabetes patients when compared
with non-diabetic subjects.

Figure 17. RBC NO production increased in patients with diabetes. Nitrite (A)
and nitrate (Nox) (B) were measured in RBCs from early type 2 diabetic patients and
from non-diabetic age-matched subjects. Values are mean /g114 SEM. P<0.001 vs.
controls (A and B), ANOVA one-way Tukey test.

74 The present study reported for the first time that NO production in the RBCs of
patients with early type 2 diabetes was significantly increased when compared with
non-diabetic subjects. Data reported here are in line with ve ry recent observation of
Ramirez-Zamora et al. showing increased nitrites conce ntration in RBCs from
patients with type 2 diabetes at differe nt stages of the disease (Ramirez-Zamora,
Mendez-Rodriguez et al. 2013). Palmerini et al. (Palmerini, Zucchi et al. 2009)
observed similar results on patie nts with metabolic syndrome and erectile
dysfunction.
The same result was observed in RB Cs of patients with diabetes and documented
hypertension in the current study (Figure 17 ). Hence, this observation suggests that
RBCs could maintain their production of NO in spite of the reduced plasma levels of
L-Arg (Figure 15 B). A possible explanation of the phenomenon could be activation
of the L-Arg transport. The effect has be en already described in uraemic platelets and
mononuclear cells, which therefore may provi de a protective mechanism against
increased aggregation and accelerated ather osclerosis characteristic of renal failure
(Mendes Ribeiro, Brunini et al. 2001; B runini, Roberts et al. 2002). As increased
aggregation and accelera ted atherosclerosis characterizes the diabetic environment, a
putative NO-mediated protective mechanism or iginating from the erythrocytes might
be also speculated.
Plasma NO production remains unmodified in patients with diabetes
Once formed, NO diffuses out of the cells and enters the ex travascular and
intraluminal spaces. In the vascular wall , NO diffuse into the vascular smooth muscle
and reacts with soluble guanylate cyclase (sGC), which catalyzes the formation of
3’,5’ -cyclic guanosine monophosphate (cGMP ) to induce vasodilation (Lancaster
1994). When extravascular, NO inhibits mitochondrial respiration by binding to the
heme group of cytochrome c oxidase, thus re gulating oxygen delivery to the tissues
(Cooper and Brown 2008). Inside the lumen, an important part of NO enters the
erythrocyte where is mainly scavenged in normoxia by reacting with oxygenated
hemoglobin (Eich, Li et al. 1996). When int ravascular, NO may also regulate certain

75 rheologic proprieties of the blood by inter action with the heme group of guanylate
cyclase expressed on erythrocytes a nd platelets thus modulating erythrocyte
deformability and platelet-platelet ad hesion (Cerwinka, Cooper et al. 2002; Bor-
Kucukatay, Wenby et al. 2003). Moreove r, it can react with plasma constituents to
form various active compounds, such is: nitrosylated species (i.e. nitrosothiols),
nitrated lipids, and nitrite. Thus, through these sp ecies NO is able of transducing its
bioactivity far from where is generated (Cosby, Partovi et al. 2003).

Figure 18. Plasma NO production remains unmodified in patients with diabetes.
Nitrite (A) and nitrite plus nitrate (Nox) (B) were assayed in plasma from patients
with type 2 diabetes at first clinical onset and from age-matched non-diabetic
subjects.

Conflicting data are referring to NO bioava ilability in the serum of patients with
diabetes. Thus, NO metabolites are either increase d (Zahedi Asl, Ghasemi et al. 2008;
Ramirez-Zamora, Mendez-Rodrigue z et al. 2013), decreased (Huszka, Kaplar et al.
1997; Vanizor, Orem et al. 2001) or uncha nged (Ferlito and Gallina 1999) in patients
with early type 2 diabetes mellitus. The same conflicting results are also reported in
the presence of chronic complications of diabe tes (Maejima, Nakano et al. 2001). In
the present study no differences were re ported in NO metabolites in the plasma of all

76 patients with type 2 diabe tes included when compared with non-diabetic controls
(Figure 18).
The presented data here suggest a putative incr ease of RBC NO availability. It is well
known that RBCs are the major intravascular storage sites of nitrite in human blood
(Dejam, Hunter et al. 2005) and a lso that they have important roles in NO
bioavailability (Kim-Shapiro, Schechter et al. 2006; Chen and Popel 2009).
Production of intracellular nitrite in RBCs involves several pathways (Dejam, Hunter
et al. 2005). However, recent data (Sibmooh, Piknova et al. 2008) provide evidences
for the transport of NO via hemoglobin within RBCs. Nitrite has the potential to be a
major intravascular NO storage molecule in humans that is capable of transducing NO
bioactivity distal to its site of formation (Cosby, Partovi et al. 2003).
In other words, the erythrocytes seem to pla y a dual role in regulating NO availability.
On one side they scavenge and transform NO ac cording to intracellular oxygen status,
as follows: under aerobic condit ions oxyhemoglobin (HbO 2) converts NO to inactive
nitrate (NO 3-) and methemoglobin (MetHb, where heme irons are ferric) (Eich, Li et
al. 1996) while under (relatively) anaerobiosis NO is converted by deoxyhemoglobin
(Hb, deoxygenated hemoglobin) to iron- nitrosyl-hemoglobin (HbNO) that was
classically considered a stable and iner t end product (Cassoly and Gibson 1975).
On the other side, they can serve as a sit e for NO-related reactions involving iron-
nitrosyl-hemoglobin (HbNO) – recently reconsidered as an important source of
bioactive NO (Nagababu, Ramasamy et al. 2003), S-nitroso hemoglobin (SNOHb),
nitrite reduction, and enzyma tic cleavage by NOS 3 expressed on erythrocytes (Chen
and Popel 2009).
The reaction of NO with HbO 2is predicted to be the major way by which the
erythrocytes inactivate intravascular NO . Though, there are several mechanisms that
might limit the intensity of the (natural) NO scavenging capacity of the RBCs (Kim-
Shapiro, Schechter et al. 2006). First, blood flow velocity gradients are generated
along the close proximity of the endothelial wall. Thus, in the center of the blood
vessels the pressure is higher than near the vessel wall. Therefore, a cell-free and a

77 hemoglobin-free zone are created alon g the walls that allow NO to escape the
scavenging effect of RBCs in a higher extent. Second, an intrinsically slower rate of
NO uptake by RBCs when compared with cell-f ree Hb has been described, although it
is expected that NO to have similar pr operties in traversing membranes as oxygen.
Third, the extravasation of cell-free Hb into the subendothelial space allows Hb to
come closer to the source of NO tha t could increase NO consumption.

The S-NOHb contributes to the preservation of NO bioactivity in the RBCs (Chen and
Popel 2009). The proposed mechanism assumes that first NO binds to deoxygenated
(ferrous) hemoglobin to form Hb(Fe2+)NO. Then, during Hb oxigenation the NO
group is transferred to the cysteine residue at position 93 in the β chain (ß -93
cysteine) of the hemoglobin molecule, thus forming the SNOHb. Further, under
hypoxic conditions, SNOHb transfers of the NO group to the thiols of the anion
exchange protein present on the membrane. The NO is exported from the erythrocytes
and might regulate blood flow. In spite current data supporting that the
intraerythrocytic SNOHb could be an important NO source in the intraluminal region,
the role of SNOHb in hypoxic vasodilation is still debated.

The erythrocyte’s NOS 3 expression is another mechanism that potentially preserves
RBCs NO bioactivity (Chen and Popel 2009) . In spite of controversies it is thought
that NO synthesized by NOS 3 located in erythrocytes can escape scavenging by
hemoglobin and it could serve as another important source regulating vascular tone
and hemorheological properties of erythrocy tes and platelets. Though, it is not
established how much NO from this source is available to the intraluminal region or
the vascular wall.

Nitrite is actually considered the major vasc ular storage pool of NO (Cosby, Partovi
et al. 2003). Here, the erythrocytes contain the majority of intravascular nitrite in the
whole blood (Cosby, Partovi et al. 2003). This assumption was validated also in vivo
on healthy individuals where has been shown that two thirds of intravascular nitrite is
located in erythrocytes, the majority of nitrite in erythrocytes is located in the cytosol,
and its concentration reac h to 300 nM (Dejam, Hunter et al. 2005). The erythrocytic
NO is a relatively stable because its reacti on rate with heme prote ins is really low
compared to that of authentic NO. Recen t experimental evidence suggests that nitrite

78 represents in fact a reservoir that preserve s NO bioactivity that can be enzymatically
reduced to NO by hemoglobin under hypox ic conditions (Huang, Shiva et al. 2005).
This is the reductase activity of hemoglobin ( Huang, Shiva et al. 2005). That specific
enzymatic activity of the hemoglobin is possible due to the equilibrium between the
oxygenated and deoxygenated state of the hemoglobin, which is essential particularly
at the pre-capillary arterioles where the ex changes between erythrocytic hemoglobin
and tissue bed are performed. In other words, in oxygenated state the hemoglobin has
a reduced redox potential for the hemes – a condition that is thermodynamically
favorable for nitrite reduction, while the deoxygenated hemoglobin exposes more
ligand-free hemes as the reaction site with nitrite (Huang, Shiva et al. 2005). Apart
from the nitrite reduction by hemoglobin, other certain proteins located in the
extracellular region (i.e. xanthine reductase or mitochondr ial proteins such is
cytochrome c), might reduce nitrite to NO a nd therefore regulate tissue oxygenation
(Lundberg and Weitzberg 2005; Basu, Azarova et al. 2008).
The significance of present original observati on may rely in the fact that erythrocytes
are essential in mediating NO bioavailability under specific conditions characterizing
endothelial dysfunction. Hence, as previous ly mentioned there are data suggesting
that RBC nitrite reservoir can be enzymatical ly reduced to NO by hemoglobin under
hypoxic conditions (Cosby, Partovi et al. 2003). These results suggest that RBC
hemoglobin acts as a nitrite reductase, potentially contributing to hypoxic vasodilation
in tissues with low oxygen tension. In medical conditions characterized by chronic
hypoxia, such as diabetes mellitus, these mechanisms may represent a potential
adaptive response aga inst endothelial damage.
Taking together, the present study show that L-Arg catabolism is driven mainly
towards NO synthesis in the RBCs of pa tients with type 2 diabetes, even when
hypertension was documented at first cli nical onset. Despite previous data stating that
production of intracellular nitrite in RBCs involves severa l pathways (Dejam, Hunter
et al. 2005), the actual observation – showing a decrease in RBCs arginase activity –
could be considered a potential mechanism of increased RBC NO production in early
diabetes. Hence, the RBC pool would represent a potentially compensatory
intravascular compartm ent for endothelial dysfunction in diabetes.

/g889/g891 Section I –Original contributions
I.4. The impact of basal insulin analog ues on glucose variability in patients with
type 2 diabetes undergoing renal replacement therapy for end stage renal disease

8/g882 I.4. The impact of basal insulin analog ues on glucose variability in patients with
type 2 diabetes undergoing renal replacement therapy for end stage renal disease
–the state of the art
As for the number of subjects with diabetes (S haw, Sicree et al. 2010), there is a
continuous increase in patients with diabetes who reach end stage renal disease
(ESRD) (Collins, Foley et al. 2012). It is nowadays established the essential
contribution of chronic hyperglycemia to the development of vascular complications
in diabetes, including in subjects with ESRD (Mehrotra , Kalantar-Zadeh et al. 2011).
It has been also extensively shown that hypo glycemic events per se have crucial
impact on mortality and vascular outcomes in patients with type 2 diabetes (T2DM)
(Patel, MacMahon et al. 2008; Bonds, Miller et al. 2010). Accumulating data
demonstrate the importance of acute fluctuations of blood glucose reflected as glucose
variability (GV), and more recently of HbA1c variabil ity for the progression of
diabetes complications, including subjects with established diabetic nephropathy
(Smith-Palmer, Brandle et al. 2014). It is now accepted that acute GV is increased in
patients with T2DM under maintenance hemodi alysis (HD) for ESRD, with no
evidence for a specific underlying mechanism (Kazempour-Ardebil i, Lecamwasam et
al. 2009; Riveline and Hadjadj 2009). Moreover, the variability in HbA1c might be of
importance in the development of nephropathy in patie nts with T2DM (Smith-Palmer,
Brandle et al. 2014). In a very recent paper, it has been shown that higher HbA1c
level is correlated with higher variabilit y in chronic glycemic control assessed by
standard deviation (SD) for HbA 1c, and use of insulin therapy is associated with
increased risk of hypoglycemia in individuals with diabetes and ESRD (Williams,
Garg et al. 2014). However, limited amount of information is available about the
HbA1c variability in T2DM pa tients on dialysis. It has been shown that patients with
T2DM and ESRD exhibit insulin resistance (IR) as demonstrated by significantly
higher HOMA-IR values when compared to the ESRD patients without diabetes
(Bodlaj, Berg et al. 2006). Nevertheless, GV is increased in patients with diabetes and
IR (Pitsillides, Anderson et al. 2011; Giordani, Di Flaviani et al. 2014). The efficacy
of basal insulin therapy with human analogues on GV in pa tients with diabetes has
been proved in various studies (Smith-Palmer, Brandle et al. 2014). Though, there is a
lack of information about the influence of dif ferent basal insulin regimens on GV in

8/g883 patients on dialysis with T2DM and IR. The present study aims to evaluate the
influence of basal insulin analogues on GV – reflected as either acute blood glucose
fluctuations or HbA1c va riability in patients with T2DM on HD as replacement
therapy for ESRD .
I.4. The impact of basal insulin analog ues on glucose variability in patients with
type 2 diabetes undergoing renal replacement therapy for end stage renal disease
–original contributions beyo nd the state of the art
As distinctive part of my research interest, I analyzed the impact of basal insulin
analogues on glucose variability (GV) in patients with type 2 diabetes (DM)
undergoing renal replacement therapy. Thus, va rious glycemic profiles (Coefficient of
variation – CV of mean glucose) over 5 days period of continuous glucose monitoring
were compared between the day on (HD-on) and the day off (HD-off) dialysis. The
CV of at least 3 values of HbA1c (HPL C) since replacement therapy has been applied
was used to assay the long term GV. Endogenous insulin and insulin resistance
(HOMA using fasting glucose and C-peptide levels), fasting lipid profile, quantitative
C-reactive protein (CRP) and ferritin (values adjusted for Hb) were measured in
serum at inclusion.
I found that, while all subjects were insulin resistant, the overnight HD-off and HD-on
short term (CV CGMS) GV, overa ll long term (CV of HbA 1c) GV, CRP and ferritin
were reduced in subjects treated with detemir.
This original contribution show for the first ti me that insulin resistant patients with
type 2 diabetes undergoing hemodialysis for end stage renal disease on insulin
detemir exhibit lower glycemic variabilit y and pro-inflammatory profile than with
insulin glargine.
Insulin detemir was more efficient than insulin glargine in reducing intraday
nocturnal glycemic variability in pat ients with type 2 on hemodialysis.

8/g884 The subgroup on glargine sequentially included subjects on basal – bolus insulin
regimen, while the subgroup on detemir consi sted of participants on basal insulin,
only. Therefore, the overnight glucose varia bility was only assessed, in order to limit
the bias of short acting analog insulin regimen on glucose profiles. Moreover, we
observed a significant reduction of BMI in subjects treated with insulin detemir than
with insulin glargine ( 35.1±1.9 vs . 28.4±1.5 kg/m2, p=0.018, T -paired). In spite of
strong clinical evidence of weight redu ction effect induced by insulin detemir vs.
glargine (Niswender, Piletic et al. 2014); (Swinnen, Simon et al. 2011), our result
might reflect a possible weight gain effect in patients treated with insulin glargine, as
all the subjects included in this subgroup re ceived basal bolus insulin regimen.
Figure 19 Insulin detemir was more e fficient than insulin glargine in reducing
intraday nocturnal glycem ic variability in patients w ith type 2 diabetes on
hemodialysis Coefficient of variation (CV) for blood glucose levels over 5 days
period of continuous glucose monitoring. (A) HD- on=day of dialysis; (B) HD-off=the
following inter-dialytic period. P= 0.0001 (A) and P=0.0011 (B), paired t-test.
Though, we here report the first prospectiv e study comparing the influence of basal
insulin analogues on glucose variability in pa tients with type 2 diabetes ongoing HD
for ESRD (figure 19).

8/g885 Nocturnal hypoglycemic events were redu ced either as number and duration
with insulin detemir than with insul in glargine in patients with type 2 diabetes
on hemodialysis.
Several mechanisms may explain the higher incidence rate of hypoglycemia in
patients with renal failure, i.e. impaired renal glucone ogenesis, malnutrition, altered
metabolism of insulin and hypoglycemic agents or as a consequence of HD itself
(Haviv, Sharkia et al. 2000; Jackson, Holland et al. 2000). Insulin resistance is
common in uraemic pati ents, which may favour the progression of diabetic
nephropathy (Rigalleau and Gin 2005). Thus, HD patients with type 2 diabetes might
not be only insulin resistant but also prone to hypoglycaemia, with mild
hypoglycaemic episodes frequently precedin g severe or even fatal hypoglycaemia
(Haviv, Sharkia et al. 2000). Therefore, CGM can be eff iciently used to detect acute
and unrecognized blood glucose oscillations and thus to reduce the high
cardiovascular mortality in these patients (Riveline, Teynie et al. 2009). We were able
to show that nocturnal hypoglycemia events were lower either as number and duration
in the subgroup of patients treated with detemir (F igure 20). No severe hypoglycemia
was reported.
Figure 20. Nocturnal hypoglycemic even ts were reduced either as number and
duration with insulin detemir than with insulin glargine in patients with type 2
diabetes on hemodialysis HD-on=day of dialysis; HD-off=the following inter-
dialytic period.

8/g886 Variability in chronic glyce mic control in patients with type 2 diabetes on
hemodialysis on insulin detemir was lower than with insulin glargine.
Very recent data on diabetic hemodialysis patients (Williams, Garg et al. 2014)
demonstrate that higher baseline HbA1c categories were associated with greater mean
SDs of HbA1c levels over 3-year of analysis and increased odds ratio of
hypoglycemia hospitalization. That is, high va riability in chronic glycemic control is
associated with high risk of hypoglycemia related hospitalization in these patients.
The lower CV for HbA1c reported in the present study with insulin detemir than with
insulin glargine (figure 21) might suggest an immediate beneficial im pact of reducing
variability in chronic glycemic control on hypo glycemia events. However, large-scale
studies are required to confirm these findings on hypoglycemia related cardiovascular
risk in HD patients with type 2 diabetes.
Figure 21 Variability in chronic glycemic control in patients with type 2 diabetes
on hemodialysis on insulin dete mir was lower than with insulin glargine

8/g887 Coefficient of variation (CV) for HbA1c from at least 3 most recent values. P= 0.036
between groups, paired t-test.
Lower pro-inflammatory profile in pat ients with type 2 diabetes on hemodialysis
on insulin detemir than glargine.
End-stage renal disease affects HDL metabolism in patients with diabetes (Tan 1986;
Cacciagiu, Gonzalez et al. 2014). In general, patients with this disorder exhibit a
decrease of HDL cholesterol levels (Tan 1986; Cacciagiu, Gonzalez et al. 2014).
When compared with non-diabetes subjects on HD, the atherogenic effect of lipid
alterations in HD patients with type 2 diabetes is probably explained by concomitant
decrease in HDL cholesterol and increase in triglyceride-rich remnant lipoproteins, as
in spite of levels above 150 mg/dl there is no difference in triglyceride values, and the
paradoxical LDL cholesterol decrease is more likely linked to malnutrition and
inflammatory state (Cacciagiu, Gonzalez et al. 2014). Besides, the chronic
inflammation is also an emerging risk fac tor for accelerated a therosclerosis in diabetic
patients with ESRD (Zoccali, Mallamaci et al. 2004). Among various markers, ferritin
and quantitative C-reactive pr otein levels might be considered inflammatory proteins
that predict cardiovascular disease in patients with ESRD (Zoccali, Mallamaci et al.
2004). Though, in the presence of insulin resistance conditions, neither the pro-
inflammatory profile nor the atheroge nic lipoprotein levels, but HDL cholesterol only
has been reduced in HD patients with ty pe 2 diabetes when compared with HD non-
diabetes patients (Cacciagiu, Gonza lez et al. 2014). Moreover, it has been shown
(Bodlaj, Berg et al. 2006) that low HDL cholesterol level was the only predictor for higher HOMA-IR in HD pati ents with type 2 diabetes.

8/g888 We found similar low HDL cholesterol va lues between two subgroups, while total
cholesterol, HOMA-IR and both markers of inflamm ation were reduced in patients on
detemir only (figure 22). Thus, our result mi ght suggest an efficient modulation of
pro-inflammatory profile by insulin detemir than insulin glar gin in patients with type
2 diabetes and insulin resistance undergoing renal replacement therapy for end stage renal disease.
Figure 22 Lower pro-inflammatory prof ile in patients with type 2 diabetes on
hemodialysis on insul in detemir than glargine. P<0.001 between groups, paired t-
test.
#
#

8/g889 Section I –Original Contributions
I.5. Concluding remarks

8/g890 I.5. Concluding remarks
I.5.1. HIF- 1α stabilization is essential for wou nd healing whereas mitochondrial
ROS mediated mtDNA damages are su ccessfully compensated by intrinsic
repairing mechanisms in diabetes
Specific chronic complications of diabetes are nowadays considered as a major
medical and economical concern.
In spite of the important progre ss in understanding the specific pathogenic
mechanisms or in developing different therapeutic stra tegies, the morbidity and
mortality related with diabetes is still important suggesting a lack of efficacy in
management. Therefore, a better understanding of the specific pathogenic
mechanisms involved in chronic complica tions of diabetes might contribute to
progress in therapeutic approaches and future drug development.
Therefore, by focusing on mitochondrial DNA stability and HIF behavior as main tool
for oxygen sensing in chronic hyperglycemia characterizing the diabetic environment,
I have primarily investigated the signific ance of these two pathogenic mechanisms for
the chronic complications of diabetes in order to identify new therapeutic approaches.
Furthermore, I have specifically charac terized the mechanisms of glucose-mediated
inference on HIF- 1α stability and function, and have also described the efficacy of
HIF induction in diabetic wound healing process. Besides, I have specifically
analysed the combined effect of chronic hyperglycemia and hypoxia together on
mtDNA stability, and I have also investigated how mitochondrial ROS production
influence the mtDNA integrity in diabetes.
By original data provided here I was able to demonstrate that, in spite of the VHL-
mediated repressive effect of high glucose on its stability and function, HIF- 1α is an
essential factor and a valuable potential therapeutic target for improving the defective
wound healing process in diabetes, as its local st abilization activated all the defective
essential steps of this process.

/g890/g891 Moreover, the original data showed here represent the first observation that
pathogenic mechanisms relevant in diabetes (i.e. the combined hyperglycemia and
hypoxia) can induce critical levels of mitochondria originating ROS responsible for
mtDNA damages that were successfully compens ated by the repairing mechanisms in
diabetic animals. The evidence of compe nsation further suggests that, at least in
diabetic animals, the combined hyperglycemia-hypoxia induced mitochondria ROS
production may therefore not represent a majo r factor for the development of chronic
complications.
I.5.2. The antioxidant status is early activate d in plasma and er ythrocytes of
patients with type 2 diabetes
The blood should be probably one of the f irst organs specifically targeted in diabetes.
In spite of sufficient data attesting that redox imbalance is essentially involved in
diabetes progression and occurrence of spec ific chronic complications, the antioxidant
status of plasma is controversial and there is a lack of information related to the
antioxidant defense of the erythrocytes in diabetes. Besides, the controversial effect of
antioxidants supplementation in diabetes has const antly emerged in spite of
accumulating efforts reflected by numerous clinical studies.
Therefore, I have primarily inve stigated the antioxidant status and markers of
oxidative stess in the serum and erhytrocytes of patients with early type 2 diabetes,
focusing on special subgroups –i.e. those with no previous medical history or with no
evidence of specific cronic complications of diabetes.
The original data provided here demonstrate that, in spite of increased oxidative
aggression, both non-enzymatic and enzy matic antioxidant defense is early activated
in the blood stream of patients with type 2 diabete s, and occurs even in RBCs with a
shortened life span.
The present result could support a possible ex planation for the controversial effects of
antioxidants supplementation in diabetes.

9/g882 Furthermore, as perspective, the evaluation of antioxidant status (in blood) has
probably to be considered for clinical applicability since early clinical stages in
patients with type 2 diabetes.
I.5.3. L-Arginine drives to NO synthesis in erythrocytes of early type 2 diabetic
patients
L-Arginine is an important source of nitric oxide in many NOS expressing human
cells and exerts its cardiova scular role essentially vi a nitric oxide-dependent
processes. Besides, its main metabolic pa thway implies the arginase-mediated
conversion to ornithine into urea cycle. Th e erythrocyte’s pool is generally acce pted
as the most important intravascular nitrate originating NO reservoir.
In spite evidence of the erythrocyte’s implications in NO-dependent L-Arginine
metabolic pathways, clinical studies using L-arginine supplementation in subjects
with diabetes are still conflicting while there is a lack of information analyzing the
potential involvement of the RBCs in L-Arginine metabolism in early diabetes.
Hence, I have investigated the L-Arg inine-nitric oxide metabolic pathway and
arginase activity in RBCs and plasma of subjects with type 2 diabetes with no
previous medical history of diabetes.
The original results showed here represe nt the first observation that L-Arginine pool
is driven to NO synthesis when low arginase acti vity is expressed in erythrocytes of
patients with early type 2 diabetes.
Hence, the L- Arginine erythrocyte’s pool drives to NO synthesis that may constitute
an intravascular compensatory mechanism for endothelial dysfunction in early type 2
diabetes.
I.5.4. Insulin resistant patients with type 2 di abetes undergoing hemodialysis for
end stage renal disease on insulin detem ir exhibit lower glycemic variability and
pro-inflammatory profile than with insulin glargine.

9/g883 Patients with diabetes who reach end stage rena l disease (ESRD) are at higher risk of
morbidity and mortality. Accumulating data suggest that ac ute fluctuations of blood
glucose reflected as glucose va riability (GV) and, more recently HbA1c variability
are important for the progression of diabe tes complications, also in patients with
established diabetic nephropathy.
In spite of significant data demonstrate the efficacy of basal insulin therapy with
human analogues on glucose variability in patients with diabetes there is a lack of
information about the influence of different basa l insulin regimens on GV in patients
on dialysis with diabetes, including those with type 2 diabetes (T2DM).
Therefore, I have evaluated the influen ce of basal insulin analogues on GV – reflected
as either acute blood glucose fluctuations or HbA1c variability in patients with T2DM
on hemodialysis (HD) as replacement therapy for ESRD.
The original data reported here represe nt the first proof of a different influence of
various basal insulin regimens on glucose va riability in subjects with diabetes, insulin
resistance and ESRD.

9/g884 Section II –Perspectives
General aim
Continuous, open, and undoubted prof essional development, ei ther from medical,
research or academic perspective, that certifies valid recognition and solid and
promoting career.
Specific aims
– To develop a multi-disciplinary research team able to achieve and manage
competitive research projects.
– To obtain research grants able to se lf-sustain and development.
– To establish and consolidate a competitive rese arch unit able to perform excellence
activities in the field of diabetes.
Research directions
– Sirtuin, L-arginine mediated NO pr oduction and redox status in relation to caloric
restriction in type 2 diabetes.
– Amyloid, sirtuin, and AGE receptors re sponse to diet AGEs in type 1 diabetes.
Background and aims
Sirtuins (SIRT) are enzymes involved in post-translational modifications of proteins,
that possess either mono-ADP-ribosyltransferase or deacylase activity (Michan and
Sinclair 2007). Three differe nt classes of de-acylase are described (Michan and
Sinclair 2007). SIRT are NAD-dependent class III de-acetylases that transfer the
acetyl group of lysine to the ADP-ribose moiety to form O-acetyl-ADP-ribose,
through hydrolysis of NAD, and generati ng free nicotin-amide. Therefore, SIRT
might be considered a class of epigenetic regulators that modulate the activity of their
targets by removing covalently attached acetyl groups (Dang 2014). Hence, by
interfering with NAD/NADH intracellular ratio SIRT influence the nutritional and

9/g885 redox state of the cell, while by genera ting O-acetyl-ADP-ribose interfere with DNA
structure, facilitating the heterochromatin formation a nd silencing (Denu 2005).
There are seven (1-7) SIRT in mammals, which are differently localized and involved
in various cellular processes (Dang 2014).
The most studied is SIRT-1 that is localize d in the nucleus, but little is known for
SIRT-2 and SIRT-3, which are locali zed mostly in cytoplasm and mitochondria,
respectively (Dang 2014). Accumulating data suggest that SIRT-1 are novel targets
for treating some diseases associated with aging, and perhaps essential for extending
human life span (Michan and Sinclair 2007). Fur ther, very recent data (Guedes-Dias
and Oliveira 2013) suggests that SIRT-2 is essen tially involved in neurodegeneration
and accelerating aging in diabetes. SIRT-relat ed genes have also been associated with
increased longevity under caloric restriction (Guarente 2005) and they appear to be
implicated in the regulation of different aspects of caloric restriction responses, such
as glucose homeostasis, insulin secretion, fat metabolism, and stress resistance (Chen
and Guarente 2007).
Very few data are referring to SIRT-3 implications in diabetes or as regulators of
mitochondrial oxidative stress. Thus, recently Ca labrese and colab. have found a
down-regulation in SIRT-1 and -2 activity as indicators of systemic cellular stress
response in patients with type 2 diabetes (Cala brese, Cornelius et al. 2012), while
Canton et al. (Caton, Rich ardson et al. 2013) reported that SIRT-3 regulates mouse
pancreatic beta cell function and is suppre ssed in pancreatic islets isolated from
patients with type 2 diabetes. Further, mi tochondrial SIRT-3 seems to be involved in
chronic complications of diabetes, such is h eart disease (Pillai, S undaresan et al.
2010) or nephropathy (Maeda, Koya et al. 2011). Nevertheless, calorie restriction
reduces oxidative stress by SIRT-3-mediated SOD 2 activation (Qiu, Brown et al.
2010).
Intensive research is also evolved to find ou t the possible therapeutic opportunities of
SIRT modulators in aging diseases (Milne, Lamb ert et al. 2007; Nogueiras, Habegger
et al. 2012).

9/g886 Thought, accumulating data in very recent years gathered much controversy around
“canonical” SIRT functions. Hence, classical effect of life span extension when SIRT –
1 is overexpressed or SIRT-2 mediated li fe span extension of calorie restriction are
questioned (Dang 2014). Therefore, this rece nt studies rise an intense debate around
SIRT functions in aging, calorie restriction, as well as age-related diseases.
In a previous study (Savu, Iosif et al. 2014) I and my colab. were able to show that
erythrocytes (RBCs) pool would represe nt a potentially compensatory intravascular
compartment for endothelial dys function in diabetes. Our observation – showing a
decrease in RBCs arginase activity – could be considered a potential mechanism of
increased RBC-NO production in early diabetes. Hence, L-Arginine (L-Arg) becomes
an important source for NO synthesis in the RBCs of patients with type 2 diabetes at
first clinical onset. In a different research article (Savu, Bradescu et al. 2013) I and
my research team found that erythrocyte caspase-3 and antiox idant defense (either
non-enzymatic and enzymatic – i.e. SOD, CAT and GPx activity) is activated in RBCs
and plasma of type 2 diabe tes patients at first clinica l onset. This result suggests that
the pattern of defense against free radical aggression is activated early in the blood
stream of patients with type 2 diabetes, and o ccurs even in RBCs with a shortened life
span.
Thought, there is a lack of data about SIRT activity in RBCs relative to oxidative
stress and diabetic environment. Hence, it has been shown that caloric restriction
increases SIRT-1 and -2 gene expression in polymorphonuclear cells (PBMCs)
(Crujeiras, Parra et al. 2008) through diff erent mechanisms (Lamming, Latorre-
Esteves et al. 2005; Wang, Nguyen et al. 2007) and this effect is accompanied by an
improvement in antioxidant status in overweight subjects (Crujeiras, Parra et al.
2008).
Hence, it would be of interest to evaluate the activity of SIRT-2 and -3 in erythrocytes
and mononuclear cells (as cellular respons e to stress) in relation to L-arg mediated
NO production from erythrocytes (a s response against endothelial dysfunction) and
redox status (as specific antioxidant response to oxidative environment) in the blood
of patients with type 2 diabetes stratified according to we ight and duration of the
disease under caloric restriction.

9/g887 The increased consumption of highly p rocessed foods in last decades (Cordain, Eaton
et al. 2005) increased the exposure to ad vanced glycation endproducts (AGEs). The
detrimental effect of high ingestion of AGEs and proteins on health and disease
promoting is well recognized (Poulsen, Hede gaard et al. 2013). Serum concentration
of AGEs has been positively correlated with the severity and progression of diabetes
complications either microvascular or macrovascular, both in type 1 and type 2
diabetes (Poulsen, Hedegaard et al. 2013). Accumulating data show that serum AGEs
correlates with dietary AGEs, and th e latter also essentially contribute to the
endogenous production of AGEs a nd associate with inflammation and oxidative stress
in patients with diabetes (Uribarr i, Peppa et al. 2003; Chao, Huang et al. 2010). In
spite of increased heterogeneity (Poulsen, Hede gaard et al. 2013), it is considered as
general agreement that carboxy-methyl-lysine (CML) – and in less extent
methylglyoxal (MGO) – is one of the most studied AGE compound, both in patients
with diabetes and in healthy subjects (Van Puyv elde, Mets et al. 2014). The beneficial
effects of AGE-restricted diet ha ve been recently confirmed (Uribarri, Cai et al. 2011)
in a 4-month follow-up study on patients with type 2 diabetes without renal disease or
overt cardiovascular disease. The authors reported a significant improve of plasma
insulin, markers of inflammation and oxidative stress. Low dietary AGEs for 6 weeks
have been also reported as reducing plasma levels of inflammatory molecules in
patients with well-controlled type 1 and ty pe 2 diabetes (Vlassara, Cai et al. 2002).
Interestingly, no adverse effect of low dieta ry AGEs has been reported for patients
with diabetes (Kellow and Savige 2013). Irrespective of its nature, it has to be noted
that the effect cannot be finally attribute d to the dietary AGE contents per se. From
this point of view, there is a lot of debate if either the deleterious impact of high
content or the protective consequence of re duced composition it can be attributed to
the effects of heated foods or diet AGEs it self (Poulsen, Hedegaard et al. 2013). In
spite of these controversies, when the effect of low dietary AGEs is analyzed the meal
plan is prepared based mainly on a food que stionnaire as recommended by Goldberg
et al (Goldberg, Cai et al. 2004) or following instructions on how to modify cooking
time and temperature but not the quantity or nutrient composit ion of food (Uribarri,
Cai et al. 2011). In addition, as deleterious ef fect of high protein intake in relation to
dietary AGEs is well doc umented (Uribarri and Tuttle 2006) protein intake may be
used as estimate for dietary AGEs (Meek, LeBoeuf et al. 2013).

9/g888 The potential toxic effects of dietary AGEs are essentially modulated by the
interactions with specific AGEs receptors (Poul sen, Hedegaard et al. 2013). Among
the AGE binding proteins, a receptor for AG Es (Hartter, Svoboda et al.) and
oligosaccharyl transferase complex protein 48 (OST-48 or AGER1) seem to be the
most important. Five of 6 isoforms of RA GE lack the transmembrane domain and are
probably secreted from cells. Generall y these isoforms are referred to as sRAGE
(soluble RAGE) or esRAGE (endogenous secretory RAGE) (Poulsen, Hedegaard et
al. 2013). RAGE is widely expressed in ti ssues, and its activation induces vascular
cell dysfunction mainly via activation of oxidative stress and inflammation. The
importance of these receptors for diabetes o ccurrence resides in the animal studies,
where it has been shown that RAGE-de ficient mice developed protection against
diabetic complications (Poulsen, Hedegaard et al. 2013). Though, the interaction
between AGEs and RAGE is much debated in vivo, where other specific ligands are
described, including beta-amy loid (Thornalley 1998). AGER1 is expressed on many
cells, mainly macrophages, both on membran e and subcellular compartments, and
mediates the AGEs uptake and degradation (Poulsen, Hedegaard et al. 2013). The
mechanisms behind these actions include suppressi on of NF-kB activity and MAPK
phosphorylation (Lu, He et al. 2004; Cai, Ramdas et al. 2012) and also the activation
of NAD-dependent SIRT-1 (Uribarri, Cai et al. 2011). The protective synergism
between AGER1 and SIRT-1 is evidenced in conditions characterized by high levels
of AGEs and oxidative stress, such is type 2 di abetes (Uribarri, Cai et al. 2011). Thus,
on one side, the AGE-induced hyper-acetylation is followed by AGER1 inactivation
and reflects SIRT-1 inefficiency; on the other side, AGER1 overexpression blocks
AGE-induced suppression of SIRT-1 and prevents AGE-induced impaired insulin
signaling, at least in adipocytes (Uribarri, Cai et al. 2011). Furthermore, the presence
of diabetic complications in patients with type 1 diabetes correlates with low
expression of AGER1 in mononuclear cells and elevated serum AGEs (He,
Koschinsky et al. 2001).
Insulin amyloid polypeptide (IAPP) is a 37 amino acid peptide that results from the
conversion of a pre-pro-protein of 89 am ino acid lengths in endoplasmic reticulum
and secretory granules of beta cells (Westermark, Andersson et al. 2011). Non-
significant amounts are also expr essed in humans from the pyloric antrum

9/g889 (Toshimori, Narita et al. 1991). IAPP is co -secreted with C-pepti de and insulin as
response to glucose in an echi-molecular ratio (Kahn, D'Alessio et al. 1990), and it
seems that exerts at least hormonal paracrine effects (Ma rtinez, Kapas et al. 2000).
IAPP aggregation as amyloid has been re cently hypothesized to initiate intra-cellular
in the secretory granules of the beta cells (Paulsson, Andersson et al. 2006) and is
described in almost all pat ients with type 2 diabetes or in some patients after islet
transplantation (Westermark, Ande rsson et al. 2011). Islet amyloid is extensively
linked to type 2 diabetes (Westermark, Andersson et al. 2011), though has been also
described in subjects without diabetes (Bel l 1959). It is to note that high levels of
IAPP exerts toxic effects on cells, mainly when insulin is absent (Paulsson and
Westermark 2005). In a very recent pape r, Paulsson et al. (Paulsson, Ludvigsson et al.
2014) found high plasma levels of IAPP in 25 of 244 children with newly diagnosed
type 1 diabetes that were not correlated with C-peptide nor with autoantibody against
IAA.
Up to date, there is no data available a bout the importance of IAPP for the
progression of type 1 diabetes.
The significance of exogenous AGEs might be therefore of great interest in relation to
amyloid for the development of type 1 diabetes. The assumption is furthermore
emphasized if the importance of cumulative exposure to AGEs on type 1 diabetes is
considered from animal studies. Hence, it has been shown that only 30% of non-obese
diabetic (NOD) mice fed with AGE-restricted diet developed type 1 diabetes at first
generation. Further, the maintenance of th e same restricted diet in both dams and
offspring decreased the inc idence of type 1 diabetes to less than 15% in the next two
generations. Finally, the disease recurred when offspring were returned to the
standard diet (Peppa, He et al. 2003).
Hence, it would be of interest to eva luate the amyloid, sirtuin and AGE receptors
response to diet AGEs in blood from patients wi th type 1 diabetes at different stages
of disease.
Team establishment

9/g890 The material resources gained once the fund s have been achieved allow the
establishment of a permanent research team that will be composed from clinicians,
biochemists and biologists. The team will a lso include students in their final years of
study and young PhD students, who will therefore benefit from support aimed to
fulfill their scientific activit y from bench to bedside.
Funding resources
Diabetes mellitus is nowadays a serious he alth problem, that is spreading almost
epidemic, either worldwide or in our country. Thus, while in Romanian population it
already affects more than 1.5 million a dults, the global prevalence is expected to
reach 366 million people by 2030.
Hence, diabetes becomes a major healt h, social and economical concern that
generates a tremendous interest from both scientific communit y and governmental
authorities aimed to reduce the impact on medical resources. As consequence, the
number of specific financed research programs has been constantly increased.
The funding resources those are potentially available may include as follows:
1. Direct financial support from European Union research platforms, such is Horizon
2020, Fit for Health and IMI programs.
2. Research programs financed from Romanian Government, such is:
a. Funding resources targeting internal re search, i.e. “Programul Parteneriate” or
“Programul Operational Sectorial pe ntru Cresterea C ompetitivitatii Economice”
(POSCCE).
b. Funding resources supporting young researchers, i.e. small internal grants
supported by universities.
c. Bilateral cooperative programs with spec ific research teams from countries inside
or outside of European Union.
3. Research funds or fellowships supported by int ernational organizations for study of
diabetes, i.e. EASD or IDF.
Risk analysis
1. Human resources drop out. In actual socia l-economic climate this estimated risk
might have several possible explanations. Probably one of the first reasons is low self-

/g891/g891 motivation for research activities as a direct consequence of insufficient specific
salary for a generally highly time -consuming work. The problem is moreover
exacerbated due to financial instability affecting general economy.
2. Delayed or cessation of funds procur ement. The main reason behind this possible
risk is the financial instability affecting gene ral economy, also. Exchange variability
and funds insufficiency might be other major pitfalls, too.
3. Economic crisis.
Expected impact
1. Positive impact on my professional development.
– Increase ability in obtaining scientific funds and grants.
– Increase ability in managing scientific funds and grants.
2. Positive impact on human resources.
– Increase their performance for good research practice, laboratory skills, and
scientific writing.
– Increase their ability to understand scientific information.
– Increase their capacities to be enr olled and/or to obtain scientific projects, funds and
grants for the future activity as independent researchers/scientists.
3. Positive impact on my professional network.
– Establish and extend new professional contacts.
– Establish and extend future research directions, scientific projects and funding
sources.
4. Benefit of the patients suffering from diabetes, who live especially in Romania.
– Underline at least that relative simple modificat ion in their life-style (i.e. calorie
restriction and ingestion of healthy prep ared food) might have important
consequences on the occurrence and pr ogression of their disea se (i.e. diabetes).
5. Benefit of the pharmaceutical companies.
– The output of the research will be a subst antial body of data that might form the
basis for further study and developme nt work dedicated to sp ecific drug discovery.
Specifically, potential use for sirtuin treatment along with insulin therapy in type 1
diabetes will be of interest.
6. Development of a center of excellence dedicated for the study of diabetes.

10/g882 SWOT analysis
Strengths
– Medical expertise in diabetes, nutrition and metabolic disease as clinician working in the
“N Paulescu” National Institute for Diabetes, Nutrition and Metabolic Diseases. – Experience
in clinical trials. – Work-experience in two prestigious clinics from abroad, i.e. Udine, Italy and Karolinska Institutet, Sweden. – Licentiate degree in medical sciences at Karolinska Institutet, Sweden. – Very good skills in elaborating and conducting scientific work, from lab bench,through the final original scientific paper able to be published in internationaldatabases of medical journals. – Good skills for team working.
Weaknesses
– Limited experience in obtaining scientific funds and grants. –
Limited experience in managing scientific funds and grants.
Opportunities
-Effectively working in the “N Paulescu” National Institute for Diabetes, Nutrition and
Metabolic Diseases.-Working as collaborator assistant professor in Univ. Med. Ph. “Carol Davila”.
– Permissive access to professional-targeted training programs.- Permissive access to national and international research framework. – Access to medical literature and databases through faculty library.
Threats
– Increasing competition to access research funds.
– Increasing costs for publication, as a consequence of extended number of open-access ISI journals./g16/g3/g40/g70/g82/g81/g82/g80/g76/g70/g3/g70/g85/g76/g86/g76/g86/g17

10/g883 Section III – Bibliography
Aguirre, F., I. Martin, et al. (1998 ). "Oxidative damage, plasma antioxidant
capacity, and glucemic control in elderly NIDDM patients." Free Radic Biol
Med 24(4): 580-585.
Ahmed, F. N., F. N. Naqvi, et al. (2006 ). "Lipid peroxidation a nd serum antioxidant
enzymes in patients with type 2 dia betes mellitus." Ann N Y Acad Sci
1084: 481-489.
Ahmed, N. (2005). "Advanced glycation endproducts–role in pathology of
diabetic complications." Diabetes Res Clin Pract 67(1): 3- 21.
Alderton, W. K., C. E. Cooper, et al. (2 001). "Nitric oxide synthases: structure,
function and inhibition." Biochem J 357 (Pt 3): 593-615.
Anson, R. M., E. Hudson, et al. (2000 ). "Mitochondrial endogenous oxidative
damage has been overestimated." FASEB J 14(2): 355-360.
Antonetti, D. A., A. J. Barber, et al. (2006 ). "Diabetic retinopathy: seeing beyond
glucose-induced microvascular disease." Diabetes 55(9): 2401-2411 .
Arjamaa, O. and M. Nikinmaa (2006). "Ox ygen-dependent diseases in the retina:
role of hypoxia-induci ble factors." Exp Eye Res 83(3): 473-483.
Bae, S. H., J. W. Jeong, et al. (2004). "S umoylation increases HIF-1alpha stability
and its transcriptional activity. " Biochem Biophys Res Commun 324(1 ):
394-400.
Bagnati, M., C. Perugini, et al. (1999). "Whe n and why a water-soluble antioxidant
becomes pro-oxidant during copper-i nduced low-density lipoprotein
oxidation: a study using ur ic acid." Biochem J 340 ( Pt 1) : 143-152.
Ballinger, S. W., J. M. Shoffner, et al. ( 1994). "Mitochondrial diabetes revisited."
Nat Genet 7(4): 458-459.
Ballinger, S. W., J. M. Shoffner, et al. (1992). "Maternally transmitted diabetes and
deafness associated with a 10.4 kb mitochondrial DNA deletion." Nat
Genet 1(1): 11-15.
Barbas, C., N. Adeva, et al. (1998). "Quant itative determination of short-chain
organic acids in urine by cap illary electrophoresis." Clin Chem 44(6 Pt 1) :
1340-1342.
Basu, S., N. A. Azarova, et al. (2008). "Nit rite reductase activity of cytochrome c." J
Biol Chem 283 (47): 32590-32597.
Batandier, C., E. Fontaine, et al. (2002 ). "Determination of mitochondrial reactive
oxygen species: methodological aspects." J Cell Mol Med 6(2): 175-187.
Baumann, C. A., V. Ribon, et al. (2000). "CAP defines a second signalling pathway
required for insulin-stimu lated glucose transport." Nature 407 (6801):
202-207.
Bell, E. T. (1959). "Hyalinization of the islets of Langerhans in nondiabetic
individuals." Am J Pathol 35(4): 801-805.
Bender, A., K. J. Krishnan, et al. (2006 ). "High levels of mitochondrial DNA
deletions in substantia nigra neurons in aging and Parki nson disease." Nat
Genet 38(5): 515-517.
Berchner-Pfannschmidt, U., S. Frede, et a l. (2008). "Imaging of the hypoxia-
inducible factor pathway: insights in to oxygen sensing." Eur Respir J
32(1): 210-217.

10/g884 Berra, E., E. Benizri, et al. (2003). "HIF prolyl-hydroxylase 2 is the key oxygen
sensor setting low steady-state levels of HIF-1alpha in normoxia." EMBO J
22(16): 4082-4090.
Berta, M. A., N. Mazure, et al. (2007). "S UMOylation of hypoxia-inducible factor-
1alpha reduces its transcripti onal activity." Biochem Biophys Res
Commun 360 (3): 646-652.
Beyer, R. E. (1992). "An analysis of the role of coenzyme Q in free radical
generation and as an antioxidant." Biochem Cell Biol 70(6): 390-403.
Bjelakovic, G., D. Nikolova, et al. (2 012). "Antioxidant supplements for prevention
of mortality in healthy participants and patients with various diseases."
Cochrane Database Syst Rev 3 : CD007176.
Bjornheden, T., M. Levin, et al. (1 999). "Evidence of hypoxic areas within the
arterial wall in vivo." Arterioscler Thromb Vasc Biol 19(4): 870-876.
Bo, S., G. Ciccone, et al. (200 5). "Renal damage in patien ts with Type 2 diabetes: a
strong predictor of morta lity." Diabet Med 22(3): 258-265.
Bodlaj, G., J. Berg, et al. (2006). " Prevalence, severity and predictors of HOMA-
estimated insulin resistance in diabetic and nondiabetic patients with end-stage renal disease." J Nephrol 19 (5): 607-612.
Boger, R. H. (2003). "Association of asy mmetric dimethylarginine and
endothelial dysfunction." Clin Chem Lab Med 41(11): 1467-1472.
Boger, R. H. (2004). "Asymm etric dimethylarginine, an endogenous inhibitor of
nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor." J Nutr 134(10 Suppl): 2842S-2847S
;
discussion 2853S.
Bonds, D. E., M. E. Miller, et al. (2 010). "The association between symptomatic,
severe hypoglycaemia and mortality in type 2 diabetes: retrospective
epidemiological analysis of the ACCORD study." BMJ 340: b4909.
Bor-Kucukatay, M., R. B. Wenby, et al. (2 003). "Effects of nitric oxide on red blood
cell deformability." Am J Physiol Heart Circ Physiol 284(5): H1577-1584.
Bosch-Marce, M., H. Okuyama, et al. (20 07). "Effects of aging and hypoxia-
inducible factor-1 activity on angiog enic cell mobilization and recovery of
perfusion after limb ischemia." Circ Res 101(12): 1310-1318.
Botusan, I. R., V. G. Sunkari, et al. (2008). "S tabilization of HIF-1alpha is critical to
improve wound healing in diabetic mice." Proc Natl Acad Sci U S A
105(49): 19426-19431.
Boulton, A. J., L. Vileikyte, et al. (2005). "The global burden of diabetic foot
disease." Lancet 366(9498): 1719-1724.
Bourdon, E. and D. Blache (2001). "The imp ortance of proteins in defense against
oxidation." Antioxid Redox Signal 3(2): 293-311.
Boxen, I. (1985). "Mechanisms of atherog enesis: endothelial hypoxia proposed as
the major initiator." Med Hypotheses 18(3): 297-311.
Brahimi-Horn, M. C. and J. Pouyssegur (2 009). "HIF at a glance." J Cell Sci 122(Pt
8): 1055-1057.
Breimer, L. H., G. Wannamethee, et al. ( 1995). "Serum bilirubin and risk of
ischemic heart disease in middle-aged British men." Clin Chem 41(10):
1504-1508.
Brownlee, M. (1995). "Advanced protein glycosylation in diabetes and aging."
Annu Rev Med 46: 223-234.

10/g885 Brownlee, M. (2001). "Biochemistry an d molecular cell biology of diabetic
complications." Nature 414(6865): 813-820.
Brunini, T. M., N. B. Roberts, et al. (2002 ). "Activation of L-arginine transport in
peripheral blood mononuclear cells in chr onic renal failure." Pflugers
Arch 445 (1): 147-151.
Bryant, N. J., R. Govers, et al. (2 002). "Regulated transp ort of the glucose
transporter GLUT4." Nat Rev Mol Cell Biol 3(4): 267-277.
Buga, G. M., R. Singh, et al. (1996 ). "Arginase activity in endothelial cells:
inhibition by NG-hydroxy-L-arginine during high-output NO production."
Am J Physiol 271(5 Pt 2): H1988-1998.
Cacciagiu, L., A. I. Gonzalez, et al. ( 2014). "Do insulin resistance conditions
further impair the lipid and inflammatory profile in end-stage renal
disease patients on hemodialy sis?" Metab Syndr Relat Disord 12(4): 220-
226.
Cai, W., M. Ramdas, et al. (2012). "Oral advanced glycation endproducts (AGEs)
promote insulin resistance and diab etes by depleting the antioxidant
defenses AGE receptor-1 and sirtuin 1." Proc Natl Acad Sci U S A 109 (39):
15888-15893.
Calabrese, V., C. Cornelius, et al. (2 012). "Oxidative stress, glutathione status,
sirtuin and cellular stress response in type 2 diabetes." Biochim Biophys
Acta 1822(5): 729-736.
Calderon-Salinas, J. V., E. G. Munoz-Reyes, et al. (201 1). "Eryptosis and oxidative
damage in type 2 diabetic mellitus patients with chronic kidney disease." Mol Cell Biochem 357(1-2): 171-179.
Cameron, N. E., S. E. Eaton, et al. (2001). "Vascular factors and metabolic
interactions in the pathogenesis of diabetic neuropathy." Diabetologia
44(11): 1973-1988.
Cassoly, R. and Q. Gibson (1975). "Confo rmation, co-operativity and ligand
binding in human hemoglobi n." J Mol Biol 91(3): 301-313.
Caton, P. W., S. J. Richardson, et al. (2 013). "Sirtuin 3 regulates mouse pancreatic
beta cell function and is suppressed in pancreatic islets isolated from human type 2 diabetic pat ients." Diabetologia 56(5): 1068-1077.
Catrina, S. B. (2014). "Impaired hypoxia -inducible factor (HIF) regulation by
hyperglycemia." J Mol Med (Berl).
Ceballos, I., J. M. Delabar, et al. (1988). "Expression of transfected human CuZn
superoxide dismutase gene in mouse L cells and NS20Y neuroblastoma
cells induces enhancement of glutat hione peroxidase activity." Biochim
Biophys Acta 949(1): 58-64.
Ceriello, A. (2000). "Oxidative stress an d glycemic regulation." Metabolism 49(2
Suppl 1): 27-29.
Ceriello, A., F. Mercuri, et al. (2001). " Detection of nitrotyrosine in the diabetic
plasma: evidence of oxidat ive stress." Diabetologia 44(7): 834-838.
Cerwinka, W. H., D. Cooper, et al. (2 002). "Nitric oxide modulates endotoxin-
induced platelet-endothelial cell adhesion in intestinal venules." Am J
Physiol Heart Circ Physiol 282(3): H1111-1117.
Chandel, N. S., D. S. McClintock, et al. ( 2000). "Reactive oxy gen species generated
at mitochondrial complex III stabilize hy poxia-inducible factor-1alpha
during hypoxia: a mechanism of O2 sensing." J Biol.Chem. 275(33):
25130-25138.

10/g886 Chao, P. C., C. N. Huang, et al. ( 2010). "Association of dietary AGEs with
circulating AGEs, glycated LDL, IL- 1alpha and MCP-1 levels in type 2
diabetic patients." Eur J Nutr 49(7): 429-434.
Chen, D. and L. Guarente (2007). "SIR2: a potential target for calorie restriction
mimetics." Trends Mol Med 13(2): 64-71.
Chen, K. and A. S. Popel (2009). "Nit ric oxide produc tion pathways in
erythrocytes and plasma." Biorheology 46 (2): 107-119.
Chen, L. Y. and J. L. Mehta (1998). "Evide nce for the presence of L-arginine-nitric
oxide pathway in human red blood cells: relevance in the effects of red
blood cells on platelet function." J Cardiovasc Pharmacol 32(1): 57-61.
Chen, S. K., W. A. Hsieh, et al. (2003). "Age-associate d decrease of oxidative repair
enzymes, human 8-oxoguanine DNA glycosylases (hOgg1), in human
aging." J Radiat Res (Tokyo) 44(1): 31-35.
Cheng, J., X. Kang, et al. (2007). "SUMO-specific protease 1 is essential for
stabilization of HIF1alpha during hypoxia." Cell 131(3): 584-595.
Chiarelli, F., F. Santilli, et al. (2000 ). "Role of growth factors in the development of
diabetic complications." Horm Res 53(2): 53-67.
Chien, R.-L. and D. S. Burgi (1991). "Field amplified sample injection in high-
performance capillary electrophoresis. " Journal of Chromatography A
559(1–2): 141-152.
Chin-Dusting, J. P., C. T. Alexander, et al. (1996). "Effects of in vivo and in vitro L-
arginine supplementation on healthy hum an vessels." J Cardiovasc
Pharmacol 28(1): 158-166.
Clayton, D. A. (1982). "Replication of animal mitochondrial DNA." Cell 28(4):
693-705.
Closs, E. I., J. S. Scheld, et al. (2000). "Substrate supply for nitric -oxide synthase in
macrophages and endothelial cells: role of cationic amino acid
transporters." Mol Pharmacol 57(1): 68-74.
Collins, A. J., R. N. Foley, et al. (2 012). "'United States Renal Data System 2011
Annual Data Report: Atlas of chronic kidney disease & end-stage renal
disease in the United St ates." Am J Kidney Dis 59(1 Suppl 1): A7, e1-420.
Cooper, C. E. and G. C. Brown (2008 ). "The inhibition of mitochondrial
cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen
cyanide and hydrogen sulfide : chemical mechanism and physiological
significance." J Bioenerg Biomembr 40(5): 533-539.
Cordain, L., S. B. Eaton, et al. (2005 ). "Origins and evolution of the Western diet:
health implications for the 21st century." Am J Clin Nutr 81(2): 341-354.
Cosby, K., K. S. Partovi, et al. (2003 ). "Nitrite reduction to nitric oxide by
deoxyhemoglobin vasodilates the human circulation." Nat Med 9(12):
1498-1505.
Crawford, T. N., D. V. Alfaro, 3rd, et al. (2009). "Diabetic retinopathy and
angiogenesis." Curr Diabetes Rev 5 (1): 8-13.
Creager, M. A., S. J. Gallagh er, et al. (1992). "L-arginine improves endothelium-
dependent vasodilation in hyperchol esterolemic humans." J Clin Invest
90(4): 1248-1253.
Crews, S. T. and C. M. Fan (1999). " Remembrance of things PAS: regulation of
development by bHLH-PAS protein s." Curr Opin Genet Dev 9(5): 580-587.

10/g887 Crow, J. P. and H. Ischiropoulos (1996). "Detecti on and quantitation of
nitrotyrosine residues in proteins: i n vivo marker of peroxynitrite."
Methods Enzymol 269 : 185-194.
Crujeiras, A. B., D. Parra, et al. ( 2008). "Sirtuin gene expression in human
mononuclear cells is modulated by caloric restriction." Eur J Clin Invest
38(9): 672-678.
Curtin, J. F., M. Donovan, et al. (2002 ). "Regulation and measurement of oxidative
stress in apoptosis." J Immunol Methods 265 (1-2): 49-72.
Curtis, T. M., T. A. Gardiner, et al. (2009). "Microvascular lesions of diabetic
retinopathy: clues towards understanding pathogenesis?" Eye (Lond)
23(7): 1496-1508.
Dang, W. (2014). "The controversial worl d of sirtuins." Drug Discov Today
Technol 12: e9-e17.
Dayani, P. N., M. C. Bishop, et al. (2 004). "Desferoxamine (DFO)–mediated iron
chelation: rationale for a novel approach to therapy for brain cancer." J
Neurooncol 67(3): 367-377.
Dejam, A., C. J. Hunter, et al. (2005). "Erythrocytes are the major intravascular
storage sites of nitrite in hum an blood." Blood 106(2): 734-739.
Denu, J. M. (2005). "The Sir 2 family of protein deacetylases." Curr Opin Chem
Biol 9 (5): 431-440.
Deves, R., P. Chavez, et al. (1992). "Identification of a new transport system (y+L)
in human erythrocytes that recognizes lysine and leucine with high
affinity." J Physiol 454: 491-501.
Dioguardi, F. S. (2011). "To give or not to give? Lessons from the arginine
paradox." J Nutrig enet Nutrigenomics 4(2): 90- 98.
Du, X., T. Matsumura, et al. (2003). "Inhibition of GAPDH activity by poly(ADP-
ribose) polymerase activates three major pathways of hyperglycemic
damage in endothelial cells." J Clin Invest 112(7): 1049-1057.
Du, X. L., D. Edelstein, et al. (2000 ). "Hyperglycemia-induced mitochondrial
superoxide overproduction act ivates the hexosamine pathway and
induces plasminogen activator inhibit or-1 expression by increasing Sp1
glycosylation." Proc Natl Acad Sci U S A 97(22): 12222-12226.
Ducluzeau, P. H., L. M. Fletcher, et al. (2002). "Molecular mechanisms of insulin-
stimulated glucose uptake in adi pocytes." Diabetes Metab 28(2): 85-92.
Duncan, M. W. (2003). "A review of approaches to the analysis of 3-
nitrotyrosine." Amino Acids 25(3-4): 351-361.
Durante, W., F. K. Johnson, et al. (2007). "Arginase: a critical regulator of nitric
oxide synthesis and vascular f unction." Clin Exp Pharmacol Physiol 34(9 ):
906-911.
Eich, R. F., T. Li, et al. (1996). "Mechan ism of NO-induced oxidation of myoglobin
and hemoglobin." Biochemistry 35(22): 6976-6983.
Ekstrand, M. I., M. Falkenberg, et al. (2 004). "Mitochondrial transcription factor A
regulates mtDNA copy number in mammals." Hum Mol Genet 13(9): 935-
944.
El Boghdady, N. A. and G. A. Badr (201 2). "Evaluation of oxidative stress markers
and vascular risk factors in patients wi th diabetic peripheral neuropathy."
Cell Biochem Funct 30(4): 328-334.

10/g888 Elson, D. A., G. Thurston, et al. (2001 ). "Induction of hypervascularity without
leakage or inflammation in transgenic mice overexpressing hypoxia-
inducible factor-1alpha." Genes Dev 15(19): 2520-2532.
Emerit, J., C. Beaumont, et al. (2001 ). "Iron metabolism, free radicals, and
oxidative injury." Biomed Pharmacother 55 (6): 333-339.
Esposito, L. A., S. Melov, et al. (1999). "Mitochondrial disease in mouse results in
increased oxidative stress. " Proc Natl Acad Sci U S A 96(9): 4820-48 25.
Feillet-Coudray, C., E. Rock, et al. (19 99). "Lipid peroxidation and antioxidant
status in experimental diabe tes." Clin Chim Acta 284(1): 31-43.
Feldman, E. L. (2003). "Oxidative stress and diabetic neuropathy: a new
understanding of an old problem." J Clin Invest 111(4): 431-433.
Feldser, D., F. Agani, et al. (1999). "Reciprocal positive regulation of hypoxia-
inducible factor 1alpha and insulin -like growth factor 2." Cancer Res
59(16): 3915-3918.
Ferlito, S. and M. Gallina (1999). "Nitrite p lasma levels in type 1 and 2 diabetics
with and without complications. " Minerva Endocrinol 24(3-4): 117-121.
Fernandez-Silva, P., J. A. Enriquez, et al. (2003). "Replication and transcription of
mammalian mitochondrial DNA." Exp Physiol 88(1): 41-56.
Fine, L. G., D. Bandyopadhay, et al. (2000). "Is there a common mechanism for the
progression of different types of ren al diseases other than proteinuria?
Towards the unifying theme of chronic hypoxia." Kidney Int Suppl 75:
S22-26.
Fine, L. G. and J. T. Norman (2008). "Chronic hypoxia as a mechanism of
progression of chronic kidney d iseases: from hypothesis to novel
therapeutics." Kidney Int 74(7): 867-872.
Flam, B. R., D. C. Eichler, et al. (2 007). "Endothelial nitric oxide production is
tightly coupled to the citrulline-NO cycle." Nitric Oxide 17 (3-4): 115-121.
Fridovich, I. (1995). "Superoxide radical and superoxide dismutases." Annu Rev
Biochem 64: 97-112.
Gallagher, K. A., Z. J. Liu, et al. (2007 ). "Diabetic impairments in NO-mediated
endothelial progenitor cell mobilization and homing are reversed by
hyperoxia and SDF-1 alpha." J Clin Invest 117(5): 1249-1259.
Garcia Soriano, F., L. Virag, et al. (2001 ). "Diabetic endothelial dysfunction: the
role of poly(ADP-ribose) poly merase activation." Nat Med 7(1): 108-113.
Garcia-Ramirez, M., G. Francisco, et al. (2 008). "Mitochondrial DNA oxidation and
manganese superoxide dismutase activity in peripheral blood
mononuclear cells from type 2 diabetic patients." Diabetes Metab 34(2):
117-124.
Gaut, J. P., J. Byun, et al. (2002). "Myelop eroxidase produces nitrating oxidants in
vivo." J Clin Invest 109(10): 1311-1319.
Gill, G. and M. Ptashne (1988). "Negative effect of the transcriptional activator
GAL4." Nature 334(6184): 721-724.
Giordani, I., A. Di Flaviani, et al. (2014). "Acute hyperglycemia reduces
cerebrovascular reactivity: the role of glycemic variability." J Clin
Endocrinol Metab 99(8): 2854-2860.
Giugliano, D., A. Ceriello, et al. (1996). "Oxidative stress and diabetic vascular
complications." Diabetes Care 19(3): 257-267.

10/g889 Giugliano, D., R. Marfella, et al. (1997 ). "L-arginine for testing endothelium-
dependent vascular functions in health and disease." Am J Physiol 273 (3
Pt 1): E606-612.
Golbidi, S., S. A. Ebadi, et al. (2011). "Antioxidants in the treatment of diabetes."
Curr Diabetes Rev 7(2): 106-125.
Goldberg, T., W. Cai, et al. (2004). "A dvanced glycoxidation end products in
commonly consumed foods ." J Am Diet Assoc 104 (8): 1287-1291.
Goth, L., P. Rass, et al. (2004). "Catalase enzyme mutations and their association
with diseases." Mol Diagn 8(3): 141-149.
Grody, W. W., C. Argyle, et al. (1989). "Differential expression of the two human
arginase genes in hyperargininemia . Enzymatic, pathologic, and
molecular analysis." J Clin Invest 83(2): 602-609 .
Guarente, L. (2005). "Calorie restriction and SIR2 genes–towards a mechanism."
Mech Ageing Dev 126(9): 923-928.
Guedes-Dias, P. and J. M. Oliveira (2013). "Lysine deacetylases and mitochondrial
dynamics in neurodegeneration." Biochim Biophys Acta 1832 (8): 1345-
1359.
Guldiken, B., M. Demir, et al. (2009). "Oxidative stress and total antioxidant
capacity in diabetic and nondiabetic acute ischemic stroke patients." Clin
Appl Thromb Hemost 15(6): 695-700.
Gutteridge, J. M. and B. Halliwell (2007). "Free Radicals in Biology and Medicine,
forth edition." Oxford University Press Inc. NY.
Haffner, S. M. (2000). "Coronary heart disease in patients with diabetes." N Engl J
Med 342(14): 1040-1042.
Halliwell, B. and J. M. Gutteridge (19 90). "The antioxidants of human
extracellular fluids. " Arch Biochem Biophys 280 (1): 1-8.
Halliwell, B. and J. M. Gutteridge (1995). "The definition and measurement of
antioxidants in biologic al systems." Free Radic Biol Med 18(1): 125-126 .
Hanssen, H., T. M. Brunini, et al. (1998). "Increased L-arginine transport in
human erythrocytes in chronic heart failure." Clin Sci (Lond) 94(1): 43-
48.
Harman, D. (1972). "The biologic clock : the mitochondria?" J Am Geriatr Soc
20(4): 145-147.
Hartter, E., T. Svoboda, et al. (1990). "R educed islet-amyloid polypeptide in
insulin-dependent diab etes mellitus." Lancet 335(8693): 854.
Haviv, Y. S., M. Sharkia, et al. (2000 ). "Hypoglycemia in patients with renal
failure." Ren Fail 22(2): 219-223.
He, C. J., T. Koschinsky, et al. (2001). "Presence of diabetic complications in type 1
diabetic patients correlates with low expression of mononuclear cell AGE-
receptor-1 and eleva ted serum AGE." Mol Med 7(3): 159-168.
Hecker, M., W. C. Sessa, et al. (1990 ). "The metabolism of L-arginine and its
significance for the biosynthesis of end othelium-derived relaxing factor:
cultured endothelial cells recycle L-citr ulline to L-arginine." Proc Natl
Acad Sci U S A 87(21): 8612-8616.
Hegde, M. L., T. K. Hazra, et al. (2008). "Early steps in the DNA base
excision/single-strand interruption repair pathway in mammalian cells." Cell Res 18(1): 27-47.

1/g882/g890 Hirota, K. and G. L. Semenza (2005). "Regu lation of hypoxia-inducible factor 1 by
prolyl and asparaginyl hydroxylases." Biochem Biophys Res Commun
338(1): 610-616.
Hoffman, E. C., H. Reyes, et al. (1991). "C loning of a factor required for activity of
the Ah (dioxin) receptor." Science 252 (5008): 954-958.
Holekamp, N. M., Y. B. Shui, et al. (2 006). "Lower intraocular oxygen tension in
diabetic patients: possible contribution to decreased incidence of nuclear
sclerotic cataract." Am J Ophthalmol 141 (6): 1027-1032.
Hu, F. B., M. J. Stampfer, et al. (2001). "The impact of diabetes mellitus on
mortality from all causes and coronary heart disease in women: 20 years
of follow-up." Arch Intern Med 161(14): 1717-1723.
Huang, C., Y. Han, et al. (2009). "SE NP3 is responsible for HIF-1 transactivation
under mild oxidative stress via p300 de-SUMOylation." EMBO J 28(18):
2748-2762.
Huang, Z., S. Shiva, et al. (2005). "Enz ymatic function of hemoglobin as a nitrite
reductase that produces NO und er allosteric control." J Clin Invest
115(8): 2099-2107.
Hubbi, M. E., H. Hu, et al. (2013). "Chaperone-mediate d autophagy targets
hypoxia-inducible factor-1alpha (HIF- 1alpha) for lysosomal degradation."
J Biol Chem 288 (15): 10703-10714.
Hulten, L. M. and M. Levin (2009). "The role of hypoxia in atherosclerosis." Curr
Opin Lipidol 20 (5): 409-414.
Huszka, M., M. Kaplar, et al. (1 997). "The association of reduced endothelium
derived relaxing factor-NO prod uction with endothelial damage and
increased in vivo platelet activation in patients with diabetes mellitus."
Thromb Res 86(2): 173-180.
Ignarro, L. J. (1989). "Endothelium-deriv ed nitric oxide: pharmacology and
relationship to the actions of organic nitrate esters." Pharm Res 6(8):
651-659.
Imam, S. Z., B. Karahalil, et al. (2006 ). "Mitochondrial and nuclear DNA-repair
capacity of various brain regions in mo use is altered in an age-dependent
manner." Neurobiol Aging 27(8): 1129-1136.
Ivan, M. and W. G. Kaelin, Jr. (2001). "The von Hippel-Lindau tumor suppressor
protein." Curr Opin Genet Dev 11(1): 27-34.
Ivan, M., K. Kondo, et al. (2001). "HIF alpha targeted for VHL-mediated
destruction by proline hydro xylation: implications for O2 sensing."
Science 292(5516): 464-468.
Jaakkola, P., D. R. Mole, et al. (2001). "Targeting of H IF-alpha to the von Hippel-
Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation." Science 292(5516): 468-472.
Jackson, M. A., M. R. Holland, et al. (2000). "Hemodialysis-ind uced hypoglycemia
in diabetic patients." Clin Nephrol 54(1): 30-34.
Jarvilehto, M. and P. Tuohimaa (2009). "V asa vasorum hypoxia: initiation of
atherosclerosis." Med Hypotheses 73(1): 40-41.
Jay, D., H. Hitomi, et al. (2006). "Oxidative stress and diabetic cardiovascular
complications." Free Radic Biol Med 40(2): 183-192.
Jeong, J. W., M. K. Bae, et al. (2002). "Regulation and destabilization of HIF-1alpha
by ARD1-mediated acetylation." Cell 111 (5): 709-720.

1/g882/g891 Jiang, M., Y. Ding, et al. (2006). "Arginase-flotillin interaction brings arginase to
red blood cell membrane." FEBS Lett 580 (28-29): 6561-6564.
Jiang, M., L. Jia, et al. (2003). "Prote in disregulation in red blood cell membranes
of type 2 diabetic patients." Biochem Biophys Res Commun 309 (1): 196-
200.
Johnson, R. J., S. D. Kivlighn, et al. (1999). "Reappraisal of the pathogenesis and
consequences of hyperuricemia in hypertension, cardiovascular disease,
and renal disease." Am J Kidney Dis 33(2): 225-234.
Jones, D. P., L. Eklow, et al. (1981). "M etabolism of hydrogen peroxide in isolated
hepatocytes: relative contributions of catalase and glutathione peroxidase
in decomposition of endog enously generated H2O2." Arch Biochem
Biophys 210(2): 505-516.
Kadowaki, T., H. Kadowaki, et al. (1994). "A subtype of diabetes mellitus
associated with a mutation of mitochondrial DNA." N Engl J Med 330(14):
962-968.
Kagan, V., V. A. Tyurin, et al. (2003). "Mishandling of copper by albumin: role in
redox cycling and oxidative stress in preeclampsia plasma." Hypertension
Pregn: 221-241.
Kahn, S. E., D. A. D'Alessio, et al. (1990 ). "Evidence of cosecretion of islet amyloid
polypeptide and insulin by beta-cells." Diabetes 39(5): 634-638.
Kallio, P. J., K. Okamoto, et al. (1998 ). "Signal transduction in hypoxic cells:
inducible nuclear translocation and recruitment of the CBP/p300
coactivator by the hypoxia-inducible factor-1alpha." EMBO J 17(22):
6573-6586.
Kamitani, T., K. Kito, et al. (1 997). "Characterization of NEDD8, a
developmentally down-regulated ubiq uitin-like protein." J Biol Chem
272(45): 28557-28562.
Kamiya, J. and Y. Aoki (2003). "A ssociations between hyperglycaemia and
somatic transversion mutations in mitochondrial DNA of people with diabetes mellitus." Diabetologia 46(11): 1559-1566.
Kaneto, H., N. Katakami, et al. (2007 ). "Involvement of oxidative stress in the
pathogenesis of diabetes. " Antioxid Redox Signal 9(3): 355-366.
Kashyap, S. R., A. Lara, et al. (2008 ). "Insulin reduces plasma arginase activity in
type 2 diabetic pat ients." Diabetes Care 31(1): 134-139.
Kazempour-Ardebili, S., V. L. Lecamw asam, et al. (2009). "Assessing glycemic
control in maintenance hemodialysis patients with type 2 diabetes."
Diabetes Care 32(7): 1137-1142.
Ke, Q. and M. Costa (2006). "Hypoxia-inducible factor-1 (HIF-1)." Mol Pharmacol
70(5): 1469-1480.
Kedziora-Kornatowska, K. Z., M. Luciak, e t al. (1998). "Lipid peroxidation and
activities of antioxidant enzymes in e rythrocytes of patients with non-
insulin dependent diabetes with o r without diabetic nephropathy."
Nephrol Dial Transplant 13(11): 2829-2832.
Kellow, N. J. and G. S. Savige (2013). "Dietary advanced glycation end-product
restriction for the attenuation of in sulin resistance, oxidative stress and
endothelial dysfunction: a systemati c review." Eur J Clin Nutr 67(3): 239-
248.
Kelner, M. J. and R. Bagnell (1990). "Alteration of endogenous glutathione
peroxidase, manganese superoxide dismutase, and glutathione

11/g882 transferase activity in cells transfected with a copper-zinc superoxide
dismutase expression vector. Explanation for variations in paraquat
resistance." J Biol Chem 265(19): 10872-10875.
Kesavulu, M. M., R. Giri, et al. (2000). "Lip id peroxidation and antioxidant enzyme
levels in type 2 diabetics with microvascular complications." Diabetes
Metab 26(5): 387-392.
Khaidakov, M., R. H. Heflich, et al. (2 003). "Accumulation of point mutations in
mitochondrial DNA of aging mice." Mutat Res 526(1-2): 1-7.
Kim, P. S., R. K. Iyer, et al. (2002). "E xpression of the liver form of arginase in
erythrocytes." M ol Genet Metab 76(2): 100-110.
Kim, W. Y., M. Safran, et al. (2006). "F ailure to prolyl hydr oxylate hypoxia-
inducible factor alp ha phenocopies VHL inactivation in vivo." EMBO J
25(19): 4650-4662.
Kim-Shapiro, D. B., A. N. Schechter, et al. (2006). "Unraveling the reactions of
nitric oxide, nitrite, and hemogl obin in physiology and therapeutics."
Arterioscler Thromb Vasc Biol 26(4): 697-705.
King, G. L. (2008). "The role of inflamm atory cytokines in d iabetes and its
complications." J Periodontol 79(8 Suppl): 1527-1534.
Klein, R., B. E. Klein, et al. (1992). "Epidemiology of proliferative diabetic
retinopathy." Diabetes Care 15(12): 1875-1891.
Kleinbongard, P., R. Schulz, et al. (20 06). "Red blood cells express a functional
endothelial nitric ox ide synthase." Blood 107(7): 2943-2951.
Kolm-Litty, V., U. Sauer, et al. (1998). "High glucose-induced transforming
growth factor beta1 production is mediated by the hexosamine pathway
in porcine glomerular mesan gial cells." J Clin Invest 101(1): 160-169.
Kowluru, R. A., V. Kowluru, et al. (2006). "Overexpression of mitochondrial
superoxide dismutase in mice protects the retina from diabetes-induced
oxidative stress." Free Radic Biol Med 41(8): 1191-1196.
Koya, D. and G. L. King (1998). "Prote in kinase C activation and the development
of diabetic complicat ions." Diabetes 47(6): 859-866.
Kujoth, G. C., A. Hiona, et al. (2005). "M itochondrial DNA mutations, oxidative
stress, and apoptosis in mammalian aging." Science 309(5733): 481-484.
Kukat, A. and A. Trifunovic (2009). "S omatic mtDNA mutations and aging–facts
and fancies." Exp Gerontol 44(1-2): 101-105.
Kurz, S. and D. G. Harrison (1997). "Insulin and the arginine paradox." J Clin
Invest 99(3): 369-370.
Lamming, D. W., M. Latorre-Esteves, et al. (2005). "HST2 mediates SIR2-
independent life-span extension by calorie restriction." Science
309(5742): 1861-1864.
Lancaster, J. R., Jr. (1994). "Simulation of the diffusion and reaction of
endogenously produced nitric oxid e." Proc Natl Acad Sci U S A 91(1 7):
8137-8141.
Lando, D., D. J. Peet, et al. (2002 ). "Asparagine hydroxylation of the HIF
transactivation domain a hypo xic switch." Science 295(5556): 858-861.
Lang, F., E. Gulbins, et al. (2010). "C eramide in suicidal death of erythrocytes."
Cell Physiol Biochem 26(1): 21-28.
Lebovitz, R. M., H. Zhang, et al. (1996 ). "Neurodegeneration, myocardial injury,
and perinatal death in mitochond rial superoxide dismutase-deficient
mice." Proc Natl Acad Sci U S A 93(18): 9782-9787.

11/g883 Lee, A. Y., S. K. Chung, et al. (1995). "Demonstration that polyol accumulation is
responsible for diabetic cataract by the use of transgenic mice expressing
the aldose reductase gene in the lens." Proc Natl Acad Sci U S A 92(7):
2780-2784.
Lee, H. Y., C. S. Choi, et al. (2010). "Targeted expression of catalase to
mitochondria prevents age-associated reductions in mitochondrial
function and insulin resistance." Cell Metab 12(6): 668-674.
Legault, J., C. Carrier, et al. (2000). "M itochondrial GPx1 decreases induced but
not basal oxidative damage to mtDNA in T47D cells." Biochem Biophys
Res Commun 272 (2): 416-422.
Leo, R., D. Pratico, et al. (1997). "Plat elet activation by superoxide anion and
hydroxyl radicals intrinsically generate d by platelets that had undergone
anoxia and then reoxygenated." Circulation 95(4): 885-891.
Li, H., H. Cui, et al. (2008 ). "Nitric oxide production from nitrite occurs primarily
in tissues not in the blood: critical r ole of xanthine oxidase and aldehyde
oxidase." J Biol Chem 283 (26): 17855-17863.
Li, H., C. J. Meininger, et al. (2001). "R egulatory role of arginase I and II in nitric
oxide, polyamine, and proline syntheses in endothelial cells." Am J Physiol
Endocrinol Metab 280(1): E75-82.
Li, H., C. J. Meininger, et al. (2002). "A ctivities of arginase I and II are limiting for
endothelial cell proliferation." Am J Phy siol Regul Integr Comp Physiol
282(1): R64-69.
Li, W., Y. Li, et al. (2007). "Extracellu lar heat shock protein-90alpha: linking
hypoxia to skin cell motility and wound healing." EMBO J 26(5): 1221-
1233.
Liang, P., V. Hughes, et al. (1997). "Increased prevalence of mitochondrial DNA
deletions in skeletal muscle of older individuals with impaired glucose
tolerance: possible marker of glycemic stress." Diabetes 46(5): 920-923.
Lipcsey, M., E. Soderberg, et al. (2008). "F2-isoprostane, inflammation, cardiac
function and oxygenation in the endotoxaemic pig." Prostaglandins
Leukot Essent Fatty Acids 78(3): 209-217.
Lisy, K. and D. J. Peet (2008). "Turn me on: regulating HIF transcriptional
activity." Cell Death Differ 15(4): 642-649.
Liu, P., L. Qian, et al. (2008). "Removal of oxidative DNA damage via FEN1-
dependent long-patch base excision re pair in human cell mitochondria."
Mol Cell Biol 28(16): 4975-4987.
Lodovici, M., E. Bigagli, et al. (2009). "L ipoperoxidation and an tioxidant capacity
in patients with poorly controlled type 2 diabetes." Toxicol Ind Health
25(4-5): 337-341.
Longo, N., G. I. Bell, et al. (1990). "Human fibroblasts express the insulin-
responsive glucose transporter (GLUT4)." Trans Assoc Am Physicians
103: 202-213.
Lu, C., J. C. He, et al. (2004). "Advanced glycation endproduct (AGE) receptor 1 is
a negative regulator of the inflammat ory response to AGE in mesangial
cells." Proc Natl Acad Sci U S A 101(32): 11767-11772.
Lucotti, P., E. Setola, et al. (2006). "Beneficial effects of a long-term oral L-
arginine treatment added to a hypocaloric diet and exercise training
program in obese, insulin-resistant type 2 diabetic patients." Am J Physiol
Endocrinol Metab 291(5): E906-912.

11/g884 Lundberg, J. O. and E. Weitzberg (2005). "NO generation from nitrite and its role
in vascular control." Art erioscler Thromb Vasc Biol 25(5): 915-922.
Lynch, R. E. and I. Fridovich (1978). "P ermeation of the erythrocyte stroma by
superoxide radical." J Biol Chem 253 (13): 4697-4699.
Maahs, D. M., N. A. West, et al. "Epid emiology of type 1 diabetes." Endocrinol
Metab Clin North Am 39(3): 481-497.
Maeda, S., D. Koya, et al. (2011 ). "Association between single nucleotide
polymorphisms within genes encodin g sirtuin families and diabetic
nephropathy in Japanese subjects with type 2 diabetes." Clin Exp Nephrol
15(3): 381-390.
Maejima, K., S. Nakano, et al. (2001 ). "Increased basal levels of plasma nitric
oxide in Type 2 diabetic subj ects. Relationship to microvascular
complications." J Diabetes Complications 15(3): 135-143.
Maellaro, E., S. Leoncini, et al. (2011 ). "Erythrocyte caspase-3 activation and
oxidative imbalance in erythrocytes an d in plasma of type 2 diabetic
patients." Acta Diabetol.
Makino, Y., R. Cao, et al. (2001). "Inhibitory PAS dom ain protein is a negative
regulator of hypoxia-induci ble gene expression." Nature 414(6863): 550-
554.
Malaga-Trillo, E., U. Laessing, et al. (2 002). "Evolution of duplicated reggie genes
in zebrafish and goldfish." J Mol Evol 54(2): 235-245.
Malik, R. A., S. Tesfaye, et al. (1993 ). "Endoneurial localisation of microvascular
damage in human diabetic neurop athy." Diabetologia 36(5): 454-459.
Manalo, D. J., A. Rowan, et al. (2005). "Transcrip tional regulation of vascular
endothelial cell responses to hypoxi a by HIF-1." Blood 105 (2): 659-669.
Mann, G. E., D. L. Yudilevich, et al. (2003). "Regulation of amino acid and glucose
transporters in endothelial and smooth muscle cells." Physiol Rev 83(1 ):
183-252.
Marchington, D. R., V. Macaulay, et al. (1 998). "Evidence from human oocytes for
a genetic bottleneck in an mtDNA disease." Am J Hum Genet 63(3): 769-
775.
Marfella, R., F. Nappo, et al. (2 000). "Hemodynamic effects of acute
hyperglycemia in type 2 diabet ic patients." Diabetes Care 23(5): 658-663.
Martinez, A., S. Kapas, et al. ( 2000). "Coexpression of receptors for
adrenomedullin, calcitonin gene-relate d peptide, and amylin in pancreatic
beta-cells." Endocrinology 141 (1): 406-411.
Mathai, J. C. and V. Sitaramam (1994). "Stretch sensitivity of transmembrane
mobility of hydrogen peroxide thr ough voids in the bilayer. Role of
cardiolipin." J Biol Chem 269(27): 17784-17793.
Mayer, M. (2000). "Association of serum bilirubin concentration with risk of
coronary artery disease." Clin Chem 46 (11): 1723-1727.
Maynard, S., S. H. Schurman, et al. (2 009). "Base excision repair of oxidative DNA
damage and association with cancer a nd aging." Carcinogenesis 30(1): 2-
10.
Meek, R. L., R. C. LeBoeuf, et al. (2013 ). "Glomerular cell death and inflammation
with high-protein diet and di abetes." Nephrol Dial Transplant 28(7):
1711-1720.

11/g885 Mehrotra, R., K. Kalantar-Zadeh, et al. (2011). "Assessment of glycemic control in
dialysis patients with diabetes: glycosylated hemoglobin or glycated
albumin?" Clin J Am Soc Nephrol 6(7): 1520-1522.
Meisinger, C., W. Koenig, et al. (2008 ). "Uric acid levels are associated with all-
cause and cardiovascular disease mor tality independent of systemic
inflammation in men from the general population: the MONICA/KORA cohort study." Arter ioscler Thromb Vasc Biol 28(6): 1186-1192.
Mendes Ribeiro, A. C., T. M. Brunini, et al. (2001). "Abnormalities in L-arginine
transport and nitric oxide biosynthesis in chronic renal and heart failure." Cardiovasc Res 49 (4): 697-712.
Mendes Ribeiro, A. C., T. M. Brunini, et al. (1999). "Identification of system y+L as
the high-affinity transporter for L -arginine in human platelets: up-
regulation of L-arginine influx in uraemia." Pflugers Arch 438 (4): 573-
575.
Michan, S. and D. Sinclair (2007). "Sirtuins in mammals: insights into their
biological function." Biochem J 404(1): 1-13.
Michiels, C., M. Raes, et al. (1994). "Importance of Se-glutathione peroxidase,
catalase, and Cu/Zn-SOD for cell su rvival against oxidative stress." Free
Radic Biol Med 17(3): 235-248.
Milne, J. C., P. D. Lambert, et al. ( 2007). "Small molecule activators of SIRT1 as
therapeutics for the treatment of type 2 diabetes." Nature 450 (7170):
712-716.
Miyazawa, T., K. Nakagawa, et al. (2012). "Lipid glycation and protein glycation
in diabetes and at herosclerosis." Amino Acids 42(4): 1163-1170.
Morris, S. M., Jr. (2007). "Arginine metabolism: boundaries of our knowledge." J
Nutr 137(6 Suppl 2): 1602S-1609S.
Moss, M. B., T. M. Brunini, et al. (2 004). "Diminished L-argin ine bioavailability in
hypertension." Clin Sci (Lond) 107(4): 391-397.
Moss, M. B., M. A. Siqueira, et al. (2010). "Platelet aggregation in arterial
hypertension: is there a nitric oxide-urea connection?" Clin Exp
Pharmacol Physiol 37(2): 167-172.
Mott, J. L., D. Zhang, et al. (2001). "Oxidative stress is not an obligate mediator of
disease provoked by mitochondrial DNA mutations." Mutat Res 474 (1-2):
35-45.
Mullen, M. J., D. Wright, et al. (2000). "Atorvastatin but not L-arginine improves
endothelial function in type I diabe tes mellitus: a double-blind study." J
Am Coll Cardiol 36(2): 410-416.
Murdock, D. G., N. C. Christacos, et al. (2000). "The age-related accumulation of a
mitochondrial DNA control region muta tion in muscle, but not brain,
detected by a sensitive PNA-directed PCR clamping based method."
Nucleic Acids Res 28(21): 4350-4355.
Murphy, M. P. (2009). "How mitochondria produce reactive oxygen species."
Biochem J 417 (1): 1-13.
Murray, H. J. and A. J. Boulton (1995). "The pathophysiology of diabetic foot
ulceration." Clin Podiatr Med Surg 12(1): 1-17.
Nagababu, E., S. Ramasamy, et al. (2003). "Active nitric oxide produced in the red
cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite
reduction." J Biol Chem 278(47): 46349-46356.

11/g886 Nakagawa, T., H. Hu, et al. (2006). "A causal ro le for uric acid in fructose-induced
metabolic syndrome." Am J Physiol Renal Physiol 290(3): F625-631.
Nakhjavani, M., A. Esteghamati, et al. ( 2010). "Type 2 diabetes mellitus duration:
an independent predictor of seru m malondialdehyde levels." Singapore
Med J 51(7): 582-585.
Nangaku, M. (2006). "Chronic hypoxia and tubulointerstitial injury: a final
common pathway to end-stage renal failure." J Am Soc Nephrol 17(1): 17-
25.
Neri, S., S. Calvagno, et al. (2010). "Eff ects of antioxidants on postprandial
oxidative stress and endothelial dysfuncti on in subjects with impaired
glucose tolerance and type 2 diabetes." Eur J Nutr 49(7): 409-416.
Newsholme, P., E. P. Haber, et al. (2007). "Diabetes associated cell stress and
dysfunction: role of mitochondrial and non-mitochondrial ROS
production and activity." J Physiol 583 (Pt 1): 9- 24.
Ngo, B. T., K. D. Hayes, et al. (2005 ). "Manifestations of cutaneous diabetic
microangiopathy." Am J Clin Dermatol 6(4): 225-237 .
Nishikawa, T., D. Edelstein, et al. (2000). "Normalizing mitochondrial superoxide
production blocks three pathw ays of hyperglycaemic damage." Nature
404(6779): 787-790.
Niswender, K., M. Piletic, et al. (2014). "Weight change upon once-daily initiation
of insulin detemir with or without dietary intervention in overweight or
obese insulin-naive individuals with type 2 diabetes: results from the
DIET trial." Diabetes Obes Metab 16(2): 186-192.
Nitenberg, A., F. Paycha, et al. (1998). "Coronary artery responses to
physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal
coronary arteries and no other risk fact ors." Circulation 97(8): 736-743
.
Nogueiras, R., K. M. Habegger, et al. ( 2012). "Sirtuin 1 and sirtuin 3: physiological
modulators of metabolism." Physiol Rev 92(3): 1479-1514.
Nomiyama, T., Y. Tanaka, et al. (2004). "Accumulation of somatic mutation in
mitochondrial DNA and atherosclerosis in diabetic patients." Ann N Y
Acad Sci 1011 : 193-204.
Nourooz-Zadeh, J., J. Tajaddini-Sarmad i, et al. (1995). "Elevated levels of
authentic plasma hydroperoxides i n NIDDM." Diabetes 44(9): 1054-1058.
Opara, E. C. (2002). "Oxidative stress, micronutrients, diabetes mellitus and its
complications." J R Soc Promot Health 122(1): 28-34.
Packer, J. E., T. F. Slater, et al. (1979 ). "Direct observation of a free radical
interaction between vitamin E and vitamin C." Nature 278(5706): 737-
738.
Paddenberg, R., B. Ishaq, et al. (2003 ). "Essential role of complex II of the
respiratory chain in hypoxia-induced ROS generation in the pulmonary
vasculature." Am J Physiol Lung Cell Mol Physiol 284(5): L710-719.
Palmeira, C. M., A. P. Rolo, et al. ( 2007). "Hyperglycemia decreases mitochondrial
function: the regulatory role of mitochond rial biogenesis." Toxicol Appl
Pharmacol 225 (2): 214-220.
Palmerini, C. A., A. Zucchi, et al. (2009). "Erectile dysfunction and NO: variations
of NO penile blood levels before and after sildenafil treatment." Int J
Impot Res 21 (5): 321-325.

11/g887 Pasaoglu, H., B. Sancak, et al. (2004). "Lipid peroxidation and resistance to
oxidation in patients with type 2 d iabetes mellitus." Tohoku J Exp Med
203(3): 211-218.
Patel, A., S. MacMahon, et al. (2008). "Intensive blood glucose control and
vascular outcomes in patients with type 2 diabetes." N Engl J Med
358(24): 2560-2572.
Paulsson, J. F., A. Andersson, et al. (2006 ). "Intracellular amyloid-like deposits
contain unprocessed pro-islet amyloid pol ypeptide (proIA PP) in beta cells
of transgenic mice overexpressing the gene for human IAPP and
transplanted human islets. " Diabetologia 49(6): 1237-1246.
Paulsson, J. F., J. Ludvigsson, et al. (2 014). "High plasma levels of islet amyloid
polypeptide in young with new-onset of type 1 diabetes mellitus." PLoS
One 9(3): e93053.
Paulsson, J. F. and G. T. Westermark (2005). "Aberrant processing of human
proislet amyloid polypept ide results in increased amyloid formation."
Diabetes 54(7): 2117-2125.
Peppa, M., C. He, et al. (2003). "Fet al or neonatal low-glycotoxin environment
prevents autoimmune diabetes in NOD mice." Diabetes 52(6): 1441-1448.
Pereira, T., X. Zheng, et al. (2003 ). "Identification of residues critical for
regulation of protein stability and the transactivation function of the
hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor
suppressor gene pro duct." J Biol Chem 278(9): 6816-6823.
Peters, T. J. (1996). "All ab out albumin." Academic Press.
Peuchant, E., M. C. Delmas- Beauvieux, et al. (1997). "Short-term insulin therapy
and normoglycemia. Effects on erythrocyte lipid peroxidation in NIDDM patients." Diabetes Care 20(2): 202-207.
Piatti, P. M., L. D. Monti, et al. (2001 ). "Long-term oral L-arginine administration
improves peripheral and hepatic insulin sensitivity in type 2 diabetic
patients." Diabetes Care 24(5): 875-880.
Pillai, V. B., N. R. Sundaresan, et al. ( 2010). "Mitochondrial SIRT3 and heart
disease." Cardiovasc Res 88(2): 250-256.
Pitsillides, A. N., S. M. Anderson, et al. (2011). "Hypoglycemia risk and glucose
variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of i nsulin sensitivity and epinephrine
counterregulation." Diabetes Technol Ther 13(1): 11-17.
Poulsen, M. W., R. V. Hedegaard, et al. (201 3). "Advanced glycation endproducts
in food and their effects on hea lth." Food Chem Toxicol 60: 10-37.
Pournaras, C. J., E. Rungger-Brandle, e t al. (2008). "Regulat ion of retinal blood
flow in health and disease. " Prog Retin Eye Res 27(3): 284-330.
Poyton, R. O., K. A. Ball, et al. (2009). "Mit ochondrial generation of free radicals
and hypoxic signaling." Trends Endocrinol Metab 20(7): 332-340.
Poyton, R. O., P. R. Castello, et al. (2009). "Mitochondria and hypoxic signaling: a
new view." Ann N Y Acad Sci 1177: 48-56.
Prior, R. L. and G. Cao (1999). "In vivo total antioxidant capacity: comparison of
different analytical methods." Free Radic Biol Med 27(11-12): 1173-1181.
Qiu, X., K. Brown, et al. (2010). "Calor ie restriction reduces oxidative stress by
SIRT3-mediated SOD2 activation." Cell Metab 12(6): 662-667.

11/g888 Rachek, L. I., S. I. Musiyenko, et al. (2007). "Palmitate induced mitochondrial
deoxyribonucleic acid damage and apop tosis in l6 rat skeletal muscle
cells." Endocrinology 148 (1): 293-299.
Ramirez-Zamora, S., M. L. Mendez-Rodri guez, et al. (2013). "Increased
erythrocytes by-products of argin ine catabolism are associated with
hyperglycemia and could be involv ed in the pathogenesis of type 2
diabetes mellitus." PLoS One 8(6): e66823.
Regazzetti, C., P. Peraldi, et al. (20 09). "Hypoxia decreases insulin signaling
pathways in adipocytes." Diabetes 58(1): 95-103.
Rhee, S. G., H. Z. Chae, et al. (2005). "Peroxiredoxins: a historical overview and
speculative preview of novel mechanisms and emerging concepts in cell
signaling." Free Radic Biol Med 38(12): 1543-1552.
Ricco, J. B., L. Thanh Phong, et al. (2 013). "The diabetic foot: a review." J
Cardiovasc Surg (Torino) 54(6): 755-762.
Rigalleau, V. and H. Gin (2005). "Carboh ydrate metabolism in uraemia." Curr
Opin Clin Nutr Metab Care 8 (4): 463-469.
Riveline, J. P. and S. Hadjadj (2009). "Assessing glycemic control in maintenance
hemodialysis patients with type 2 d iabetes: response to Kazempour-
Ardebili et al." Diabetes Care 32(12): e155; author reply e156.
Riveline, J. P., J. Teynie, et al. (2009 ). "Glycaemic control in type 2 diabetic
patients on chronic haemodialysis: use of a continuous glucose
monitoring system." Nephrol Dial Transplant 24(9): 2866-2871.
Roche, M., P. Rondeau, et al. (2008). "The antioxidant properties of serum
albumin." FEBS Lett 582 (13): 1783-1787.
Ryu, J. H., S. H. Li, et al. (2011). "Hypoxia-inducible factor alpha subunit
stabilization by NEDD8 conjugation is reactive oxygen species-
dependent." J Biol Chem 286(9): 6963-6970.
Sadrzadeh, S. M., E. Graf, et al. (1984). "Hemoglobin. A biologic fenton reagent." J
Biol Chem 259 (23): 14354-14356.
Sailaja, Y. R., R. Baskar, et al. (2003). "The antioxidant status during maturation
of reticulocytes to erythrocytes in type 2 diabetics." Free Radic Biol Med
35(2): 133-139.
Santhanam, L., D. W. Christianson, et al. (2008). "Arginase and vascular aging." J
Appl Physiol (1985) 105 (5): 1632-1642.
Santos, C. X., E. I. Anjos, et al. (1 999). "Uric acid oxidat ion by peroxynitrite:
multiple reactions, free radical formation, and amplification of lipid
oxidation." Arch Biochem Biophys 372 (2): 285-294.
Santos, J. H., J. N. Meyer, et al. (2 006). "Quantitative PCR-based measurement of
nuclear and mitochondrial DNA damage and repair in mammalian cells." Methods Mol Biol 314: 183-199.
Sarge, K. D. and O. K. Park-Sarge (2 009). "Sumoylation and human disease
pathogenesis." Trends Biochem Sci 34 (4): 200-205.
Sarkar, A., S. Dash, et al. (2010). "Copper and ceruloplasmin levels in relation to
total thiols and GST in type 2 diabetes mellitus patients." Indian J Clin
Biochem 25(1): 74-76.
Savu, O., O. M. Bradescu, et al. (2013). "Erythrocyte caspase-3 and antioxidant
defense is activated in red blood cells and plasma of type 2 diabetes
patients at first clinical onset." Redox Rep 18(2): 56-62.

11/g889 Savu, O., L. Iosif, et al. (2014). "L- arginine catabolism is driven mainly towards
nitric oxide synthesis in the erythrocytes of patients with type 2 diabetes
at first clinical onset." Ann Clin Biochem.
Sayeski, P. P. and J. E. Kudlow (1996). "Glucose metabolism to glucosamine is
necessary for glucose stimulation of transforming growth factor-alpha
gene transcripti on." J Biol Chem 271 (25): 15237-15243.
Schulman, S. P., L. C. Becker, et al. (2006). "L-arginine therapy in acute
myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial." JAMA 295(1): 58-64.
Schulman, S. P., T. K. Hartmann, et al. (2006). "Intensive care after resuscitation
from cardiac arrest: a focus on heart and brain injury." Neurol Clin 24(1):
41-59, vi.
Schwartz, M. and J. Vissing (2002). "Pat ernal inheritance of mitochondrial DNA."
N Engl J Med 347(8): 576-580.
Scott, G. S. and D. C. Hooper (2001). "T he role of uric acid in protection against
peroxynitrite-mediated pa thology." Med Hypotheses 56(1): 95-100.
Seghrouchni, I., J. Drai, et al. (2002). "Oxidative stress parameters in type I, type
II and insulin-treated type 2 dia betes mellitus; insulin treatment
efficiency." Clin Chim Acta 321(1-2): 89-96.
Semenza, G. L. (2003). "Ta rgeting HIF-1 for cancer therapy." Nat Rev Cancer
3(10): 721-732.
Semenza, G. L. (2011). "Hypoxia-inducib le factor 1: regulator of mitochondrial
metabolism and mediator of ischemic preconditioning." Biochim Biophys
Acta 1813(7): 1263-1268.
Shaw, J. E. and A. J. Boulton (1997). "The pathogenesis of diabetic foot problems:
an overview." Diabetes 46 Suppl 2 : S58-61.
Shaw, J. E., R. A. Sicree, et al. "Glo bal estimates of the prevalence of diabetes for
2010 and 20 30." Diabetes Res Clin Pract 87(1): 4-14.
Shaw, J. E., R. A. Sicree, et al. ( 2010). "Global estimates of the prevalence of
diabetes for 2010 and 2030." Diabetes Res Clin Pract 87(1): 4-14.
Sheetz, M. J. and G. L. King (2002). "Molecular understanding of hyperglycemia's
adverse effects for diab etic complications." JAMA 288(20): 2579-2588.
Shichiri, M., H. Iwamoto, et al. (1990). " Diabetic hypouricemia as an indicator of
clinical nephropathy." Am J Nephrol 10(2): 115-122.
Shichiri, M., H. Iwamoto, et al. (1987). " Diabetic renal hypouricemia." Arch Intern
Med 147(2): 225-228.
Shokolenko, I., N. Vened iktova, et al. (2009). "Oxidative stress induces
degradation of mitochondria l DNA." Nucleic Acids Res 37(8): 2539-2548.
Sibmooh, N., B. Piknova, et al. (2008). "Oxidation of iron-nitrosyl-hemoglobin by
dehydroascorbic acid releases nitric oxide to form nitrite in human
erythrocytes." Biochemistry 47(9): 2989-2996.
Sima, A. A. (2008). "The heterogeneity of diabetic neuropathy." Front Biosci 13:
4809-4816.
Sluimer, J. C., J. M. Gasc, et al. (2008). "H ypoxia, hypoxia-inducible transcription
factor, and macrophages in human at herosclerotic plaques are correlated
with intraplaque angiogenesi s." J Am Coll Cardiol 51(13): 1258-1265.
Smith-Palmer, J., M. Brandle, et al. (2014). "Assessment of the association
between glycemic variability and diab etes-related complications in type 1
and type 2 diabetes." Diabetes Res Clin Pract 105 (3): 273-284.

1/g883/g890 Soga, T. and M. Imaizumi (2001). "Capillary electrophoresis method for the
analysis of inorganic anions, organ ic acids, amino acids, nucleotides,
carbohydrates and other anioni c compounds." Electrophoresis 22(16):
3418-3425.
Solomonson, L. P., B. R. Flam, et al. (2003). "The caveolar nitric oxide
synthase/arginine regeneration system for NO production in endothelial
cells." J Exp Biol 206 (Pt 12): 2083-2087.
Stocker, R. (2004). "Antioxidant activiti es of bile pigments." Antioxid Redox
Signal 6(5): 841-849.
Stocker, R., A. N. Glazer, et al. (1 987). "Antioxidant activity of albumin-bound
bilirubin." Proc Natl Acad Sci U S A 84(16): 5918-5922.
Sundaram, R. K., A. Bhaskar, et al. ( 1996). "Antioxidant status and lipid
peroxidation in type II diabetes mellitus with and without complications."
Clin Sci (Lond) 90(4): 255-260.
Suzuki, S., Y. Hinokio, e t al. (1999). "Oxidative damage to mitochondrial DNA and
its relationship to diabetic comp lications." Diabetes Res Clin Pract 45(2-
3): 161-168.
Swinnen, S. G., A. C. Simon, et al. (2 011). "Insulin detemir versus insulin glargine
for type 2 diabetes mellitus." Cochran e Database Syst Rev(7): CD006383.
Szczesny, B., A. W. Tann, et al. (2 008). "Long patch base excision repair in
mammalian mitochondrial g enomes." J Biol Chem 283 (39): 26349-26356.
Tan, M. H. (1986). "Effect of diabet es mellitus and end-stage renal disease on
HDL metabolism." Adv Exp Med Biol 201 : 51-59.
Thornalley, P. J. (1998). "Cell activation by glycated proteins. AGE receptors,
receptor recognition factors and functi onal classification of AGEs." Cell
Mol Biol (Noisy-le-grand) 44(7): 1013-1023.
Thornberry, N. A. and Y. Lazebnik (1 998). "Caspases: enemies within." Science
281 (5381): 1312-1316.
Thurston, G., C. Suri, et al. (1999). "L eakage-resistant blood vessels in mice
transgenically overexpressing ang iopoietin-1." Science 286 (5449): 2511-
2514.
Toshimori, H., R. Narita, et al. (1991). "Islet amy loid polypeptide in insulinoma
and in the islets of the pancreas of non-diabetic and diabetic subjects."
Virchows Arch A Pa thol Anat Histopathol 418 (5): 411-417.
Toth, C., L. L. Rong, et al. (2008). "Recep tor for advanced gly cation end products
(RAGEs) and experimental diabet ic neuropathy." Diabetes 57(4): 1002-
1017.
Treins, C., S. Giorgetti-Peraldi, et al. ( 2005). "Regulation of h ypoxia-inducible
factor (HIF)-1 activity and expressi on of HIF hydroxylases in response to
insulin-like growth fact or I." Mol Endocrinol 19(5): 1304-1317.
Tretiach, M., M. C. Madigan, et al. (2005 ). "Effect of Muller cell co-culture on in
vitro permeability of bovine re tinal vascular endothelium in normoxic
and hypoxic conditions." Neurosci Lett 378 (3): 160-165.
Trifunovic, A. (2006). "Mitochondrial DNA and ageing." Biochim Biophys Acta
1757 (5-6): 611-617.
Trifunovic, A. and N. G. Larsson (2008). "Mitochondrial dysfunction as a cause of
ageing." J Intern Med 263 (2): 167-178.

1/g883/g891 Trifunovic, A., A. Wredenberg, et a l. (2004). "Premature ageing in mice
expressing defective mitochondrial DNA polymerase." Nature 429 (6990):
417-423.
Tsumoto, H., M. Ra, et al. (2008). "C hemical derivatization of peptides containing
phosphorylated serine/threonine for efficient ionization and
quantification in matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry." Rapid Commun Mass Spectrom 22(7): 965-
972.
Turko, I. V., L. Li, et al. (2003). "Pr otein tyrosine nitration in the mitochondria
from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes." J Biol Chem 278 (36): 33972-33977.
Turrens, J. F. and A. Boveris (1980). "Generation of superoxide anion by the
NADH dehydrogenase of bovine heart mitochondria." Biochem J 191 (2):
421-427.
Uribarri, J., W. Cai, et al. (2011). " Restriction of advanced gly cation end products
improves insulin resistance in human type 2 diabetes: potential role of
AGER1 and SIRT1." Diabetes Care 34(7): 1610-1616.
Uribarri, J., M. Peppa, et al. (2003). " Restriction of dietary glycotoxins reduces
excessive advanced glycation end products in renal failure patients." J Am
Soc Nephrol 14(3): 728-731.
Uribarri, J. and K. R. Tuttle (2006). "A dvanced glycation end products and
nephrotoxicity of high-protein diets." Clin J Am Soc Nephrol 1(6): 1293-
1299.
Valkonen, M. and T. Kuusi (1997). "Spect rophotometric assay for total peroxyl
radical-trapping antioxidant potential in human serum." J Lipid Res
38(4): 823-833.
van der Vliet, A., J. P. Eiserich, et al. (1996). "Nitroty rosine as biomarker for
reactive nitrogen speci es." Methods Enzymol 269 : 175-184.
Van Puyvelde, K., T. Mets, et al. (2014). "Effect of advanced glycation end product
intake on inflammation and aging: a systematic review." Nutr Rev 72(10):
638-650.
Vanizor, B., A. Orem, et al. (2001). "Decr eased nitric oxide end-products and its
relationship with high den sity lipoprotein and oxi dative stress in people
with type 2 diabetes without complications." Diabetes Res Clin Pract
54(1): 33-39.
Vermulst, M., J. Wanagat, e t al. (2008). "DNA deletions and clonal mutations drive
premature aging in mitochondrial mutator mice." Nat Genet 40(4): 392-
394.
Viinikka, L. (1996). "Nitric oxid e as a challenge for the clinical chemistry
laboratory." Scan d J Clin Lab Invest 56(7): 577-581.
Villaret, A., J. Galitzky, et al. (2010). "Adipose tissue endothelia l cells from obese
human subjects: differences among depots in angiogenic, metabolic, and
inflammatory gene expression and cellular senescence." Diabetes 59(11):
2755-2763.
Vincent, A. M., J. W. Russell, et al. (2 004). "Oxidative stress in the pathogenesis of
diabetic neuropathy." Endocr Rev 25(4): 612-628.
Vlassara, H., W. Cai, et al. (2002). "Inflammatory mediators are induced by
dietary glycotoxins, a maj or risk factor for diabet ic angiopathy." Proc Natl
Acad Sci U S A 99(24): 15596-15601.

12/g882 Vos, R. M. and P. J. Van Bladeren (1990 ). "Glutathione S-transferases in relation
to their role in the biotransformation of xenobiotics." Chem Biol Interact
75(3): 241-265.
Waddington, S. N., F. W. Tam, et al. (1 998). "Arginase activity is modulated by IL-
4 and HOArg in nephritic glomeru li and mesangial cells." Am J Physiol
274 (3 Pt 2): F473-480.
Wallace, D. C. (1992). "Mitochondrial genetics: a paradigm for aging and
degenerative diseases?" Science 256 (5057): 628-632.
Wang, E., A. Wong, et al. ( 1997). "The rate of mitochondrial mutagenesis is faster
in mice than humans." Mutat Res 377 (2): 157-166.
Wang, F., M. Nguyen, et al. (2007). "SIR T2 deacetylates FOXO3a in response to
oxidative stress and caloric restr iction." Aging Cell 6(4): 505-514.
Wang, G. L., B. H. Jiang, et al. (1995). "H ypoxia-inducible fact or 1 is a basic-helix-
loop-helix-PAS heterodimer regulated by cellular O2 tension." Proc Natl
Acad Sci U S A 92(12): 5510-5514.
Wang, G. L. and G. L. Semenza (1995 ). "Purification and characterization of
hypoxia-inducible factor 1." J Biol Chem 270 (3): 1230-1237.
Wang, X., G. Wang, et al. (2009). "Intravitreous V ascular Endothelial Growth
Factor and Hypoxia-Inducible Factor 1a in Patients with Proliferative
Diabetic Retinopathy." Am J Ophthalmol.
Wardman, P. (2007). "Fluor escent and luminescent pro bes for measurement of
oxidative and nitrosative species in cells and tissues: progress, pitfalls,
and prospects." Free Radic Biol Med 43(7): 995-1022.
Waring, W. S., S. R. Maxwell, et al. (2002). "Uric acid concentrations and the
mechanisms of cardiov ascular disease." Eur Heart J 23(23): 1888-1889.
Wassmann, S., K. Wassmann, et al. (2004). "Modulation of oxidant and
antioxidant enzyme expression and function in vascular cells."
Hypertension 44(4): 381-386.
Weidig, P., D. McMaster, et al. (2004 ). "High glucose mediate s pro-oxidant and
antioxidant enzyme activities i n coronary endothelial cells." Diabetes
Obes Metab 6(6): 432-441.
Westermark, P., A. Andersson, et al. (2011 ). "Islet amyloid polypeptide, islet
amyloid, and diabetes mellitus." Physiol Rev 91(3): 795-826.
Williams, M. E., R. Garg, et al. (2014). "High Hemoglobin A1c levels and glycemic
variability increase risk of severe hyp oglycemia in diabetic hemodialysis
patients." Hemodial Int 18(2): 423-432.
Wong, A., S. Merritt, et al. (2008). "Eff ect of hypoxia on circulating levels of
retina-specific messenger RNA in type 2 diabetes mellitus." Ann N Y Acad
Sci 1137 : 243-252.
Wood, Z. A., E. Schroder, et al. (2003 ). "Structure, mechanism and regulation of
peroxiredoxins." Trends Biochem Sci 28(1): 32-40.
Wright, E., Jr., J. L. Scism-Bacon, et al. ( 2006). "Oxidative stress in type 2 diabetes:
the role of fasting and postprand ial glycaemia." Int J Clin Pract 60(3):
308-314.
Wu, G. and C. J. Meininger (2000 ). "Arginine nutrition and cardiovascular
function." J Nutr 130 (11): 2626-2629.
Wu, G. and S. M. Morris, Jr. (1998). "Arginine metabolism: nitric oxide and
beyond." Biochem J 336 ( Pt 1) : 1-17.

12/g883 Wu, G. Y. and J. T. Brosnan (1992). "M acrophages can convert citrulline into
arginine." Biochem J 281 ( Pt 1): 45-48.
Xie, L. and S. S. Gross (1997). "Argininosuccinate synthetase overexpression in
vascular smooth muscle cells potentia tes immunostimulant-induced NO
production." J Biol Chem 272(26): 16624-16630.
Yakes, F. M. and B. Van Houten (1997). "Mitochondrial DNA damage is more
extensive and persists longer than nuclear DNA damage in human cells
following oxidative stre ss." Proc Natl Acad Sci U S A 94(2): 514-519.
Yan, Q., S. Bartz, et al. (20 07). "The hypoxia-inducible factor 2alpha N-terminal
and C-terminal transactivation doma ins cooperate to promote renal
tumorigenesis in vivo." Mol Cell Biol 27(6): 2092-2102.
Yao, D. and M. Brownlee (2010). "Hyp erglycemia-induced reactive oxygen
species increase expression of the rece ptor for advanced glycation end
products (RAGE) and RAGE ligands." Diabetes 59(1): 249-255.
Zahedi Asl, S., A. Ghasemi, et al. (2008). "Serum nitric oxide metabolites in
subjects with metabolic sy ndrome." Clin Biochem 41(16-17): 1342-1347.
Zelzer, E., Y. Levy, et al. (1998). "I nsulin induces transcription of target genes
through the hypoxia-inducible f actor HIF-1alpha/ARNT." EMBO J 17(1 7):
5085-5094.
Zhang, C., V. W. Liu, et al. (1998). "Differential occurrence of mutations in
mitochondrial DNA of human skeletal muscle during aging." Hum Mutat
11(5): 360-371.
Zoccali, C., F. Mallamaci, et al. (2004). "I nflammatory proteins as predictors of
cardiovascular disease in patients with end-stage renal disease." Nephrol
Dial Transplant 19 Suppl 5 : V67-72.
Zweier, J. L., P. Wang, et al. (1995). "E nzyme-independent formation of nitric
oxide in biological ti ssues." Nat Med 1(8): 804-809.